



(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2020/05/29  
(87) Date publication PCT/PCT Publication Date: 2020/12/03  
(85) Entrée phase nationale/National Entry: 2021/11/23  
(86) N° demande PCT/PCT Application No.: AU 2020/050546  
(87) N° publication PCT/PCT Publication No.: 2020/237320  
(30) Priorités/Priorities: 2019/05/31 (US62/855,590);  
2019/09/13 (US62/900,105)

(51) Cl.Int./Int.Cl. *A61K 39/395* (2006.01),  
*A61P 37/02* (2006.01), *C07K 16/28* (2006.01)  
(71) Demandeur/Applicant:  
THE COUNCIL OF THE QUEENSLAND INSTITUTE OF  
MEDICAL RESEARCH, AU  
(72) Inventeurs/Inventors:  
WYKES, MICHELLE, AU;  
PULUKKUNAT, DILEEP K., US  
(74) Agent: RIDOUT & MAYBEE LLP

(54) Titre : MOLECULES DE LIAISON ANTI-GAL9 A INHIBITION IMMUNITAIRE  
(54) Title: ANTI-GAL9 IMMUNE-INHIBITING BINDING MOLECULES

(57) **Abrégé/Abstract:**

Inhibitory anti-GAL9 binding molecules, antibody constructs, pharmaceutical compositions comprising the binding molecules and antibody constructs, and methods of use thereof are presented.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

03 December 2020 (03.12.2020)



(10) International Publication Number

WO 2020/237320 A1

## (51) International Patent Classification:

A61K 39/395 (2006.01) A61P 37/02 (2006.01)

C07K 16/28 (2006.01)

## (21) International Application Number:

PCT/AU2020/050546

## (22) International Filing Date:

29 May 2020 (29.05.2020)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/855,590 31 May 2019 (31.05.2019) US

62/900,105 13 September 2019 (13.09.2019) US

## (71) Applicant: THE COUNCIL OF THE QUEENSLAND

INSTITUTE OF MEDICAL RESEARCH [AU/AU];

300 Herston Road, Herston, Queensland 4006 (AU).

## (72) Inventors: WYKES, Michelle; 300 Herston Road, Her-

ston, Queensland 4006 (AU). PULUKKUNAT, Dileep K.;

c/o- Invenra Inc., 505 South Rosa Road, Suite 235, Madi-

son, Wisconsin 53719 (US).

## (74) Agent: CLARKE, Andrew et al.; James &amp; Wells, GPO

1920, Brisbane, Queensland, 4001, Brisbane, 4001 (AU).

## (81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,

TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

## (84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,

KM, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report (Art. 21(3))

(54) Title: ANTI-GAL9 IMMUNE-INHIBITING BINDING MOLECULES

(57) Abstract: Inhibitory anti-GAL9 binding molecules, antibody constructs, pharmaceutical compositions comprising the binding molecules and antibody constructs, and methods of use thereof are presented.



WO 2020/237320 A1

## ANTI-GAL9 IMMUNE-INHIBITING BINDING MOLECULES

### 1. CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. 119(e) of prior co-pending U.S. Provisional Patent Application No. 62/900,105, filed on September 13, 2019 and U.S. Provisional Patent Application No. 62/855,590, filed on May 31, 2019.

### 2. SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated herein by reference in its entirety. Said ASCII copy, created on Month XX, 2020, is named XXXXXUS\_sequencelisting.txt, and is X,XXX,XXX bytes in size.

### 3. BACKGROUND

[0003] Autoimmune diseases arise from an imbalance within the immune system that results in immune-mediated attack on the body's own cells and tissues. The current “gold standard” of care for autoimmune diseases is systemic immune suppression by immunosuppressive agents, including corticosteroids, anti-cytokine antibodies such as anti-TNF- $\alpha$ , anti-IL-1, anti-IL-5, anti-IL-6, anti-IL-17 antibodies, and anti-IL-23 antibodies, and small molecule drugs that reduce inflammatory cytokine signaling, such as JAK/STAT inhibitors. However, nonspecific systemic immune suppression predisposes the patient to infectious disease and can have other serious side effects.

[0004] Immune therapy has great potential for the treatment of autoimmune disease. Galectin-9 (GAL9) is an S-type lectin beta-galactoside-binding protein with N- and C-terminal carbohydrate-binding domains connected by a linker peptide. GAL9 has been implicated in modulating cell-cell and cell-matrix interactions. GAL9 has been shown to bind soluble PD-L2, and at least some of the immunological effects of PD-L2 have been suggested to be mediated through binding of multimeric PD-L2 to GAL9, rather than through PD-1 (WO 2016/008005, which is incorporated herein by reference in its entirety). However, mechanisms by which GAL9 and PD-L2 impact immune effector function are not yet fully characterized.

[0005] There remains a need for more targeted therapies that can reestablish balance of the immune system by modulating immune effector cells to establish a more clinically favorable

cytokine profile. Such therapeutic agents may be useful for improving treatment for autoimmune and inflammatory disease.

#### 4. SUMMARY

**[0006]** The present invention has arisen in part from the unexpected discovery that PD-L2 is overexpressed in autoimmune disease and that inhibiting the Galectin-9/PD-L2 pathway modulates immune effector cells to produce a more clinically favorable cytokine profile.

**[0007]** Accordingly, disclosed herein are various GAL9 binding molecules, antigen binding portions thereof, and antibodies that specifically bind to and antagonize human GAL9 (Galectin-9). Inhibiting GAL9 using the anti-human GAL9 binding molecules disclosed herein decreases the secretion and production of proinflammatory cytokines, increases the secretion and production of anti-inflammatory cytokines, and decreases surface expression of stimulatory molecules.

**[0008]** Pharmaceutical compositions comprising the GAL9 binding molecules are also disclosed. The anti-GAL9 binding molecules, antigen binding portions thereof, and antibodies disclosed herein can be used *per se*, as a pharmaceutical composition, or in combination with other therapeutic agents or procedures to treat, prevent, and/or diagnose autoimmune disease, inflammatory disease, or a condition that invokes an inflammation response such as an infection. The anti-GAL9 binding molecules are particularly useful for a disease or condition in which GAL9/PD-L2 interaction contributes prominently to pathogenesis. The anti-GAL9 binding molecules are useful in treating, reducing inflammation, reducing autoimmune response, prolonging remission, inducing remission, re-establishing immune tolerance, improving organ function, reducing progression of a disease, reducing the risk of development of a second disease, or increasing overall survival in a subject.

**[0009]** In a first aspect, the disclosure provides a Galectin-9 (GAL9) antigen binding molecule comprising a first antigen binding site specific (ABS) for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0010]** In a second aspect, the disclosure provides a Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VL CDRs from any one of

the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0011]** In a third aspect, the disclosure provides a Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0012]** In a fourth aspect, the disclosure provides a Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site specific for a first epitope of a first GAL9 antigen, comprising the VL sequence and the VH sequence from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0013]** In some embodiments, the GAL9 antigen binding molecule comprises a full immunoglobulin heavy chain "IgG1" sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence and the VL sequence are from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0014]** In some embodiments, the GAL9 antigen binding molecule comprises a full immunoglobulin heavy chain "IgG4" sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence and the VL sequence are from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0015]** In some embodiments, the GAL9 antigen binding molecule can comprise a GAL9 antigen that is a human GAL9 antigen.

**[0016]** In some embodiments, the GAL9 antigen binding molecule can further comprise a second antigen binding site.

**[0017]** In certain embodiments, the second antigen binding site is specific for the GAL9 antigen. In other embodiments, the second antigen binding site is identical to the first antigen binding site.

**[0018]** In other embodiments, the second antigen binding site is specific for a second epitope of the first GAL9 antigen.

**[0019]** In some embodiments, the second antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from another ABS clone selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0020]** In some embodiments, the second antigen binding site comprises the VL sequence and the VH sequence from the other ABS clone.

**[0021]** In some embodiments, the second antigen binding site comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence from the other ABS clone.

**[0022]** In some embodiments, the second antigen binding site is specific for an antigen other than the first GAL9 antigen.

**[0023]** In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0024]** In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-11, P9-24, P9-34, and P9-37.

**[0025]** In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-11, P9-24, and P9-34.

**[0026]** In some embodiments the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-11.

**[0027]** In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-24.

**[0028]** In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-34.

**[0029]** In some embodiments, the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-37.

**[0030]** In some embodiments, the GAL9 antigen binding molecule comprises an antibody format selected from the group consisting of: full-length antibodies, Fab fragments, F(ab)<sup>2</sup> fragments, Fvs, scFvs, tandem scFvs, diabodies, scDiabodies, DARTs, single chain VHH camelid antibodies, tandAbs, minibodies, and B-bodies. B-bodies are described in US pre-grant publication number US 2018/0118811, which is incorporated herein by reference in its entirety.

**[0031]** In some embodiments, the GAL9 antigen binding molecule decreases TNF- $\alpha$  secretion by activated immune cells upon contact, wherein the decrease is about at least a 30%, 35%, 40%, 45%, 50%, 55%, or 60% decrease relative to activated immune cells treated with a control agent.

**[0032]** In some embodiments, the GAL9 antigen binding molecule decreases IFN- $\gamma$  secretion by activated immune cells upon contact, wherein the decrease is about at least a 20%, 25%, 30%, 35%, 40%, 45%, or 50% decrease relative to activated immune cells treated with a control agent.

**[0033]** In some embodiments, the GAL9 antigen binding molecule increases IL-10 secretion by activated immune cells upon contact, wherein the increase is about at least a 5%, 10%, 15%, 20%, 25%, 30%, 35% or 40% increase relative to activated immune cells treated with a control agent.

**[0034]** In some embodiments, the GAL9 antigen binding molecule does not modulate PD-1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

**[0035]** In some embodiments, the GAL9 antigen binding molecule does not modulate PD-L1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

**[0036]** In some embodiments, the GAL9 antigen binding molecule does not modulate CTLA-4 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

**[0037]** In some embodiments, the GAL9 antigen binding molecule does not modulate TIM3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

**[0038]** In some embodiments, the GAL9 antigen binding molecule does not modulate LAG3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

**[0039]** In some embodiments, the GAL9 antigen binding molecule decreases 4-1BB surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent.

**[0040]** In some embodiments, the GAL9 antigen binding molecule decreases CD40L surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent.

**[0041]** In some embodiments, the GAL9 antigen binding molecule decreases OX40 surface expression activated on CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent.

**[0042]** In some embodiments, the control agent is a negative control agent or positive control agent.

**[0043]** In some embodiments, the control agent is a control antibody.

**[0044]** In some embodiments, the control antibody is selected from the group consisting of: an ECA42 clone anti-GAL9 antibody, an RG9.1 clone anti-GAL9 antibody, an RG9.35 clone anti GAL9 antibody, an anti-PD1 antibody, an 108A2 clone anti-GAL9 antibody, and a non-GAL9 binding isotype control antibody.

**[0045]** In some embodiments, the activated immune cells, activated CD8<sup>+</sup> T-cells, or activated DCs were activated by were activated by peptide stimulation, anti-CD3, or dendritic cells.

**[0046]** In a fifth aspect, the disclosure provides a GAL9 antigen binding molecule that decreases TNF- $\alpha$  secretion by activated immune cells, wherein the decrease is about at least a 30%, 35%, 40%, 45%, 50%, 55%, or 60% decrease relative to activated immune cells treated with a control agent.

**[0047]** In a sixth aspect, the disclosure provides a GAL9 antigen binding molecule that decreases IFN- $\gamma$  secretion by activated immune cells, wherein the decrease is about at least a 20%, 25%, 30%, 35%, 40%, 45%, or 50% decrease relative to activated immune cells treated with a control agent.

**[0048]** In a seventh aspect, the disclosure provides a GAL9 antigen binding molecule that increases IL-10 secretion by activated immune cells, wherein the increase is about at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% increase relative to activated immune cells treated with a control agent

[0049] In an eighth aspect, the disclosure provides a GAL9 antigen binding molecule does not modulate PD-1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

[0050] In a ninth aspect, the disclosure provides a GAL9 antigen binding molecule does not modulate PD-L1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

[0051] In a tenth aspect, the disclosure provides a GAL9 antigen binding molecule does not modulate CTLA-4 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

[0052] In an eleventh aspect, the disclosure provides a GAL9 antigen binding molecule does not modulate TIM3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

[0053] In a twelfth aspect, the disclosure provides a GAL9 antigen binding molecule does not modulate LAG3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

[0054] In a thirteenth aspect, the disclosure provides a GAL9 antigen binding molecule decreases 4-1BB surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent.

[0055] In a fourteenth aspect, the disclosure provides a GAL9 antigen binding molecule decreases CD40L surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent.

[0056] In a fifteenth aspect, the disclosure provides a GAL9 antigen binding molecule decreases OX40 surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent.

[0057] In a sixteenth aspect, the disclosure provides a GAL9 antigen binding molecule demonstrates one or more of the following properties: A) decreases TNF- $\alpha$  secretion by activated immune cells, wherein the decrease is about at least a 30%, 35%, 40%, 45%, 50%, 55%, or 60% decrease relative to activated immune cells treated with a control agent; B) decreases IFN- $\gamma$  secretion by activated immune cells, wherein the decrease is about at least a 20%, 25%, 30%, 35%, 40%, 45%, or 50% decrease relative to activated immune cells treated with a control agent; C) increases IL-10 secretion by activated immune cells, wherein the increase is about at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% increase relative to activated immune cells treated with a control agent; D) does not modulate PD-1 surface expression on activated immune cells relative to activated immune cells treated with a control

agent; E) does not modulate PD-L1 surface expression on activated immune cells relative to activated immune cells treated with a control agent; F) does not modulate CTLA-4 surface expression on activated immune cells relative to activated immune cells treated with a control agent; G) does not modulate TIM3 surface expression on activated immune cells relative to activated immune cells treated with a control agent; H) does not modulate LAG3 surface expression on activated immune cells relative to activated immune cells treated with a control agent; I) decreases 4-1BB surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent; J); decreases CD40L surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent; or K) decreases OX40 surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with a control agent.

**[0058]** In some embodiments, the control agent is a negative control agent or positive control agent.

**[0059]** In some embodiments, the control agent is a control antibody.

**[0060]** In some embodiments, the control antibody is selected from the group consisting of: an ECA42 clone anti-GAL9 antibody, an RG9.1 clone anti-GAL9 antibody, an RG9.35 clone anti GAL9 antibody, an anti-PD1 antibody, an 108A2 clone anti-GAL9 antibody, and a non-GAL9 binding isotype control antibody.

**[0061]** In some embodiments, the activated immune cells, were activated by were activated by peptide stimulation, anti-CD3 or dendritic cells.

**[0062]** In some embodiments, the GAL9 antigen binding molecule of the fifth-fifteenth aspects provided herein comprise a first antigen binding site specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0063]** In some embodiments, the VL sequence and the VH sequence from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0064]** In some certain embodiments, the GAL9 antigen binding molecule comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence

and the VL sequence are from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0065]** In some embodiments, the GAL9 antigen is a human GAL9 antigen.

**[0066]** In some embodiments, the GAL9 antigen binding molecule further comprises a second antigen binding site.

**[0067]** In some embodiments, the second antigen binding site is specific for the GAL9 antigen.

**[0068]** In some embodiments, the second antigen binding site is identical to the first antigen binding site.

**[0069]** In some embodiments, the second antigen binding site is specific for a second epitope of the first GAL9 antigen.

**[0070]** In some embodiments, the second antigen binding site comprises all three VH CDRs and all three VL CDRs from another ABS clone selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

**[0071]** In some embodiments, the second antigen binding site comprises the VL sequence and the VH sequence from the other ABS clone.

**[0072]** In some embodiments, the second antigen binding site comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence from the other ABS clone.

**[0073]** In some embodiments, the second antigen binding site is specific for an antigen other than the first GAL9 antigen.

**[0074]** In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-11, P9-24, P9-34, and P9-37.

**[0075]** In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-11, P9-24, and P9-34.

**[0076]** In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-11.

**[0077]** In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-24.

**[0078]** In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-34.

**[0079]** In some embodiments, the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-37.

**[0080]** In some embodiments, the GAL9 antigen binding molecule comprises an antibody format selected from the group consisting of: full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, and B-bodies.

**[0081]** In a seventeenth aspect, the disclosure provides a GAL9 antigen binding molecule which binds to the same epitope as a GAL9 antigen binding molecule of any one of the preceding claims.

**[0082]** In an eighteenth aspect, the disclosure provides a GAL9 antigen binding molecule which competes for binding with a GAL9 antigen binding molecule of any one of the preceding claims.

**[0083]** In some embodiments, the GAL9 antigen binding molecule is purified.

**[0084]** In a nineteenth aspect, the disclosure provides a pharmaceutical composition comprising the GAL9 antigen binding molecule of any one of the preceding claims and a pharmaceutically acceptable diluent.

**[0085]** In a twentieth aspect, the disclosure provides a method for treating a subject with an autoimmune disease comprising administering a therapeutically effective amount of the pharmaceutical composition as provided herein to the subject.

**[0086]** In some embodiments, the subject with an autoimmune disease has increased expression of PD-L2 on dendritic cells, as compared to dendritic cells from a healthy control.

**[0087]** In some embodiments, the autoimmune disease is selected from the group consisting of: inflammatory bowel disease, Crohn's disease, ulcerative colitis, colitis, celiac disease, rheumatoid arthritis, Behçet's disease, amyloidosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus nephritis, graft-versus-host disease (GVHD), nonalcoholic steatohepatitis (NASH), and ankylosing spondylitis.

**[0088]** In some embodiments, administering a therapeutically effective amount of the GAL binding molecule *per se* or a pharmaceutical composition results in reducing inflammation, reducing autoimmune response, prolonging remission, inducing remission, re-establishing immune tolerance, improving organ function, reducing the progression of a disease, reducing the risk of progression or development of a second disease, or increasing overall survival.

## 5. BRIEF DESCRIPTION OF THE DRAWINGS

[0089] **FIGs. 1A and 1B** show an illustrative example of various CDR and framework numbering systems – Chothia, Martin (ABA), and Kabat – as applied to the P9-01 anti-human Gal9 candidate antibody provided herein.

[0090] **FIG. 2** shows density contour plots of the percentage of CD11c<sup>+</sup> blood dendritic cells from a Crohn's Disease patient detected as positive for PD-L1 or PD-L2 expression compared to labelling isotype IgG control.

[0091] **FIGs. 3A and 3B** show scatter plots of the percentage of PD-L1 or PD-L2 expressing blood dendritic cells in healthy controls or Crohn's Disease patients. **FIGs. 3C and 3D** show scatter plots of the Geometric Mean Fluorescence (GMI) of PD-L1 or PD-L2 surface expression on blood dendritic cells in healthy controls or Crohn's Disease patients.

[0092] **FIGs. 4A and 4B** show representative confocal images of DNA (DAPI; blue), PD-L1 (green), and PD-L2 (red) expression on dendritic cells from two healthy control donors (**4A**) and three Crohn's Disease patients (**4B**); rendered in gray scale in the attached figures.

[0093] **FIGs. 5A-5C** show the mean concentration of cytokines secreted by PMBCs from Crohn's Disease (CD) patients after treatment with anti-CD3 to mimic TCR activation and either anti-PD-L2 ( $\alpha$ PD-L2) or IgG control. **FIGs. 5A-5B** show the mean concentration of TNF- $\alpha$  and IFN- $\gamma$  after treatment with anti-PD-L2 or IgG control in PMBCs from CD patients. **FIG. 5C** shows the mean ratio of IL-10:TNF- $\alpha$  secretion after treatment with anti-PD-L2 and IgG control in PMBCs from CD patients.

[0094] **FIG. 6** shows TNF- $\alpha$  secretion by anti-CD3 activated mouse CD4<sup>+</sup> T-cells after treatment with either sPD-L2 or both sPD-L2 and inhibitory anti-mouse anti-GAL9 (108A2).

[0095] **FIG. 7** shows representative confocal images of DNA (DAPI; blue), PD-L1 (green), PD-1 (red) and OX40 (yellow) expression in CD4<sup>+</sup> T-cells from malaria-infected mice after treatment with mouse inhibitory anti-mouse GAL9 (108A2) and activating anti-mouse GAL9 (RG9.1) antibodies; rendered in gray scale in the attached figures.

[0096] **FIGs. 8A and 8B** show bar graphs of the percentage of surviving mouse CD4<sup>+</sup> and CD8<sup>+</sup> T-cells after treatment with either sPD-L2 or sPD-L2 and mouse inhibitory anti-GAL9 (108A2) antibody.

[0097] **FIGs. 9A and 9B** show bar graphs of INF- $\gamma$  (**9A**) and TNF- $\alpha$  (**9B**) secretion from mouse CD4<sup>+</sup> T-cells co-cultured with dendritic cells (stimulated) and treated with either blocking anti-PD-L2 (clone Ty25) or inhibitory anti-GAL9 (108A2) mouse antibodies, compared to control, unstimulated CD4<sup>+</sup> T-cells.

[0098] FIGs. 10A and 10B show INF- $\gamma$  (10A) and TNF- $\alpha$  (10B) secretion from HCMV peptide, *in vitro*-stimulated PBMCs after treatment with various anti-human GAL9 candidates, a known activating tool antibody (Tool mAb), an anti-PD-1 antibody, a IgG control antibody (IgG Ctrl), and a vehicle control (PBS Ctrl). Black diamond shapes show secretion from activated PBMCs stimulated by Tool mAb and anti-PD-1 antibody.

[0099] FIGs. 11A-11C show INF- $\gamma$  and TNF- $\alpha$  secretion from HCMV peptide, *in vitro*-stimulated PBMCs after treatment with anti-human GAL9 P9-11, P9-37, or P9-57 compared to IgG control antibody (IgG).

[0100] FIGs. 12A-12C show TNF- $\alpha$  (12A), INF- $\gamma$  (12B), and IL-10 (12C) secretion from HCMV peptide, *in vitro*-stimulated PBMCs after treatment with anti-human GAL9 candidates P9-11, P9-24, or P9-34 compared to IgG control antibody (IgG).

[0101] FIGs. 13A and 13B show bar graphs of the ratio of TNF- $\alpha$ :IL-10 secretion (13A) and ratio of IFN- $\gamma$ :IL-10 secretion (13B) from anti-CD3 activated mouse CD3<sup>+</sup> T-cells after treatment with inhibitory anti-mouse GAL9 (108A2) and anti-human GAL9 P9-11, P9-24, or P9-34.

## 6. DETAILED DESCRIPTION

### 6.1. Definitions

[0102] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. As used herein, the following terms have the meanings ascribed to them below.

[0103] By “**antigen binding site**” or “**ABS**” is meant a region of a GAL9 binding molecule that specifically recognizes or binds to a given antigen or epitope.

[0104] As used herein, the terms “**treat**” or “**treatment**” are used in their broadest accepted clinical sense. The terms include, without limitation, lessening a sign or symptom of disease; improving a sign or symptom of disease; alleviation of symptoms; diminishment of extent of disease; stabilized (i.e., not worsening) state of disease; delay or slowing of disease progression; amelioration or palliation of the disease state; remission (whether partial or total), whether detectable or undetectable; cure; prolonging survival as compared to expected survival if not receiving treatment. Unless explicitly stated otherwise, “**treat**” or “**treatment**” do not intend prophylaxis or prevention of disease.

[0105] By “**subject**” or “**individual**” or “**animal**” or “**patient**” or “**mammal**,” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include humans, domestic animals, farm animals, and zoo, sports, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, and so on. Unless otherwise stated, “patient” intends a human “subject.”

[0106] The term “**sufficient amount**” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate protein aggregation in a cell.

[0107] The term “**therapeutically effective amount**” is an amount that is effective to ameliorate a symptom of a disease.

[0108] The term “**prophylactically effective amount**” is an amount that is effective to prevent a symptom of a disease.

## 6.2. Other interpretational conventions

[0109] Unless otherwise specified, all references to sequences herein are to amino acid sequences.

[0110] Unless otherwise specified, antibody constant region residue numbering is according to the Eu index as described at

[www.imgt.org/IMGTScientificChart/Numbering/Hu\\_IGHGnber.html#refs](http://www.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html#refs)

(accessed Aug. 22, 2017), which is hereby incorporated by reference in its entirety, and residue numbers identify the residue according to its location in an endogenous constant region sequence regardless of the residue’s physical location within a chain of the GAL9 binding molecules described herein.

[0111] Unless otherwise specified as “Kabat CDR”, “Chothia CDR”, “Contact CDR”, or “IMGT CDR”, all references to “**CDRs**” are to CDRs defined using the Martin (ABA) definition.

[0112] By “**endogenous sequence**” or “native sequence” is meant any sequence, including both nucleic acid and amino acid sequences, which originates from an organism, tissue, or cell and has not been artificially modified or mutated.

[0113] Polypeptide chain numbers (*e.g.*, a “first” polypeptide chains, a “second” polypeptide chain. *Etc.* or polypeptide “chain 1,” “chain 2,” *etc.*) are used herein as a unique identifier for specific polypeptide chains that form a binding molecule and is not intended to connote order or quantity of the different polypeptide chains within the binding molecule.

[0114] In this disclosure, “**comprises,**” “**comprising,**” “**containing,**” “**having,**” “**includes,**” “**including,**” and linguistic variants thereof have the meaning ascribed to them in U.S. Patent law, permitting the presence of additional components beyond those explicitly recited.

[0115] As used herein, the singular forms “**a,**” “**an,**” and “**the**” include the plural referents unless the context clearly indicates otherwise. The terms “include,” “such as,” and the like are intended to convey inclusion without limitation, unless otherwise specifically indicated.

[0116] **Ranges** provided herein are understood to be shorthand for all of the values within the range, inclusive of the recited endpoints. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.

[0117] Unless specifically stated or otherwise apparent from context, as used herein the term “**about**” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value.

### 6.3. General Overview

[0118] The present disclosure provides Galectin-9 (GAL9) antigen binding molecules, such as anti-GAL9 antibodies and antigen-binding fragments thereof; compositions comprising the GAL9-binding molecules; pharmaceutical compositions comprising the GAL9-binding molecules; and methods of using the GAL9 binding molecules to treat subjects with a disease or a condition. The disclosure particularly provides various GAL9 antigen binding molecules that are inhibitory, acting as inhibitors of the immune system, decreasing the secretion and production of pro-inflammatory cytokines and increasing the secretion and production of anti-inflammatory cytokines in various immune cells and decreasing surface expression of stimulatory molecules.

[0119] The GAL9 antigen binding molecules are particularly useful for the treatment of an autoimmune disease or inflammatory disease in a subject. In some embodiments, the compositions and methods are used to treat an infection that causes an inflammatory response in a subject. The anti-GAL9 binding molecules are particularly useful for treating a disease or condition in which GAL9/PD-L2 interaction contributes prominently to pathogenesis. In some embodiments, the anti-GAL9 binding molecules are administered to a subject *per se*, as a pharmaceutical composition, or in combination with other therapeutic agents or procedures.

#### 6.4. GAL9 antigen binding molecules

[0120] In a first aspect, antigen binding molecules are provided. In every embodiment, the antigen binding molecule includes at least a first antigen binding site specific for a GAL9 antigen; the binding molecules are therefore termed GAL9 antigen binding molecules or GAL9 binding molecules.

[0121] The GAL9 antigen binding molecules described herein bind specifically to GAL9 antigens.

[0122] As used herein, “GAL9 antigens” refer to Galectin-9 family members and homologs. GAL9 is also referred to as LGALS9, HUAT, LGALS9A, tumor antigen HOM-HD-21, and ecalectin. In particular embodiments, the GAL9 binding molecule has antigen binding sites that specifically bind to at least a portion of more than one GAL9 domain, such as the junction between a first and a second GAL9 domain.

[0123] In specific embodiments, the GAL9 antigen is human. GenBank Accession # NP\_033665.1 describes a canonical human GAL9 protein, including its sequences and domain features, and is hereby incorporated by reference in its entirety. SEQ ID NO:6 provides the full-length GAL9 protein sequence.

```
MAFSGSQAPYLSPAVPFSGTIQGGLQDGLQITVNGTVLSSSGTRFAVNFQTGFSGND
IAFHFNPRFEDGGYVVCNTRQNGSWGPEERKTHMPFQKGMPFDLCFLVQSSDFKVMV
NGILFVQYFHRVPFHRVDTISVNGSVQLSYISFQNPRTVPVQPAFSTVPFSPVCFP
PRPRGRRQKPPGVWPANPAPITQTVIHTVQSAPGQMFSTPAIPPMYPHPAYPMPFI
TTILGGLYPSKSIILSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDN
SWGSEERSLPRKMPFVRGQSFVWILCEAHCLKVAVDGQHLFEYYHRLRNLPTINRL
EVGGDIQLTHVQT [SEQ ID NO: 6]
```

[0124] In various embodiments, the GAL9 binding molecule additionally binds specifically to at least one antigen additional to a GAL9 antigen.

##### 6.4.1. Functional Characteristics of the GAL9 antigen binding molecules

[0125] In typical embodiments, upon contact therewith, the GAL9 antigen binding molecule modulates cytokine secretion (e.g., increases or decreases cytokine secretion) of immune cells or activated immune cells. In some embodiments, the immune cells are peripheral blood

mononuclear cells (PBMCs). In some embodiments, the immune cells are T cells. In some embodiments, the T cells are effector T cells. In some embodiments, the T cells are CD8<sup>+</sup> T cells. In some embodiments, the T cells are CD4<sup>+</sup> T cells. In some embodiments, the T cells are CD3<sup>+</sup> T cells.

**[0126]** The impact of the GAL9 antigen binding molecule on immune cell cytokine secretion may be determined by any suitable means. For instance, the impact of the GAL9 antigen binding molecule on immune cell cytokine secretion may be determined in vivo, ex vivo, or in vitro. In some embodiments, cytokine secretion is determined in activated immune cells contacted with a GAL9 antigen binding molecule, as compared to activated immune cells contacted with a control agent, e.g., a control antigen binding molecule or vehicle control. The immune cells may be activated by peptide stimulation. For example, the immune cells may be activated by a peptide or plurality of peptides known to induce an immune response. A plurality of peptides known to induce an immune response can be from an infection from a pathogen such as a viral infection or bacterial infection.

**[0127]** The control agent can be a negative control or a positive control. In some embodiments, the GAL9 antigen binding molecule increases cytokine secretion in immune cells, relative to a negative control agent or negative control antigen binding molecule. In some embodiments, the negative control antigen binding molecule is an isotype control binding molecule that does not bind GAL9. In some embodiments, the positive control antibody is an anti-PD1 antibody, such as nivolumab. In some embodiments, the positive control antibody is a GAL9 control antibody. The GAL9 control antibody can be Gal9 antibody clone RG9.1 (Cat. No. BE0218, InVivoMab Antibodies) or RG9.35. RG9.1 and RG9.35 are both described in Fukushima A, Sumi T, Fukuda K, Kumagai N, Nishida T, *et al.* (2008), which is incorporated herein by reference in its entirety. Roles of galectin-9 in the development of experimental allergic conjunctivitis in mice. *Int Arch Allergy Immunol* 146: 36–43, which is hereby incorporated by reference in its entirety. The GAL9 control antibody can be GAL9 antibody clone ECA42 (Cat. No. LS-C179449, LifeSpan BioScience). The GAL9 control antibody can be GAL9 antibody clone 108A2 (BioLegend® San Diego, CA). In some embodiments, the GAL9 antigen binding molecule decreases cytokine secretion of proinflammatory cytokine in immune cells, relative to a control antibody. In some embodiments, the GAL9 antigen binding molecule increases cytokine secretion of inhibitory cytokine in immune cells, relative to a control antibody.

**[0128]** Cytokine secretion by the immune cells can be assessed by any suitable means. By way of example only, cytokine secretion by in vitro or ex vivo immune cell culture models may be assessed by analyzing cytokine content of the cultured cell supernatants, e.g., by cytokine bead array.

**[0129]** In some embodiments, the cytokine is TNF- $\alpha$ . In some embodiments, the GAL9 antigen binding molecule decreases TNF- $\alpha$  secretion in activated immune cells by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%, as compared to a control agent described herein. In some embodiments, the GAL9 antigen binding molecule decreases TNF- $\alpha$  secretion in activated immune cells by at least 1%-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35%-40%, 40%-45%, 45%-50%, 50%-55%, 55%-60%, 60%-65%, 70% -75%, 75%-80%, 80%-85%, or 85%-90% decrease, as compared to a control agent described herein. In some embodiments, the GAL9 antigen binding molecule decreases TNF- $\alpha$  secretion in activated immune cells by about 30% - 50% decrease, as compared to a control agent described herein.

**[0130]** In some embodiments, the cytokine is IFN- $\gamma$ . In some embodiments, the GAL9 antigen binding molecule decreases IFN- $\gamma$  secretion in activated immune cells by at least at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75% as compared to a control agent described herein. In some embodiments, the GAL9 antigen binding molecule decreases IFN- $\gamma$  secretion in activated immune cells by at least 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35%-40%, 40%-45%, 45%-50%, 50%-55%, 55%-60%, 60%-65%, or 70% -75% decrease, as compared to a control agent described herein. In some embodiments, the GAL9 antigen binding molecule decreases IFN- $\gamma$  secretion in activated immune cells by about 20%-40% decrease, as compared to a control agent described herein.

**[0131]** In some embodiments, the cytokine is IL-10. In some embodiments, the GAL9 antigen binding molecule increases IL-10 secretion in activated immune cells by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% increase, as compared to a control agent described herein. In some embodiments, the GAL9 antigen binding molecule increases IL-10 secretion in activated immune cells by at least 1%-5%, 5%-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35%-40%, 40%-45%, or 45%-50% increase, as compared to a control agent described herein. In some embodiments, the GAL9 antigen binding molecule increases IL-10 secretion in activated immune cells by about 5%-30% increase, as compared to a control agent described herein.

**[0132]** In some embodiments, upon contact therewith, the GAL9 antigen binding molecule does not modulate surface expression of immune checkpoint molecule(s) (e.g., stimulatory or inhibitory checkpoint molecules) relative to activated immune cells treated with a control agent. The term “does not modulate” means that there is no substantial increase or decrease in the expression of the immune checkpoint molecule after treatment with a GAL9 binding molecule provided herein, compared to a control agent. In some embodiments, no substantial increase in surface expression (e.g., does not modulate expression) is an increase of cell surface expression that is no more than 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, 1.1X, 1.2X, or 1.3X fold change, relative to activated immune cells treated with a control agent. In some embodiments, no substantial decrease in surface expression (e.g., does not modulate expression) is a decrease of cell surface expression that is no more than 0.01X, 0.02X, 0.03X, 0.04X, 0.05X, 0.06X, 0.07X, 0.08X, 0.09X, 0.1X, or 0.2X fold change, relative to activated immune cells treated with a control agent.

**[0133]** In some embodiments, no substantial increase in surface expression (e.g., does not modulate expression) is an increase of surface expression about a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, or 15% increase, relative to activated immune cells treated with a control agent. In some embodiments, no substantial decrease in surface expression (e.g., does not modulate expression) is a decrease of surface expression about a 1% decrease, 2% decrease, 3% decrease, 4% decrease, 5% decrease, 6% decrease, 7% decrease, 8% decrease, 9% decrease, 10% decrease, 11% decrease, 12% decrease, 13% decrease, 14% decrease, or 15% decrease, relative to activated immune cells treated with a control agent.

**[0134]** In some embodiments, no substantial increase or decrease in surface expression is determined by comparing the level of surface expression to the level of noise in the assay (e.g., in vivo, ex vivo, or in vitro). In some embodiments, no substantial increase or decrease in surface expression is determined by comparing the level of surface expression to the standard deviation in the assay (e.g., in vivo, ex vivo, or in vitro).

**[0135]** The impact of the GAL9 antigen binding molecule on surface expression of the one or more immune checkpoint molecules may be determined by any suitable means. For instance, the impact of the GAL9 antigen binding molecule on surface expression of the one or more costimulatory molecules may be determined in vivo, ex vivo, or in vitro.

**[0136]** In some embodiments, one or more immune checkpoint molecules are selected from PD-1, PD-L1, CTLA-4, TIM3, LAG3, TIGIT, and PVRIG. In some embodiments, one or more checkpoint molecules is selected from PD-1, PD-L1, TIM3, and LAG3. In some embodiments, the immune checkpoint molecule is PD-1 or PD-L1. In various embodiments, the activated (e.g., stimulated) immune cells are T-cells, CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, CD3<sup>+</sup> T cells, or PBMCs.

**[0137]** In some embodiments, the immune checkpoint molecule is PD-1. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, 1.1X, 1.2X, or 1.3X fold change in PD-1 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease in surface expression that is no more than 0.01X, 0.02X, 0.03X, 0.04X, 0.05X, 0.06X, 0.07X, 0.08X, 0.09X, 0.1X, or 0.2X fold change in PD-1 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0138]** In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than about a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, or 15% increase in PD-1 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease that is no more than about a 1% decrease, 2% decrease, 3% decrease, 4% decrease, 5% decrease, 6% decrease, 7% decrease, 8% decrease, 9% decrease, 10% decrease, 11% decrease, 12% decrease, 13% decrease, 14% decrease, or 15% decrease in PD-1 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0139]** In some embodiments, the immune checkpoint molecule is PD-L1. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than fold change in PD-L1 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, 1.1X, 1.2X, or 1.3X fold change in PD-L1 surface expression,

relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease in surface expression that is no more than 0.01X, 0.02X, 0.03X, 0.04X, 0.05X, 0.06X, 0.07X, 0.08X, 0.09X, 0.1X, or 0.2X fold change in PD-L1 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0140]** In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibit an increase that is no more than about a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, or 15% increase in PD-L1 surface expression relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease that is no more than about a 1% decrease, 2% decrease, 3% decrease, 4% decrease, 5% decrease, 6% decrease, 7% decrease, 8% decrease, 9% decrease, 10% decrease, 11% decrease, 12% decrease, 13% decrease, 14% decrease, or 15% decrease in PD-L1 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0141]** In some embodiments, the immune checkpoint molecule is CTLA-4. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, 1.1X, 1.2X, or 1.3X fold change in CTLA-4 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease in surface expression that is no more than 0.01X, 0.02X, 0.03X, 0.04X, 0.05X, 0.06X, 0.07X, 0.08X, 0.09X, 0.1X, or 0.2X fold change in CTLA-4 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0142]** In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than about a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, or 15% increase in CTLA-4 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease that is no more than about a 1% decrease, 2% decrease, 3% decrease, 4% decrease, 5% decrease, 6% decrease, 7% decrease, 8% decrease, 9%

decrease, 10% decrease, 11% decrease, 12% decrease, 13% decrease, 14% decrease, or 15% decrease in CTLA-4 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0143]** In some embodiments, the immune checkpoint molecule is TIM3. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, 1.1X, 1.2X, or 1.3X fold change in TIM3 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease in surface expression that is no more than 0.01X, 0.02X, 0.03X, 0.04X, 0.05X, 0.06X, 0.07X, 0.08X, 0.09X, 0.1X, or 0.2X fold change in TIM3 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0144]** In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than about a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, or 15% increase in TIM3 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease that is no more than about a 1% decrease, 2% decrease, 3% decrease, 4% decrease, 5% decrease, 6% decrease, 7% decrease, 8% decrease, 9% decrease, 10% decrease, 11% decrease, 12% decrease, 13% decrease, 14% decrease, or 15% decrease in TIM3 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0145]** In some embodiments, the immune checkpoint molecule is LAG3. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits an increase that is no more than 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, 1.1X, 1.2X, or 1.3X fold change in LAG3 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease in surface expression that is no more than 0.01X, 0.02X, 0.03X, 0.04X, 0.05X, 0.06X, 0.07X, 0.08X, 0.09X, 0.1X, or 0.2X fold change in LAG3 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding

molecule exhibits an increase that is no more than about a 1% increase, 2% increase, 3% increase, 4% increase, 5% increase, 6% increase, 7% increase, 8% increase, 9% increase, 10% increase, 11% increase, 12% increase, 13% increase, 14% increase, or 15% increase in LAG3 surface expression, relative to activated CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent. In some embodiments, activated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits a decrease that is no more than about a 1% decrease, 2% decrease, 3% decrease, 4% decrease, 5% decrease, 6% decrease, 7% decrease, 8% decrease, 9% decrease, 10% decrease, 11% decrease, 12% decrease, 13% decrease, 14% decrease, or 15% decrease in LAG3 surface expression, relative activated to CD4<sup>+</sup> or CD8<sup>+</sup> T-cells treated with a control agent.

**[0146]** In some embodiments, the GAL9 antigen binding molecule decreases surface expression of one or more costimulatory molecules on immune cells, e.g., human immune cells. In certain embodiments, the GAL9 antigen binding molecule decreases surface expression of the one or more costimulatory molecules in activated immune cells. In particular embodiments, the activated immune cells are T cells. In specific embodiments, the activated immune cells are CD8<sup>+</sup> T cells. In some embodiments, the one or more costimulatory molecules is selected from 4-1BB, CD40L, and OX40. In some embodiments, the one or more costimulatory molecules is selected from 4-1BB and CD40L. In some embodiments, the costimulatory molecule is OX40.

**[0147]** The impact of the GAL9 antigen binding molecule on surface expression of the one or more costimulatory molecules may be determined by any suitable means. For instance, the impact of the GAL9 antigen binding molecule on surface expression of the one or more costimulatory molecules may be determined in vivo, ex vivo, or in vitro.

**[0148]** In some embodiments, the GAL9 antigen binding molecule decreases surface expression of the one or more costimulatory molecules on activated immune cells as compared to activated immune cells treated with a control agent. Exemplary control agents are described herein. In particular embodiments, a control agent is an isotype control binding molecule that does not bind GAL9.

**[0149]** In some embodiments, the GAL9 antigen binding molecule decreases 4-1BB surface expression on activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with the control agent. In some embodiments, activated CD8<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits at least about a 0.1X decrease, 0.2X decrease, 0.3X decrease, 0.4X decrease, 0.5X decrease, or a 0.6X decrease in 4-1BB surface expression, relative to activated

CD8<sup>+</sup> T-cells treated with the control agent. In some embodiments, activated CD8<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits about a 0.1X-.2X decrease, 0.2X-.3X decrease, 0.3X-0.4X decrease, 0.4X-0.5X decrease, or a 0.5X-0.6X decrease in 4-1BB surface expression, relative to activated CD8<sup>+</sup> T-cells treated with the control agent.

**[0150]** In some embodiments, the GAL9 antigen binding molecule decreases CD40L surface expression of activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with the control agent. In some embodiments, activated CD8<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits at least about a 0.1X decrease, 0.2X decrease, 0.3X decrease, 0.4X decrease, or a 0.5X decrease in CD40L surface expression relative to activated CD8<sup>+</sup> T-cells treated with the control agent. In some embodiments, activated CD8<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits about a 0.1X-.2X decrease, 0.2X-.3X decrease, 0.3X-0.4X decrease, or a 0.4X-0.5X decrease in CD40L surface expression, relative to activated CD8<sup>+</sup> T-cells treated with the control agent.

**[0151]** In some embodiments, the GAL9 antigen binding molecule decreases OX40 surface expression of activated CD8<sup>+</sup> T-cells, relative to activated CD8<sup>+</sup> T-cells treated with the control agent. In some embodiments, activated CD8<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits about at least a 0.1X decrease, 0.2X decrease, 0.3X decrease, 0.4X decrease, 0.5X decrease, or a 0.6X decrease in OX40 surface expression relative to activated CD8<sup>+</sup> T-cells treated with the control agent. In some embodiments, activated CD8<sup>+</sup> T-cells treated with the GAL9 antigen binding molecule exhibits about a 0.1X-.2X decrease, 0.2X-.3X decrease, 0.3X-0.4X decrease, 0.4X-0.5X decrease, or a 0.5X-0.6X decrease in OX40 surface expression, relative to activated CD8<sup>+</sup> T-cells treated with the control agent.

**[0152]** The disclosure also provides for GAL9 antigen binding molecules that have various clinical benefits that improve the health of a subject with an autoimmune or inflammatory disease. The subject can be a mammal. The mammal can be a mouse. In some embodiments, the mammal is a human.

**[0153]** In some embodiments, the GAL9 antigen binding molecule reduces an autoimmune response in a subject. In some embodiments, the GAL9 antigen binding molecule reduces inflammation in the subject. Inflammation can be systemic or localized in an organ or tissue. In some embodiments, the GAL9 antigen binding molecule prolongs remission of a disease or condition in a subject. In some embodiments, the GAL9 antigen binding molecule induces remission in a subject. In some embodiments, the GAL9 antigen binding molecule re-establishes immune tolerance (e.g., improved cytokine profile or environment) in a subject.

Re-establishing immune tolerance can be a decrease in a proinflammatory cytokine, an increase in an inhibitory cytokine, or a combination thereof. In some embodiments, the GAL9 antigen binding molecule improves organ function in a subject. In some embodiments, the GAL9 antigen binding molecule reduces the risk/likelihood of disease progression or development of a second disease, such as cancer or an infection. In some embodiments, the GAL9 antigen binding molecule increases the overall survival of a subject.

#### **6.4.2. Variable Regions**

[0154] In typical embodiments, the GAL9 binding molecules have variable region domain amino acid sequences of an antibody, including VH and VL antibody domain sequences. VH and VL sequences are described in greater detail below in **Sections 6.4.2.1 and 6.4.2.2**, respectively.

##### **6.4.2.1. VH Regions**

[0155] In typical embodiments, the GAL9 binding molecules described herein comprise antibody heavy chain variable domain sequences. In a typical antibody arrangement in both nature and in the GAL9 binding molecules described herein, a specific VH amino acid sequence associates with a specific VL amino acid sequence to form an antigen-binding site. In various embodiments, VH amino acid sequences are mammalian sequences, including human sequences, synthesized sequences, or combinations of non-human mammalian, mammalian, and/or synthesized sequences, as described in further detail above in **Sections 6.4.2.3 and 6.4.2.4**. In various embodiments, VH amino acid sequences are mutated sequences of naturally occurring sequences.

##### **6.4.2.2. VL Regions**

[0156] The VL amino acid sequences useful in the GAL9 binding molecules described herein are antibody light chain variable domain sequences. In a typical arrangement in both natural antibodies and the antibody constructs described herein, a specific VL amino acid sequence associates with a specific VH amino acid sequence to form an antigen-binding site. In various embodiments, the VL amino acid sequences are mammalian sequences, including human sequences, synthesized sequences, or combinations of human, non-human mammalian, mammalian, and/or synthesized sequences, as described in further detail below in **Sections 6.4.2.3 and 6.4.2.4**.

[0157] In various embodiments, VL amino acid sequences are mutated sequences of naturally occurring sequences. In certain embodiments, the VL amino acid sequences are lambda ( $\lambda$ ) light chain variable domain sequences. In certain embodiments, the VL amino acid sequences are kappa ( $\kappa$ ) light chain variable domain sequences. In a preferred embodiment, the VL amino acid sequences are kappa ( $\kappa$ ) light chain variable domain sequences.

#### 6.4.2.3. Complementarity Determining Regions

[0158] The VH and VL amino acid sequences comprise highly variable sequences termed “**complementarity determining regions**” (CDRs), typically three CDRs (CDR1, CDR2, and CDR3). In a variety of embodiments, the CDRs are mammalian sequences, including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CDRs are human sequences. In various embodiments, the CDRs are naturally occurring sequences. In various embodiments, the CDRs are naturally occurring sequences that have been mutated to alter the binding affinity of the antigen-binding site for a particular antigen or epitope. In certain embodiments, the naturally occurring CDRs have been mutated in an *in vivo* host through affinity maturation and somatic hypermutation. In certain embodiments, the CDRs have been mutated *in vitro* through methods including, but not limited to, PCR-mutagenesis and chemical mutagenesis. In various embodiments, the CDRs are synthesized sequences including, but not limited to, CDRs obtained from random sequence CDR libraries and rationally designed CDR libraries. Martin numbering scheme was used to determine the CDR boundaries. See **FIGs. 1A-1B** as applied to the P9-01 anti-human GAL9 candidate provided herein.

[0159] In various embodiments, CDRs identified as binding an antigen of interest are further mutated (*i.e.*, “affinity matured”) to achieve a desired binding characteristic, such as an increased affinity for the antigen of interest relative to the original CDR. For example, targeted introduction of diversity into the CDRs, including those CDRs identified to bind an antigen of interest, can be introduced using degenerate oligonucleotides. Various randomization schemes can be employed. For example, “soft-randomization” can be used that provides a high bias towards the identity of wild-type sequence at a given amino acid position, such as allowing a given position in CDRs to vary among all twenty amino acids while biasing towards the wild-type sequence by doping the four bases at each codon position at non-equivalent level. As an illustrative example of soft-randomization, if achieving approximately 50% of the wild-type sequence is desired, each base of each codon is kept 70% wild-type and 10% each of other nucleotides and the degenerate oligonucleotides are

used to make a focused phage library around the selected CDRs with the resulting phage particles used for phage panning under various stringent selection conditions depending on the need.

#### **6.4.2.4. Framework Regions and CDR Grafting**

**[0160]** The VH and VL amino acid sequences comprise “framework region” (FR) sequences. FRs are generally conserved sequence regions that act as a scaffold for interspersed CDRs (see **Section 6.4.2.3**), typically in a FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 arrangement (from N-terminus to C-terminus). In a variety of embodiments, the FRs are mammalian sequences, including, but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the FRs are human sequences. In various embodiments, the FRs are naturally occurring sequences. In various embodiments, the FRs are synthesized sequences including, but not limited, rationally designed sequences.

**[0161]** In a variety of embodiments, the FRs and the CDRs are both from the same naturally occurring variable domain sequence. In a variety of embodiments, the FRs and the CDRs are from different variable domain sequences, wherein the CDRs are grafted onto the FR scaffold with the CDRs providing specificity for a particular antigen. In certain embodiments, the grafted CDRs are all derived from the same naturally occurring variable domain sequence. In certain embodiments, the grafted CDRs are derived from different variable domain sequences. In certain embodiments, the grafted CDRs are synthesized sequences including, but not limited to, CDRs obtained from random sequence CDR libraries and rationally designed CDR libraries. In certain embodiments, the grafted CDRs and the FRs are from the same species. In certain embodiments, the grafted CDRs and the FRs are from different species. In a preferred grafted CDR embodiment, an antibody is “humanized”, wherein the grafted CDRs are non-human mammalian sequences including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, and goat sequences, and the FRs are human sequences. Humanized antibodies are discussed in more detail in U.S. Pat. No. 6,407,213, the entirety of which is hereby incorporated by reference for all it teaches. In various embodiments, portions or specific sequences of FRs from one species are used to replace portions or specific sequences of another species’ FRs.

### 6.4.3. Exemplary amino acid sequences of the GAL9 binding molecules

[0162] In various embodiments, the GAL9 binding molecule comprises a particular VH CDR3 (CDR-H3) sequence and a particular VL CDR3 (CDR-L3) sequence.

[0163] In some embodiments, the GAL9 binding molecule comprises the CDR-H3 and the CDR-L3 from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57. VH CDR amino acid sequences of the ABS clones are disclosed in Table 3. VL CDR amino acid sequences of the ABS clones are disclosed in **Table 4**. For clarity, each GAL9 ABS clone is assigned a unique ABS clone number which is used throughout this disclosure.

[0164] In one currently preferred embodiment, the GAL9 binding molecule comprises the CDR-H3 and CDR-L3 of ABS clone P9-11.

[0165] In some embodiments, the GAL9 binding molecule comprises all three VH CDRs from one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57. In one currently preferred embodiment, the GAL9 binding molecule comprises all three VH CDRs from ABS clone P9-11.

[0166] In some embodiments, the GAL9 binding molecule comprises all three VL CDRs from one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57. In one currently preferred embodiment, the GAL9 binding molecule comprises all three VL CDRs from ABS clone P9-11.

[0167] In some embodiments, the GAL9 binding molecule comprises all six CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57. In one currently preferred embodiment, the GAL9 binding molecule comprises all six CDRs from ABS clone P9-11.

[0168] In some embodiments, the GAL9 binding molecule comprises a VH amino acid sequence, a VL amino acid sequence, or a VH and VL amino acid sequence from any one of

the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57. Full immunoglobulin heavy chain and immunoglobulin light chain sequences, as well as VH and VL amino acid sequences, are provided in Table 6. In one currently preferred embodiment, the GAL9 binding molecule comprises a VH amino acid sequence, a VL amino acid sequence, or a VH and VL amino acid sequence from ABS clone P9-11.

**[0169]** In some embodiments, the GAL9 binding molecule comprises the full IgG heavy chain sequence and the full IgG light chain sequence from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57. In one currently preferred embodiment, the GAL9 binding molecule comprises the full IgG heavy chain sequence and the full IgG light chain sequence from ABS clone P9-11.

#### **6.4.4. Constant Regions**

**[0170]** In some embodiments, the GAL9 binding molecules comprise an antibody constant region domain sequence. Constant region domain amino acid sequences, as described herein, are sequences of a constant region domain of an antibody. Constant regions can refer to CH1, CH2, CH3, CH4, or CL constant domain.

**[0171]** In a variety of embodiments, the constant region sequences are mammalian sequences, including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the constant region sequences are human sequences. In certain embodiments, the constant region sequences are from an antibody light chain. In particular embodiments, the constant region sequences are from a lambda or kappa light chain. In certain embodiments, the constant region sequences are from an antibody heavy chain. In particular embodiments, the constant region sequences are an antibody heavy chain sequence that is an IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM isotype. In a specific embodiment, the constant region sequences are from an IgG isotype. In a preferred embodiment, the constant region sequences are from an IgG1 isotype.

**[0172]** Exemplary constant regions and modifications thereof are described in WO2018075692, which is hereby incorporated by reference in its entirety.

#### 6.4.4.1. CH1 and CL Regions

[0173] CH1 amino acid sequences, as described herein, are sequences of the second domain of an antibody heavy chain, with reference from the N-terminus to C-terminus of a native antibody heavy chain architecture. In certain embodiments, the CH1 sequences are endogenous sequences. In a variety of embodiments, the CH1 sequences are mammalian sequences, including, but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CH1 sequences are human sequences. In certain embodiments, the CH1 sequences are from an IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM isotype. In a preferred embodiment, the CH1 sequences are from an IgG1 isotype. In preferred embodiments, the CH1 sequence is UniProt accession number P01857 amino acids 1-98.

[0174] The CL amino acid sequences useful in the GAL9 binding molecules described herein are antibody light chain constant domain sequences, with reference to a native antibody light chain architecture. In certain embodiments, the CL sequences are endogenous sequences. In a variety of embodiments, the CL sequences are mammalian sequences, including, but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, CL sequences are human sequences.

[0175] In certain embodiments, the CL amino acid sequences are lambda ( $\lambda$ ) light chain constant domain sequences. In particular embodiments, the CL amino acid sequences are human lambda light chain constant domain sequences. In preferred embodiments, the lambda ( $\lambda$ ) light chain sequence is UniProt accession number P0CG04.

[0176] In certain embodiments, the CL amino acid sequences are kappa ( $\kappa$ ) light chain constant domain sequences. In a preferred embodiment, the CL amino acid sequences are human kappa ( $\kappa$ ) light chain constant domain sequences. In a preferred embodiment, the kappa light chain sequence is UniProt accession number P01834.

[0177] In certain embodiments, the CH1 sequence and the CL sequences are both endogenous sequences. In certain embodiments, the CH1 sequence and the CL sequences separately comprise respectively orthogonal modifications in endogenous CH1 and CL sequences, as discussed below in greater detail in **Section 6.4.4.1**. CH1 and CL sequences can also be portions thereof, either of an endogenous or modified sequence, such that a domain having the CH1 sequence, or portion thereof, can associate with a domain having the CL sequence, or portion thereof.

#### 6.4.4.2. CH1 and CL Orthogonal Modifications

[0178] In certain embodiments, the CH1 sequence and the CL sequences separately comprise respectively orthogonal modifications in endogenous CH1 and CL sequences. Orthogonal mutations, in general, are described in more detail below in **Sections 6.4.6.1-6.4.6.3**.

[0179] In particular embodiments, the orthogonal modifications in endogenous CH1 and CL sequences are an engineered disulfide bridge selected from engineered cysteines at position 138 of the CH1 sequence and position 116 of the CL sequence, at position 128 of the CH1 sequence and position 119 of the CL sequence, or at position 129 of the CH1 sequence and position 210 of the CL sequence, as numbered and discussed in more detail in U.S. Pat. No. 8,053,562 and U.S. Pat. No. 9,527,927, each incorporated herein by reference in its entirety. In a preferred embodiment, the engineered cysteines are at position 128 of the CH1 sequence and position 118 of the CL Kappa sequence, as numbered by the Eu index.

[0180] In a series of preferred embodiments, the mutations that provide non-endogenous cysteine amino acids are a F118C mutation in the CL sequence with a corresponding A141C in the CH1 sequence, or a F118C mutation in the CL sequence with a corresponding L128C in the CH1 sequence, or a S162C mutations in the CL sequence with a corresponding P171C mutation in the CH1 sequence, as numbered by the Eu index.

[0181] In a variety of embodiments, the orthogonal mutations in the CL sequence and the CH1 sequence are charge-pair mutations. In specific embodiments the charge-pair mutations are a F118S, F118A or F118V mutation in the CL sequence with a corresponding A141L in the CH1 sequence, or a T129R mutation in the CL sequence with a corresponding K147D in the CH1 sequence, as numbered by the Eu index and described in greater detail in Bonisch *et al.* (*Protein Engineering, Design & Selection*, 2017, pp. 1–12), herein incorporated by reference for all that it teaches. In a series of preferred embodiments, the charge-pair mutations are a N138K mutation in the CL sequence with a corresponding G166D in the CH1 sequence, or a N138D mutation in the CL sequence with a corresponding G166K in the CH1 sequence, as numbered by the Eu index.

#### 6.4.4.3. CH2 Regions

[0182] In the GAL9 binding molecules described herein, the GAL9 binding molecules can have a CH2 amino acid sequence. CH2 amino acid sequences, as described herein, are CH2 amino acid sequences of the third domain of an antibody heavy chain, with reference from the N-terminus to C-terminus of a native antibody heavy chain architecture. In a variety of

embodiments, the CH2 sequences are mammalian sequences, including but not limited to mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CH2 sequences are human sequences. In certain embodiments, the CH2 sequences are from an IgA1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM isotype. In a preferred embodiment, the CH2 sequences are from an IgG1 isotype.

**[0183]** In certain embodiments, the CH2 sequences are endogenous sequences. In particular embodiments, the sequence is UniProt accession number P01857 amino acids 111-223.

**[0184]** In a series of embodiments, a GAL9 binding molecule has more than one paired set of CH2 domains that have CH2 sequences, wherein a first set has CH2 amino acid sequences from a first isotype and one or more orthologous sets of CH2 amino acid sequences from another isotype. The orthologous CH2 amino acid sequences, as described herein, are able to interact with CH2 amino acid sequences from a shared isotype, but not significantly interact with the CH2 amino acid sequences from another isotype present in the GAL9 binding molecule. In particular embodiments, all sets of CH2 amino acid sequences are from the same species. In preferred embodiments, all sets of CH2 amino acid sequences are human CH2 amino acid sequences. In other embodiments, the sets of CH2 amino acid sequences are from different species. In particular embodiments, the first set of CH2 amino acid sequences is from the same isotype as the other non-CH2 domains in the GAL9 binding molecule. In a specific embodiment, the first set has CH2 amino acid sequences from an IgG isotype and the one or more orthologous sets have CH2 amino acid sequences from an IgM or IgE isotype. In certain embodiments, one or more of the sets of CH2 amino acid sequences are endogenous CH2 sequences. In other embodiments, one or more of the sets of CH2 amino acid sequences are endogenous CH2 sequences that have one or more mutations. In particular embodiments, the one or more mutations are orthogonal knob-hole mutations, orthogonal charge-pair mutations, or orthogonal hydrophobic mutations. Orthologous CH2 amino acid sequences useful for the GAL9 binding molecules are described in more detail in international PCT applications WO2017/011342 and WO2017/106462, herein incorporated by reference in their entirety.

#### **6.4.4.4. CH3 Regions**

**[0185]** CH3 amino acid sequences, as described herein, are sequences of the C-terminal domain of an antibody heavy chain, with reference from the N-terminus to C-terminus of a native antibody heavy chain architecture.

[0186] In a variety of embodiments, the CH3 sequences are mammalian sequences, including, but not limited to, mouse, rat, hamster, rabbit, camel, donkey, goat, and human sequences. In a preferred embodiment, the CH3 sequences are human sequences. In certain embodiments, the CH3 sequences are from an IgA1, IgA2, IgD, IgE, IgM, IgG1, IgG2, IgG3, IgG4 isotype or CH4 sequences from an IgE or IgM isotype. In a specific embodiment, the CH3 sequences are from an IgG isotype. In a preferred embodiment, the CH3 sequences are from an IgG1 isotype.

[0187] In certain embodiments, the CH3 sequences are endogenous sequences. In particular embodiments, the CH3 sequence is UniProt accession number P01857 amino acids 224-330. In various embodiments, a CH3 sequence is a segment of an endogenous CH3 sequence. In particular embodiments, a CH3 sequence has an endogenous CH3 sequence that lacks the N-terminal amino acids G224 and Q225. In particular embodiments, a CH3 sequence has an endogenous CH3 sequence that lacks the C-terminal amino acids P328, G329, and K330. In particular embodiments, a CH3 sequence has an endogenous CH3 sequence that lacks both the N-terminal amino acids G224 and Q225 and the C-terminal amino acids P328, G329, and K330. In preferred embodiments, a GAL9 binding molecule has multiple domains that have CH3 sequences, wherein a CH3 sequence can refer to both a full endogenous CH3 sequence as well as a CH3 sequence that lacks N-terminal amino acids, C-terminal amino acids, or both.

[0188] In certain embodiments, the CH3 sequences are endogenous sequences that have one or more mutations. In particular embodiments, the mutations are one or more orthogonal mutations that are introduced into an endogenous CH3 sequence to guide specific pairing of specific CH3 sequences, as described in more detail below in **Sections 6.4.6.1-6.4.6.3**.

[0189] In certain embodiments, the CH3 sequences are engineered to reduce immunogenicity of the antibody by replacing specific amino acids of one allotype with those of another allotype and referred to herein as isoallotype mutations, as described in more detail in Stickler *et al.* (*Genes Immun.* 2011 Apr; 12(3): 213–221), which is herein incorporated by reference for all that it teaches. In particular embodiments, specific amino acids of the G1m1 allotype are replaced. In a preferred embodiment, isoallotype mutations D356E and L358M are made in the CH3 sequence.

[0190] In some embodiments, an IgG1 CH3 amino acid sequence comprises the following mutational changes: P343V; Y349C; and a tripeptide insertion, 445P, 446G, 447K. In other preferred embodiments, domain B has a human IgG1 CH3 sequence with the following

mutational changes: T366K; and a tripeptide insertion, 445K, 446S, 447C. In still other preferred embodiments, domain B has a human IgG1 CH3 sequence with the following mutational changes: Y349C and a tripeptide insertion, 445P, 446G, 447K.

[0191] In some embodiments, an IgG1 CH3 amino acid sequence comprises a 447C mutation incorporated into an otherwise endogenous CH3 sequence.

#### **6.4.5. Antigen Binding Sites**

[0192] In some embodiments, a VL or VH amino acid sequence and a cognate VL or VH amino acid sequence are associated and form a first antigen binding site (ABS). The antigen binding site (ABS) is capable of specifically binding an epitope of an antigen. Antigen binding by an ABS is described in greater detail below in **Section 6.4.5.1**.

[0193] In alternative embodiments, e.g., wherein the GAL9 binding molecule is a single domain antibody, a VH or VL amino acid sequence forms the first ABS.

[0194] In some embodiments, the GAL9 antigen binding molecule comprises a second ABS. In some embodiments, the second ABS is specific for the same GAL9 antigen as the first ABS. In some embodiments, the second ABS specifically binds the same epitope of the same GAL9 antigen as the first ABS. In some embodiments, the second ABS is identical to the first ABS.

[0195] In some embodiments, the second ABS is specific for a different epitope of the first GAL9 antigen. For example if the first ABS comprises CDRs or variable domains from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57. The second ABS may comprise CDRs or variable domains from another ABS clone selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.

[0196] In some embodiments, the GAL9 antigen binding molecule is multispecific, e.g., the second ABS of the GAL9 antigen binding molecule specifically binds an antigen that is different than the GAL9 antigen specifically bound by the first ABS.

##### **6.4.5.1. Binding of Antigen by ABS**

[0197] An ABS, and the GAL9 binding molecule comprising such ABS, is said to “**recognize**” the epitope (or more generally, the antigen) to which the ABS specifically binds, and the epitope (or more generally, the antigen) is said to be the “**recognition specificity**” or “**binding specificity**” of the ABS.

[0198] The ABS is said to bind to its specific antigen or epitope with a particular affinity. As described herein, “**affinity**” refers to the strength of interaction of non-covalent intermolecular forces between one molecule and another. The affinity, i.e. the strength of the interaction, can be expressed as a dissociation equilibrium constant ( $K_D$ ), wherein a lower  $K_D$  value refers to a stronger interaction between molecules.  $K_D$  values of antibody constructs are measured by methods well known in the art including, but not limited to, bio-layer interferometry (*e.g.*, Octet/FORTEBIO<sup>®</sup>), surface plasmon resonance (SPR) technology (*e.g.*, Biacore<sup>®</sup>), and cell binding assays. For purposes herein, affinities are dissociation equilibrium constants measured by bio-layer interferometry using Octet/FORTEBIO<sup>®</sup>.

[0199] “**Specific binding**,” as used herein, refers to an affinity between an ABS and its cognate antigen or epitope in which the  $K_D$  value is below  $10^{-6}M$ ,  $10^{-7}M$ ,  $10^{-8}M$ ,  $10^{-9}M$ , or  $10^{-10}M$ .

[0200] The number of ABSs in a GAL9 binding molecule as described herein defines the “**valency**” of the GAL9 binding molecule. A GAL9 binding molecule having a single ABS is “**monovalent**”. A GAL9 binding molecule having a plurality of ABSs is said to be “**multivalent**”. A multivalent GAL9 binding molecule having two ABSs is “**bivalent**.” A multivalent GAL9 binding molecule having three ABSs is “**trivalent**.” A multivalent GAL9 binding molecule having four ABSs is “**tetravalent**.”

[0201] In various multivalent embodiments, all of the plurality of ABSs have the same recognition specificity. Such a GAL9 binding molecule is a “**monospecific**” “multivalent” binding construct. In other multivalent embodiments, at least two of the plurality of ABSs have different recognition specificities. Such GAL9 binding molecules are multivalent and “**multispecific**”. In multivalent embodiments in which the ABSs collectively have two recognition specificities, the GAL9 binding molecule is “**bispecific**.” In multivalent embodiments in which the ABSs collectively have three recognition specificities, the GAL9 binding molecule is “**trispecific**.”

[0202] In multivalent embodiments in which the ABSs collectively have a plurality of recognition specificities for different epitopes present on the same antigen, the GAL9 binding

molecule is “**multiparatopic**.” Multivalent embodiments in which the ABSs collectively recognize two epitopes on the same antigen are “**biparatopic**.”

**[0203]** In various multivalent embodiments, multivalency of the GAL9 binding molecule improves the avidity of the GAL9 binding molecule for a specific target. As described herein, “**avidity**” refers to the overall strength of interaction between two or more molecules, e.g., a multivalent GAL9 binding molecule for a specific target, wherein the avidity is the cumulative strength of interaction provided by the affinities of multiple ABSs. Avidity can be measured by the same methods as those used to determine affinity, as described above. In certain embodiments, the avidity of a GAL9 binding molecule for a specific target is such that the interaction is a specific binding interaction, wherein the avidity between two molecules has a  $K_D$  value below  $10^{-6}M$ ,  $10^{-7}M$ ,  $10^{-8}M$ ,  $10^{-9}M$ , or  $10^{-10}M$ . In certain embodiments, the avidity of a GAL9 binding molecule for a specific target has a  $K_D$  value such that the interaction is a specific binding interaction, wherein the one or more affinities of individual ABSs do not have a  $K_D$  value that qualifies as specifically binding their respective antigens or epitopes on their own. In certain embodiments, the avidity is the cumulative strength of interaction provided by the affinities of multiple ABSs for separate antigens on a shared specific target or complex, such as separate antigens found on an individual cell. In certain embodiments, the avidity is the cumulative strength of interaction provided by the affinities of multiple ABSs for separate epitopes on a shared individual antigen.

#### **6.4.6. Orthogonal Modifications**

**[0204]** In the GAL9 binding molecules described herein, a GAL9 binding molecule can have constant region domains comprising orthogonal modifications. Constant region domain amino acid sequences are described in greater detail above in **Section 6.4.4**.

**[0205]** “Orthogonal modifications” or synonymously “orthogonal mutations” as described herein are one or more engineered mutations in an amino acid sequence of an antibody domain that increase the affinity of binding of a first domain having orthogonal modification for a second domain having a complementary orthogonal modification. In certain embodiments, the orthogonal modifications decrease the affinity of a domain having the orthogonal modifications for a domain lacking the complementary orthogonal modifications. In certain embodiments, orthogonal modifications are mutations in an endogenous antibody domain sequence. In a variety of embodiments, orthogonal modifications are modifications of

the N-terminus or C-terminus of an endogenous antibody domain sequence including, but not limited to, amino acid additions or deletions. In particular embodiments, orthogonal modifications include, but are not limited to, engineered disulfide bridges, knob-in-hole mutations, and charge-pair mutations, as described in greater detail below in **Sections 6.4.6.1-6.4.6.3**. In particular embodiments, orthogonal modifications include a combination of orthogonal modifications selected from, but not limited to, engineered disulfide bridges, knob-in-hole mutations, and charge-pair mutations. In particular embodiments, the orthogonal modifications can be combined with amino acid substitutions that reduce immunogenicity, such as isoallotype mutations, as described in greater detail above in **Section 6.4.4.4**.

#### **6.4.6.1. Orthogonal Engineered Disulfide Bridges**

[0206] In a variety of embodiments, the orthogonal modifications comprise mutations that generate engineered disulfide bridges between a first and a second domain. As described herein, “**engineered disulfide bridges**” are mutations that provide non-endogenous cysteine amino acids in two or more domains such that a non-native disulfide bond forms when the two or more domains associate. Engineered disulfide bridges are described in greater detail in Merchant *et al.* (*Nature Biotech* (1998) 16:677-681), the entirety of which is hereby incorporated by reference for all it teaches. In certain embodiments, engineered disulfide bridges improve orthogonal association between specific domains. In a particular embodiment, the mutations that generate engineered disulfide bridges are a K392C mutation in one of a first or second CH3 domains, and a D399C in the other CH3 domain. In a preferred embodiment, the mutations that generate engineered disulfide bridges are a S354C mutation in one of a first or second CH3 domains, and a Y349C in the other CH3 domain. In another preferred embodiment, the mutations that generate engineered disulfide bridges are a 447C mutation in both the first and second CH3 domains that are provided by extension of the C-terminus of a CH3 domain incorporating a KSC tripeptide sequence.

#### **6.4.6.2. Orthogonal Knob-Hole Mutations**

[0207] In a variety of embodiments, orthogonal modifications comprise knob-hole (synonymously, knob-in-hole) mutations. As described herein, knob-hole mutations are mutations that change the steric features of a first domain’s surface such that the first domain will preferentially associate with a second domain having complementary steric mutations relative to association with domains without the complementary steric mutations. Knob-hole

mutations are described in greater detail in U.S. Pat. No. 5,821,333 and U.S. Pat. No. 8,216,805, each of which is incorporated herein in its entirety. In various embodiments, knob-hole mutations are combined with engineered disulfide bridges, as described in greater detail in Merchant *et al.* (*Nature Biotech* (1998) 16:677-681)), incorporated herein by reference in its entirety. In various embodiments, knob-hole mutations, isoallotype mutations, and engineered disulfide mutations are combined.

**[0208]** In certain embodiments, the knob-in-hole mutations are a T366Y mutation in a first domain, and a Y407T mutation in a second domain. In certain embodiments, the knob-in-hole mutations are a F405A in a first domain, and a T394W in a second domain. In certain embodiments, the knob-in-hole mutations are a T366Y mutation and a F405A in a first domain, and a T394W and a Y407T in a second domain. In certain embodiments, the knob-in-hole mutations are a T366W mutation in a first domain, and a Y407A in a second domain. In certain embodiments, the combined knob-in-hole mutations and engineered disulfide mutations are a S354C and T366W mutations in a first domain, and a Y349C, a T366S, a L368A, and a Y407V mutation in a second domain. In a preferred embodiment, the combined knob-in-hole mutations, isoallotype mutations, and engineered disulfide mutations are a S354C and T366W mutations in a first domain, and a Y349C, D356E, L358M, T366S, L368A, and a Y407V mutation in a second domain.

#### **6.4.6.3. Orthogonal Charge-pair Mutations**

**[0209]** In a variety of embodiments, orthogonal modifications are charge-pair mutations. As used herein, charge-pair mutations are mutations that affect the charge of an amino acid in a domain's surface such that the domain will preferentially associate with a second domain having complementary charge-pair mutations relative to association with domains without the complementary charge-pair mutations. In certain embodiments, charge-pair mutations improve orthogonal association between specific domains. Charge-pair mutations are described in greater detail in U.S. Pat. No. 8,592,562, U.S. Pat. No. 9,248,182, and U.S. Pat. No. 9,358,286, each of which is incorporated by reference herein for all they teach. In certain embodiments, charge-pair mutations improve stability between specific domains. In a preferred embodiment, the charge-pair mutations are a T366K mutation in a first domain, and a L351D mutation in the other domain.

**[0210]** In specific embodiments, the orthogonal mutations are charge-pair mutations at the VH/VL interface. In preferred embodiments, the charge-pair mutations at the VH/VL

interface are a Q39E in VH with a corresponding Q38K in VL, or a Q39K in VH with a corresponding Q38E in VL, as described in greater detail in Igawa *et al.* (*Protein Eng. Des. Sel.*, 2010, vol. 23, 667–677), herein incorporated by reference for all it teaches.

#### **6.4.7. Trivalent and Tetravalent GAL9 binding molecules**

[0211] In another series of embodiments, the GAL9 binding molecules have three antigen binding sites and are therefore termed “**trivalent.**” In a variety of embodiments, the GAL9 binding molecules have 4 antigen binding sites and are therefore termed “**tetravalent.**”

#### **6.5. GAL9 binding molecule architecture**

[0212] The antigen binding sites described herein, including specific CDR subsets, can be formatted into any binding molecule architecture including, but not limited to, full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, camelid VHH, and other antibody fragments or formats known to those skilled in the art. Exemplary antibody and antibody fragment formats are described in detail in Brinkmann *et al.* (*MABS*, 2017, Vol. 9, No. 2, 182–212), herein incorporated by reference for all that it teaches. The antigen binding sites described herein, including specific CDR subsets, can also be formatted into a “B-body” format, as described in more detail in US pre-grant publication no. US 2018/0118811 and International Application Pub. No. WO 2018/075692, each of which is herein incorporated by reference in their entireties.

#### **6.6. Further modifications**

[0213] In a further series of embodiments, the GAL9 binding molecule has additional modifications.

##### **6.6.1. Antibody-Drug Conjugates**

[0214] In various embodiments, the GAL9 binding molecule is conjugated to a therapeutic agent (i.e. drug) to form a GAL9 binding molecule-drug conjugate. Therapeutic agents include, but are not limited to, chemotherapeutic agents, imaging agents (e.g. radioisotopes), immune modulators (e.g. cytokines, chemokines, or checkpoint inhibitors), and toxins (e.g. cytotoxic agents). In certain embodiments, the therapeutic agents are attached to the GAL9 binding molecule through a linker peptide, as discussed in more detail below in **Section 6.6.3.**

[0215] Methods of preparing antibody-drug conjugates (ADCs) that can be adapted to conjugate drugs to the GAL9 binding molecules disclosed herein are described, e.g., in US patent no. 8,624,003 (pot method), US patent no. 8,163,888 (one-step), US patent no. 5,208,020 (two-step method), US patent No. 8,337,856, US patent no. 5,773,001, US patent no. 7,829,531, US patent no. 5,208,020, US patent no. 7,745,394, WO 2017/136623, WO 2017/015502, WO 2017/015496, WO 2017/015495, WO 2004/010957, WO 2005/077090, WO 2005/082023, WO 2006/065533, WO 2007/030642, WO 2007/103288, WO 2013/173337, WO 2015/057699, WO 2015/095755, WO 2015/123679, WO 2015/157286, WO 2017/165851, WO 2009/073445, WO 2010/068759, WO 2010/138719, WO 2012/171020, WO 2014/008375, WO 2014/093394, WO 2014/093640, WO 2014/160360, WO 2015/054659, WO 2015/195925, WO 2017/160754, Storz (*MAbs*, 2015 Nov-Dec; 7(6): 989–1009), Lambert *et al.* (*Adv Ther*, 2017 34: 1015), Diamantis *et al.* (*British Journal of Cancer*, 2016, 114, 362–367), Carrico *et al.* (*Nat Chem Biol*, 2007. 3: 321-2), We *et al.* (*Proc Natl Acad Sci USA*, 2009. 106: 3000-5), Rabuka *et al.* (*Curr Opin Chem Biol.*, 2011 14: 790-6), Hudak *et al.* (*Angew Chem Int Ed Engl.*, 2012: 4161-5), Rabuka *et al.* (*Nat Protoc.*, 2012 7:1052-67), Agarwal *et al.* (*Proc Natl Acad Sci USA.*, 2013, 110: 46-51), Agarwal *et al.* (*Bioconjugate Chem.*, 2013, 24: 846–851), Barfield *et al.* (*Drug Dev. and D.*, 2014, 14:34-41), Drake *et al.* (*Bioconjugate Chem.*, 2014, 25:1331-41), Liang *et al.* (*J Am Chem Soc.*, 2014, 136:10850-3), Drake *et al.* (*Curr Opin Chem Biol.*, 2015, 28:174-80), and York *et al.* (*BMC Biotechnology*, 2016, 16(1):23), each of which is hereby incorporated by reference in its entirety for all that it teaches.

### 6.6.2. Additional Binding Moieties

[0216] In various embodiments, the GAL9 binding molecule has modifications that comprise one or more additional binding moieties. In certain embodiments the binding moieties are antibody fragments or antibody formats including, but not limited to, full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, camelid VHH, and other antibody fragments or formats known to those skilled in the art. Exemplary antibody and antibody fragment formats are described in detail in Brinkmann *et al.* (*MABS*, 2017, Vol. 9, No. 2, 182–212), herein incorporated by reference for all that it teaches.

[0217] In particular embodiments, the one or more additional binding moieties are attached to the C-terminus of the first or third polypeptide chain. In particular embodiments, the one or

more additional binding moieties are attached to the C-terminus of both the first and third polypeptide chain. In particular embodiments, the one or more additional binding moieties are attached to the C-terminus of both the first and third polypeptide chains. In certain embodiments, individual portions of the one or more additional binding moieties are separately attached to the C-terminus of the first and third polypeptide chains such that the portions form the functional binding moiety.

**[0218]** In particular embodiments, the one or more additional binding moieties are attached to the N-terminus of any of the polypeptide chains (e.g. the first, second, third, fourth, fifth, or sixth polypeptide chains). In certain embodiments, individual portions of the additional binding moieties are separately attached to the N-terminus of different polypeptide chains such that the portions form the functional binding moiety.

**[0219]** In certain embodiments, the one or more additional binding moieties are specific for a different antigen or epitope of the ABSs within the GAL9 binding molecule. In certain embodiments, the one or more additional binding moieties are specific for the same antigen or epitope of the ABSs within the GAL9 binding molecule. In certain embodiments, wherein the modification is two or more additional binding moieties, the additional binding moieties are specific for the same antigen or epitope. In certain embodiments, wherein the modification is two or more additional binding moieties, the additional binding moieties are specific for different antigens or epitopes.

**[0220]** In certain embodiments, the one or more additional binding moieties are attached to the GAL9 binding molecule using *in vitro* methods including, but not limited to, reactive chemistry and affinity tagging systems, as discussed in more detail below in **Section 6.6.3**. In certain embodiments, the one or more additional binding moieties are attached to the GAL9 binding molecule through Fc-mediated binding (e.g. Protein A/G). In certain embodiments, the one or more additional binding moieties are attached to the GAL9 binding molecule using recombinant DNA techniques, such as encoding the nucleotide sequence of the fusion product between the GAL9 binding molecule and the additional binding moieties on the same expression vector (e.g., plasmid).

### **6.6.3. Functional/Reactive Groups**

**[0221]** In various embodiments, the GAL9 binding molecule has modifications that comprise functional groups or chemically reactive groups that can be used in downstream processes, such as linking to additional moieties (e.g., drug conjugates and additional binding moieties,

as discussed in more detail above in **Sections 6.6.1.** and **6.6.2.**) and downstream purification processes.

**[0222]** In certain embodiments, the modifications are chemically reactive groups including, but not limited to, reactive thiols (e.g. maleimide based reactive groups), reactive amines (e.g., *N*-hydroxysuccinimide based reactive groups), “click chemistry” groups (e.g. reactive alkyne groups), and aldehydes bearing formylglycine (FGly). In certain embodiments, the modifications are functional groups including, but not limited to, affinity peptide sequences (e.g., HA, HIS, FLAG, GST, MBP, and Strep systems etc.). In certain embodiments, the functional groups or chemically reactive groups have a cleavable peptide sequence. In particular embodiments, the cleavable peptide is cleaved by means including, but not limited to, photocleavage, chemical cleavage, protease cleavage, reducing conditions, and pH conditions. In particular embodiments, protease cleavage is carried out by intracellular proteases. In particular embodiments, protease cleavage is carried out by extracellular or membrane associated proteases. ADC therapies adopting protease cleavage are described in more detail in Choi *et al.* (*Theranostics*, 2012; 2(2): 156–178.), which is hereby incorporated by reference for all it teaches.

#### **6.6.4. Reduced Effector Function**

**[0223]** In certain embodiments, the GAL9 binding molecule has one or more engineered mutations in an amino acid sequence of an antibody domain that reduce the effector functions naturally associated with antibody binding. Effector functions include, but are not limited to, cellular functions that result from an Fc receptor binding to an Fc portion of an antibody, such as antibody- dependent cellular cytotoxicity (ADCC, also referred to as antibody- dependent cell-mediated cytotoxicity), complement fixation (e.g. C1q binding), antibody dependent cellular-mediated phagocytosis (ADCP), and opsonization. Exemplary engineered mutations that reduce the effector functions are described in more detail in U.S. Pub. No. 2017/0137530, Armour, *et al.* (*Eur. J. Immunol.* 29(8) (1999) 2613-2624), Shields, *et al.* (*J. Biol. Chem.* 276(9) (2001) 6591-6604), and Oganessian, *et al.* (*Acta Crystallographica D* 64 (2008) 700-704), each of which are herein incorporated by reference in its entirety.

#### **6.7. Methods of Purification**

**[0224]** Methods of purifying a GAL9 binding molecule are provided herein. Purification steps include, but are not limited to, purifying the GAL9 binding molecules based on protein characteristics, such as size (e.g., size exclusion chromatography), charge (e.g., ion exchange

chromatography), or hydrophobicity (*e.g.*, hydrophobicity interaction chromatography). In one embodiment, cation exchange chromatography is performed. Other purification methods known to those skilled in the art can be performed including, but not limited to, use of Protein A, Protein G, or Protein A/G reagents. Multiple iterations of a single purification method can be performed. A combination of purification methods can be performed.

### 6.7.1. Assembly and Purity of Complexes

[0225] In the embodiments of the present invention, at least four distinct polypeptide chains associate together to form a complete complex, *i.e.*, the GAL9 binding molecule. However, incomplete complexes can also form that do not contain the at least four distinct polypeptide chains. For example, incomplete complexes may form that only have one, two, or three of the polypeptide chains. In other examples, an incomplete complex may contain more than three polypeptide chains, but does not contain the at least four distinct polypeptide chains, *e.g.*, the incomplete complex inappropriately associates with more than one copy of a distinct polypeptide chain. The method of the invention purifies the complex, *i.e.*, the completely assembled GAL9 binding molecule, from incomplete complexes.

[0226] Methods to assess the efficacy and efficiency of the purification steps are well known to those skilled in the art and include, but are not limited to, SDS-PAGE analysis, ion exchange chromatography, size exclusion chromatography, and mass spectrometry. Purity can also be assessed according to a variety of criteria. Examples of criterion include, but are not limited to: 1) assessing the percentage of the total protein in an eluate that is provided by the completely assembled GAL9 binding molecule, 2) assessing the fold enrichment or percent increase of the method for purifying the desired products, *e.g.*, comparing the total protein provided by the completely assembled GAL9 binding molecule in the eluate to that in a starting sample, 3) assessing the percentage of the total protein or the percent decrease of undesired products, *e.g.*, the incomplete complexes described above, including determining the percent or the percent decrease of specific undesired products (*e.g.*, unassociated single polypeptide chains, dimers of any combination of the polypeptide chains, or trimers of any combination of the polypeptide chains). Purity can be assessed after any combination of methods described herein.

### 6.8. Methods of Manufacturing

[0227] The GAL9 binding molecules described herein can readily be manufactured by expression using standard cell free translation, transient transfection, and stable transfection

approaches currently used for antibody manufacture. In specific embodiments, Expi293 cells (ThermoFisher) can be used for production of the GAL9 binding molecules using protocols and reagents from ThermoFisher, such as ExpiFectamine, or other reagents known to those skilled in the art, such as polyethylenimine as described in detail in Fang *et al.* (*Biological Procedures Online*, 2017, 19:11), herein incorporated by reference for all it teaches.

[0228] The expressed proteins can be readily separated from undesired proteins and protein complexes using various purification strategies including, but not limited to, use of Protein A, Protein G, or Protein A/G reagents. Further purification can be affected using ion exchange chromatography as is routinely used in the art.

### 6.9. Pharmaceutical Compositions

[0229] In another aspect, pharmaceutical compositions are provided that comprise a GAL9 binding molecule as described herein and a pharmaceutically acceptable carrier or diluent. In typical embodiments, the pharmaceutical composition is sterile.

[0230] In various embodiments, the pharmaceutical composition comprises the GAL9 binding molecule at a concentration of 0.1 mg/ml – 100 mg/ml. In specific embodiments, the pharmaceutical composition comprises the GAL9 binding molecule at a concentration of 0.5 mg/ml, 1 mg/ml, 1.5 mg/ml, 2 mg/ml, 2.5 mg/ml, 5 mg/ml, 7.5 mg/ml, or 10 mg/ml. In some embodiments, the pharmaceutical composition comprises the GAL9 binding molecule at a concentration of more than 10 mg/ml. In certain embodiments, the GAL9 binding molecule is present at a concentration of 20 mg/ml, 25 mg/ml, 30 mg/ml, 35 mg/ml, 40 mg/ml, 45 mg/ml, or even 50 mg/ml or higher. In particular embodiments, the GAL9 binding molecule is present at a concentration of more than 50 mg/ml.

[0231] In various embodiments, the pharmaceutical compositions are described in more detail in U.S. Pat No. 8,961,964, U.S. Pat No. 8,945,865, U.S. Pat No. 8,420,081, U.S. Pat No. 6,685,940, U.S. Pat No. 6,171,586, U.S. Pat No. 8,821,865, U.S. Pat No. 9,216,219, US application 10/813,483, WO 2014/066468, WO 2011/104381, and WO 2016/180941, each of which is incorporated herein in its entirety.

### 6.10. Methods of Treatment

[0232] In another aspect, methods of treatment are provided, the methods comprising administering a GAL9 binding molecule as described herein to a patient (e.g., subject) with a disease or condition in an amount effective (e.g., therapeutically effective amount) to treat the patient.

### **6.10.1. Subjects**

[0233] In some embodiments, the subject is a mammal. In some embodiments, the mammal is a mouse. In a preferred embodiment, the mammal is a human. In some embodiments, the subject's immune cells have increased PD-L2 expression, relative to immune cells from healthy individuals (e.g., healthy control), such as blood dendritic cells.

### **6.10.2. Combination therapy**

[0234] The GAL9 binding molecule can be used alone or in combination with other therapeutic agents or procedures to treat or prevent a disease or condition. The GAL9 binding molecule can be administered either simultaneously or sequentially dependent upon the disease or condition to be treated.

[0235] The anti-GAL9 binding molecules can be used in combination with an agent or procedure that is used in the clinic or is within the current standard of care to treat or prevent a disease or condition.

In some embodiments, the GAL9 binding molecule is administered in combination with a second immunosuppressive agent. In certain embodiments, the second immunosuppressive agent is a glucocorticoid (e.g, prednisone, dexamethasone, or hydrocortisone), a cytostatic, anti-cytokine antibodies including anti-TNF $\alpha$ , anti-IL1, anti-IL5, anti-IL-6, anti-IL-17 antibodies, and anti-IL-23 antibodies, and small molecule drugs that reduce inflammatory cytokine signaling, such as JAK/STAT inhibitors, methotrexate, hydroxychloroquine, chloroquine, an anti-CD25 or anti-CD52 antibody, or drugs acting on immunophilins (e.g., cyclosporine or Sirolimus, or any other drug known to inhibit or prevent activity of the immune system.

[0236] In some embodiments, the GAL9 binding molecule is administered in combination with one or more anti-inflammatory drugs.

### **6.10.3. Autoimmune or Inflammatory Diseases**

[0237] In some embodiments, the treatment comprises administration of a GAL9 binding molecule as described herein to a subject with an autoimmune or inflammatory disease in an amount effective to treat the subject.

[0238] In some embodiments, the autoimmune disease is amyotrophic lateral sclerosis (ALS), achalasia, Addison's disease, adult still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, Antiphospholipid

syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease, autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal & neuronal neuropathy (AMAN), Baló disease, Behcet's disease, benign mucosal pemphigoid, bullous pemphigoid, castleman disease, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, chronic recurrent multifocal osteomyelitis, Churg-Strauss Syndrome, Eosinophilic Granulomatosis, Cicatricial pemphigoid, Cogan's syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, dressler's syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), Herpes gestationis or pemphigoid gestationis (PG), Hidradenitis Suppurativa (HS) (Acne Inversa), Hypogammaglobulinemia, IgA Nephropathy, IgG4-related sclerosing disease, Immune thrombocytopenic purpura (ITP), Inclusion body myositis, Interstitial cystitis, Juvenile arthritis, Juvenile diabetes (Type 1 diabetes), Juvenile myositis, Kawasaki disease, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), lupus, lyme disease chronic, Meniere's disease, microscopic polyangiitis, mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, Paraneoplastic cerebellar degeneration (PCD), Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (pa), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II, or III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia, pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome, retroperitoneal

fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm & testicular autoimmunity, stiff person syndrome, subacute bacterial endocarditis, Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis, giant cell arteritis, thrombocytopenic purpura, Tolosa-Hunt syndrome, transverse myelitis, type 1 diabetes, ulcerative colitis, undifferentiated connective tissue disease, uveitis, vasculitis, vitiligo, or Vogt-Koyanagi-Harada disease.

**[0239]** In some embodiments, the autoimmune disease is selected from the group consisting of: inflammatory bowel disease, Crohn's disease, ulcerative colitis, colitis, celiac disease, rheumatoid arthritis, Behçet's disease, amyloidosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus nephritis, graft-versus-host disease (GVHD), nonalcoholic steatohepatitis (NASH), and ankylosing spondylitis. In a preferred embodiment, the disease is Crohn's Disease.

**[0240]** In some embodiments, the treatment comprises administration of a GAL9 binding molecule as described herein to a subject at risk for transplantation rejection in an amount effective to reduce transplant rejection. In some embodiments, the treatment comprises administration of a GAL9 binding molecule as described herein to a subject with graft-versus-host disease in an amount effective to reduce GvHD. In some embodiments, the treatment comprises administration of a GAL9 binding molecule as described herein to a subject with post-traumatic immune responses in an amount effective to reduce inflammation. In some embodiments, the treatment comprises administration of a GAL9 binding molecule as described herein to a subject with ischemia in an amount effective to treat the subject. In some embodiments, the treatment comprises administration of a GAL9 binding molecule as described herein to a subject who has undergone a stroke in an amount effective to treat the subject.

**[0241]** In some embodiments, the treatment comprises administration of a GAL9 binding molecule to a subject who has a viral infection in an amount effective to reduce acute respiratory distress syndrome and/or acute cytokine release syndrome (cytokine storm). In particular embodiments, the viral infection is infection with SARS-CoV-2 virus and the disease is COVID-19.

#### **6.10.4. Administration**

**[0242]** The GAL9 binding molecule may be administered to a subject by any route known in the art. For example, the GAL9 binding molecule may be administered to a human subject via, e.g., intraarterial, intramuscular, intradermal, intravenous, intraperitoneal, intranasal,

parenteral, pulmonary, subcutaneous administration, topical, oral, sublingual, intratumoral, peritumoral, intralesional, intrasynovial, intrathecal, intra-cerebrospinal, or perilesional administration. The GAL9 binding molecule may be administered to a subject *per se* or as a pharmaceutical composition. Exemplary pharmaceutical compositions are described herein.

[0243] The anti-GAL9 binding molecules disclosed herein can be administered alone or in combination with other therapeutic agents or procedures to treat or prevent a disease or condition.

[0244] Depending on the condition or disease to be treated, the treatment with a GAL9 binding molecule can improve one or more clinical endpoints in a subject. Examples of clinical endpoints improved in a subject with a disease or condition include but are not limited to, reducing inflammation, reducing autoimmune response, prolonging remission, inducing remission, re-establishing immune tolerance, improving organ function, reducing the risk of progression or development of a disease or a condition, reducing the risk of progression or development of a second disease, increasing overall survival in the subject or a combination thereof.

## 6.11. Examples

[0245] The following examples are provided by way of illustration, not limitation. In particular, methods for the expression and purification of the various antigen-binding proteins and their use in various assays described below are non-limiting and illustrative.

### 6.11.1. Methods

#### 6.11.1.1. Expi293 Expression

[0246] Various antigen-binding proteins tested were expressed using the Expi293 transient transfection system according to manufacturer's instructions. Briefly, plasmids coding for individual chains were mixed at 1:1 mass ratio, unless otherwise stated, and transfected into Expi 293 cells with ExpiFectamine 293 transfection kit. Cells were cultured at 37°C with 8% CO<sub>2</sub>, 100% humidity and shaking at 125 rpm. Transfected cells were fed once after 16-18 hours of transfections. The cells were harvested at day 5 by centrifugation at 2000 g for 10 minutes. The supernatant was collected for affinity chromatography purification.

#### 6.11.1.2. ExpiCHO Expression

[0247] Various GAL9 antigen-binding proteins are expressed using the ExpiCHO transient transfection system according to manufacturer's instructions. Briefly, plasmids coding for individual chains are mixed at, for example, a 1:1 mass ratio, and transfected with ExpiFectamine CHO transfection kit into ExpiCHO.

[0248] Cells are cultured at 37°C with 8% CO<sub>2</sub>, 100% humidity and shaking at 125 rpm. Transfected cells are generally be fed once after 16-18 hours of transfections. The cells are harvested at day 5 by centrifugation at 2000 g for 10 minutes. The supernatant is then collected for affinity chromatography purification.

#### **6.11.1.3. Protein A Purification**

[0249] Cleared supernatants containing the various antigen-binding proteins were separated using either a Protein A (ProtA) resin or an anti-CH1 resin on an Gravity flow purifier. In examples where a head-to-head comparison was performed, supernatants containing the various antigen-binding proteins were split into two equal samples. For ProtA purification, a 1 mL Protein A column (GE Healthcare) was equilibrated with PBS (5 mM sodium potassium phosphate pH 7.4, 150 mM sodium chloride). The sample was loaded onto the column at 5 ml/min. The sample was eluted using 0.1M Sodium acetate pH 3.5. The elution was monitored by absorbance at 280 nm and the elution peaks were pooled for analysis. The elution was monitored by absorbance at 280 nm and the elution peaks were pooled for analysis.

#### **6.11.1.4. SDS-Page Analysis**

[0250] Samples containing the various separated antigen-binding proteins were analyzed by reducing and non-reducing SDS-PAGE for the presence of complete product, incomplete product, and overall purity. 2 µg of each sample was added to 15 µL SDS loading buffer. Reducing samples were incubated in the presence of 10 mM reducing agent at 75°C for 10 minutes. Non-reducing samples were incubated at 70°C - for 5 minutes without reducing agent. The reducing and non-reducing samples were loaded into a 4-15% gradient TGX gel (BioRad) with running buffer and run for 30 minutes at 220 volts. Upon completion of the run, the gel was washed with DI water and stained using GelCode Blue Safe Protein Stain (ThermoFisher). The gels were destained with DI water prior to analysis. Densitometry analysis of scanned images of the destained gels was performed using standard image analysis software to calculate the relative abundance of bands in each sample.

#### **6.11.1.5. IEX Chromatography**

[0251] Samples containing the various separated antigen-binding proteins were analyzed by cation exchange chromatography for the ratio of complete product to incomplete product and impurities. Cleared supernatants were analyzed with a 5-ml MonoS (GE Lifesciences) on an AKTA Purifier FPLC. The MonoS column was equilibrated with buffer A 10 mM MES pH 6.0. The samples were loaded onto the column at 2 ml/min. The sample was eluted using a 0-30% gradient with buffer B (10 mM MES pH 6.0, 1 M sodium chloride) over 6 CV. The elution was monitored by absorbance at 280 nm and the purity of the samples were calculated by peak integration to identify the abundance of the monomer peak and contaminants peaks. The monomer peak and contaminant peaks were separately pooled for analysis by SDS-PAGE as described above.

[0252] Analytical SEC Chromatography of each sample at 1 mg/mL was loaded onto the column at 1 ml/min. The sample was eluted using an isocratic flow of PBS for 1.5 CV. The elution was monitored by absorbance at 280 nm and the elution peaks were analyzed by peak integration.

#### **6.11.1.6. Mass Spectrometry**

[0253] Samples containing the various separated antigen-binding proteins were analyzed by mass spectrometry to confirm the correct species by molecular weight. All analysis was performed by a third-party research organization. Briefly, samples were treated with a cocktail of enzymes to remove glycosylation. Samples were both tested in the reduced format to specifically identify each chain by molecular weight. Samples were all tested under non-reducing conditions to identify the molecular weights of all complexes in the samples. Mass spec analysis was used to identify the number of unique products based on molecular weight.

#### **6.11.1.7. Antibody discovery by phage display**

[0254] Phage display of human Fab libraries was carried out using standard protocols. Human GAL9 protein was purchased from Acro Biosystems (Human Gal9 His-tag Cat # LG9-H5244) and biotinylated using EZ-Link NHS-PEG<sub>12</sub>-Biotin (ThermoScientific Cat# 21312) using standard protocols. Phage clones were screened for the ability to bind the GAL9 protein by phage ELISA using standard protocols.

[0255] Briefly, Fab-formatted phage libraries were constructed using expression vectors capable of replication and expression in phage (also referred to as a phagemid). Both the heavy chain and the light chain were encoded for in the same expression vector, where the heavy chain was fused to a truncated variant of the phage coat protein pIII. The light chain

and heavy chain-pIII fusion were expressed as separate polypeptides and assembled in the bacterial periplasm, where the redox potential enables disulfide bond formation, to form the phage display antibody containing the candidate ABS.

**[0256]** The library was created using sequences derived from a specific human heavy chain variable domain (VH3-23) and a specific human light chain variable domain (Vκ-1). For the screened library, all three CDRs of the VH domain were diversified to match the positional amino acid frequency by CDR length found in the human antibody repertoire. Light chain variable domains within the screened library were generated with diversity introduced solely into the VL CDR3 (L3); the light chain VL CDR1 (L1) and CDR2 (L2) retained the human germline sequence.

**[0257]** The heavy chain scaffold (SEQ ID NO:2), light chain scaffold (SEQ ID NO:4), full heavy chain Fab polypeptide (SEQ ID NO:1), and full light chain Fab polypeptide (SEQ ID NO:3) used in the phage display library are shown below, where a lower case “x” represents CDR amino acids that were varied to create the library.

**Phage display VH scaffold [SEQ ID NO:2]:**

EVQLVESGGGLVQPGGSLRLSCAASGFTFxxxxIHWVRQAPGKGLEWVAxxxxxxxx  
xxxYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARxxxxxxxxxxxxxxxxDY  
WGQGTLVTVSSAS

**Phage display VL scaffold [SEQ ID NO:4]:**

DIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPKAPKLLIYSASSLYSG  
VPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQxxxxxTFGQGTKVEIKRT

**Phage display heavy chain Fab polypeptide [SEQ ID NO:1]:**

EVQLVESGGGLVQPGGSLRLSCAASGFTFxxxxIHWVRQAPGKGLEWVAxxxxxxxx  
xxxYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARxxxxxxxxxxxxxxxxDY  
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL  
TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVKDKKVEPKSC  
DKTHTC

**Phage display light chain Fab polypeptide [SEQ ID NO:3]:**

DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSG  
 VPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQxxxxxxTFGQGTKVEIKRTVAAPS  
 VFI FPPSDSQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS  
 TYSLSSSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC

**[0258]** Diversity was created through Kunkel mutagenesis using primers to introduce diversity into VH CDR1 (H1), CDR2 (H2) and CDR3 (H3) and VL CDR3 to mimic the diversity found in the natural antibody repertoire, as described in more detail in Kunkel, TA (*PNAS* January 1, 1985. 82 (2) 488-492), incorporated herein by reference in its entirety. Briefly, single-stranded DNA was prepared from isolated phage using standard procedures and Kunkel mutagenesis carried out. Chemically synthesized DNA was then electroporated into MC1061F- cells. Phagemid obtained from overnight culture was digested with restriction enzymes (Bam HI and Xba I) to remove the wild-type sequence. The digested sample was electroporated into TG1 cells, followed by recovery. Recovered cells were sub-cultured and infected with M13K07 helper phage to produce the phage library.

**[0259]** Phage panning was performed using standard procedures. Briefly, the first round of phage panning was performed with target immobilized on streptavidin magnetic beads which were subjected to  $\sim 5 \times 10^{12}$  phages from the prepared library in a volume of 1 mL in PBST-2% BSA. After a one-hour incubation, the bead-bound phage were separated from the supernatant using a magnetic stand. Beads were washed three times to remove non-specifically bound phage and were then added to ER2738 cells (5 mL) at  $OD_{600} \sim 0.6$ . After 20 minutes, infected cells were sub-cultured in 25 mL 2xYT + Ampicillin and M13K07 helper phage (final concentration,  $\sim 10^{10}$  pfu/ml) and allowed to grow overnight at 37 °C with vigorous shaking. The next day, phage were prepared using standard procedures by PEG precipitation. Pre-clearance of phage specific to SAV-coated beads was performed prior to panning. The second round of panning was performed using the KingFisher magnetic bead handler with 100 nM bead-immobilized antigen using standard procedures. In total, 3-4 rounds of phage panning were performed to enrich in phage displaying Fabs specific for the target antigen. Target-specific enrichment was confirmed using polyclonal and monoclonal phage ELISA. DNA sequencing was used to determine isolated Fab clones containing a candidate ABS.

**[0260]** The VL and VH domains identified in the phage screen described above were reformatted into a bivalent monospecific native human full-length IgG1 architecture.

**Native human full-length IgG1 heavy chain architecture [SEQ ID NO:5]:**

EVQLVESGGGLVQPGGSLRLSCAASGFTFxxxxIHWVRQAPGKGLEWVAxxxxxxxxx  
 xxxYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARxxxxxxxxxxxxxxxxx  
 DYWGQGTLLVTVSSASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL  
 TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC  
 DKHTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW  
 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK  
 TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY  
 KTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSSVMHEALHNHYTQKSLSLSPGK  
 [SEQ ID NO: 5]

**Native human full-length IgG1 light chain architecture:**

Equivalent to phage display light chain Fab, *see* SEQ ID NO:3

**6.11.1.8. Octet Determination of Binding Kinetics**

[0261] To measure qualitative binding affinity in GAL9 binder discovery campaigns, IgG1 reformatted binders were immobilized to a biosensor on an Octet (Pall ForteBio) biolayer interferometer.

[0262] Soluble GAL9 antigen was then added to the system and binding measured. Qualitative binding affinity was assessed by visualizing the slope of the dissociation phase of the octet sensogram from weakest (+) to strongest (+++). A slow off rate represented by a negligible drop in the dissociation phase of the sensogram and indicated a tight binding antibody (+++). To obtain accurate kinetic constants for monovalent affinities, a dilution series involving of at least five concentrations of the GAL9 analyte (ranging from approximately 10 to 20X  $K_D$  to 0.1X  $K_D$  value, 2-fold dilutions) were measured in the association step. In the dissociation step, the sensor was dipped into buffer solution that did not contain the GAL9 analyte and where the bound complex on the surface of the sensor dissociates. Octet kinetic analysis software was used to calculate the kinetic and equilibrium binding constants based on the rate of association and dissociation curves. Analysis was performed globally (global fit) where kinetic constants were derived simultaneously from all analyte concentration included in the experiment.

### 6.11.1.9. Epitope Binning

[0263] Anti-GAL9 candidates formatted into a bivalent monospecific native human full-length IgG1, as described above, were tested for GAL9 binding in a pair-wise manner using an octet-based ‘tandem’ assay. Briefly, biotinylated GAL9 was immobilized on a streptavidin sensor and two anti-GAL9 candidates were bound in tandem. A competitive blocking profile was generated determining whether a given anti-GAL9 candidate blocked binding of a panel of other anti-GAL9 candidates to GAL9. Anti-GAL9 candidates that competed for the same or non-overlapping binding regions were grouped together and referred to as belonging to the same bin.

### 6.11.1.10. PBMC activation and Galectin 9 antibody treatment

[0264] Individual aliquots of PepMix HCMVA (pp65) (>90%) Protein ID: P06725 (Cat. No. PM-PP65-2, JPT Peptide Technologies) were prepared according to manufacturer’s instructions. PepMix™ HCMVA (pp65) are complete protein-spanning mixtures of overlapping 15mer peptides through 65 kDa phosphoprotein (pp65) (Swiss-Prot ID: P06725) of Human cytomegalovirus (HHV-5), used for immunostimulation of immune cell responses.

[0265] Frozen human peripheral blood mononuclear cells (PBMCs) were thawed according to standard conditions, then resuspended in growth media (10% FBS in RPMI).

[0266] Resuspended PBMCs were seeded at  $5 \times 10^5$  cells in 96-well plates. Cells were incubated with 2  $\mu\text{g}/\text{mL}$  PepMix™ HCMVA (pp65) plus 40  $\mu\text{g}/\text{mL}$  of candidate GAL9 antibodies or control antibodies in growth media for 24 hours at 37°C, 5% CO<sub>2</sub>.

### 6.11.1.11. LEGENDplex Human Th Cytokine Assay

[0267] Following PBMC activation and Galectin 9 antibody treatment as described herein, cytokine secretion by PBMCs and immune cell subpopulations was assessed at 24 hours and 72 hours post-treatment by cytokine bead array as follows.

[0268] 200  $\mu\text{l}$  cell culture supernatant was collected and centrifuged to pellet cell debris. The resulting supernatants were analyzed using the LEGENDplex™ Human Th1 Panel (5-plex) (Cat. No. 740009, Biolegend). The LEGENDplex™ Human Th1 Panel is a bead-based assay that allows for simultaneous quantification of human cytokines IL-2, IL-6, IL-10, IFN- $\gamma$  and TNF- $\alpha$  using flow cytometry.

[0269] Briefly, cytokine standards and capture bead mixtures were prepared according to manufacturer's instructions. Assay master mixes of 1:1:1 capture bead mixture: biotinylated detection antibodies; assay buffers were prepared.

[0270] 12.5 µl of supernatant samples or cytokine standards were incubated with 37.5 µl assay master mix. Plates were sealed, covered with foil, and shaken at 600 rpm for 2 hours at room temperature. Wells were then incubated, with shaking at 600 rpm, with streptavidin-phycoerythrin (SA-PE) for 30 minutes at room temperature. Beads were then washed twice and resuspended before proceeding to flow cytometry analysis according to manufacturer's instructions.

#### 6.11.1.12. PBMC Staining with Marker Antibodies

[0271] Following PBMC activation and Galectin 9 antibody treatment as described herein, PBMCs immune cells were stained with marker antibodies according to the following procedures.

[0272] Cells were resuspended at  $5 \times 10^6$  cells/mL in growth media (10% FBS in RPMI). 200 µL of resuspended cells were aliquoted to 96 well plates, then incubated with Fixable Viability Dye eFluor® 780 for 30 minutes at 2-8°C to irreversibly label dead cells. Cells were then washed and then incubated with human Fc Block solution (Cat. No. 14-9161-73, eBiosciences) for 10 minutes at room temperature.

[0273] An antibody cocktail working solution was prepared according to the following table.

<b>Table 1</b> <b>Antibody Staining Working Solutions</b>		
	<b>Antibody</b>	<b>Dilution</b>
T cell surface markers	BV510 anti-human CD3 (Cat. No. 563109, BD Biosciences)	1 in 20
	PerCP/Cy5.5 anti-human CD56 (Cat. No. 362505, BD Biosciences)	1 in 20
Monocyte surface markers	FITC anti-human CD14 (Cat. No. 367115, BD Biosciences)	1 in 20
	Alexa Fluor® 700 anti-human CD16 (Cat. No. 302025, Biolegend)	1 in 20
Dendritic cell surface makers	Brilliant Violet 421™ anti-human CD11c (Cat. No. 301627, Biolegend)	1 in 20

<b>Table 1</b> <b>Antibody Staining Working Solutions</b>		
	<b>Antibody</b>	<b>Dilution</b>
	Alexa Fluor 647 anti-human CD123 (Cat. No. 306023, Biolegend)	1 in 40
	BV510 anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56) (Cat. No. 348807, Biolegend)	1 in 10
	FITC anti-human HLA-DR (Cat. No. 307603, Biolegend)	1 in 20
B cell surface markers	PerCP/Cy5.5 anti-human CD19 (Cat. No. 363015, Biolegend)	1 in 20
Galectin-9	PE anti-human galectin 9 (Cat. No. 348905, Biolegend)	1 in 10

**[0274]** Wells were incubated with 10  $\mu$ L of diluted antibody cocktail for 30 minutes at 2-8°C. Cells were then washed and resuspended and analyzed by flow cytometry analysis.

**[0275]** To analyze immune stimulatory markers CD27, CD40L, ICOS, 4-1BB, and OX40, the same protocol provided above was followed, but cells were incubated with the alternative antibody cocktail as detailed in **Table 2** below:

<b>Table 2</b> <b>Antibody Staining Working Solutions</b>	
<b>Antibody</b>	<b>Dilution</b>
FITC anti-human CD134 (OX40) (Cat. No. 350006, BioLegend)	1 in 50
PerCP/Cy5.5 anti-human CD3 (Cat. No. 560835, BD Biosciences)	1 in 100
AF700 anti-human CD4 (Cat. No. 344622, BioLegend)	1 in 100
eFluor™ Fixable Viability Dye (Cat. No. 65-0865-14, eBioscience™)	1 in 2000
BV421 anti-human CD8 (Cat. No. 344748, BioLegend)	1 in 100

<b>Table 2</b> <b>Antibody Staining Working Solutions</b>	
<b>Antibody</b>	<b>Dilution</b>
BV650 anti-human CD137 (4-1BB) (Cat. No. 309828, BioLegend)	1 in 50
BV711 anti-human ICOS (Cat. No. 563833, BD Biosciences)	1 in 100
PE anti-human CD154 (CD40L) (Cat. No. 310806, BioLegend)	1 in 50
PE/Cy7 anti- mouse/rat/human CD27 (Cat. No. 124216, BioLegend)	1 in 100

### **6.11.2. Example 1: Blood Dendritic Cells from Crohn's Disease patients have Increased PD-L2 Expression**

**[0276]** Programmed death 1 (PD-1)-deficient mice develop a variety of autoimmune-like diseases, which suggests that the PD-1 receptor plays an important role in immunity and autoimmunity. PD-1 has two endogenous ligands, PD-L1 and PD-L2. The PD-1/PD-L1 interaction has been implicated in autoimmunity; however, PD-L2's role in autoimmunity is less understood.

**[0277]** Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract. While the specific cause of the disease is not well understood, it is clear that CD patients have an overactive immune system that causes inflammation and damage to the gastrointestinal tract. This study was conducted to determine the expression of PD-L2 and PD-L1 on blood dendritic cells from Crohn's Disease patients.

#### **Study participants**

**[0278]** Peripheral blood was drawn from 29 adults confirmed by colonoscopy to have Crohn's disease. Patients were selected at different stages of treatment, but were excluded if they had received anti-TNF- $\alpha$  treatment. For a control, peripheral blood was drawn from 13 healthy adults undergoing colorectal cancer family history screening.

#### **Immunostaining**

**[0279]** Single-cell suspensions obtained from 10 ml whole blood were incubated with an Fc receptor binding antibody to block nonspecific Fc binding by specific antibodies. Fixable

Viability Dye eFluor780 (ebioscience, San Diego, CA) was used to exclude dead cells from analysis. The following anti-human monoclonal antibodies were used to assess cells: HLA-DR PerCP-Cy5.5 (clone G46-6; BD Bioscience, San Jose, CA); lineage cocktail BV510 [CD3 (clone OKT3)/CD14 (clone M5E2)/CD16 (clone 3G8)/CD19 (clone HIB19)/CD20 (clone 2H7) and CD56 (clone HCD56)]; CD11c BV605 (clone 3.9; BioLegend, San Diego, CA).

**[0280]** Anti-human PD-L2 monoclonal antibody (clone MIH18; BioLegend, San Diego, CA) and anti-human PD-L1 monoclonal antibody (clone 29E.2A3; BioLegend, San Diego, CA) or control IgGs were labelled in-house using the Lightning-Link Rapid DyLight 647 and Lightning-Link Rapid DyLight 488, respectively (BioNovus Life Sciences, Cherrybrook, NSW, Australia). Cells were stained with anti-HLA-DR, anti-PD-L2, or anti-PD-L1 or IgG control for 30 mins at room temperature, and then washed twice with PBS for 5 mins, and then fixed in 1% paraformaldehyde–PBS, pH 7.25.

### **Flow Cytometry**

**[0281]** Cells were stained with Fixable Viability Dyes (FVD) and gated to capture only viable cells in the mononuclear cell region of a side scatter versus forward scatter plot. Dendritic cells were defined as HLA-DR<sup>+</sup> and Lin<sup>+</sup>, followed by gating CD11c<sup>+</sup> within the total peripheral blood population. For each donor at least  $1 \times 10^4$  events were collected.

**[0282]** Cells were analyzed using a BD LSR Fortessa flow cytometer and data analyzed using either BD FACSDiva software (Becton & Dickinson, Franklin Lakes, NJ), FCS express (De Novo software, Glendale, CA) or FlowJo software (Tree Star; a subsidiary of Becton, Dickinson and Company, Ashland, OR).

### **Statistical Analyses**

**[0283]** Non-parametric Mann-Whitney *U* test based on 2-sided tail was conducted using GraphPad Prism (GraphPad Software).

### **Microscopy**

**[0284]** Microscopy samples were made by mounting stained, sorted cells onto a glass slide. Images were collected using a confocal microscope.

### **Results/Conclusion**

**[0285]** **FIG. 2** shows contour plots of CD11c<sup>+</sup> dendritic cells (DCs) cells from Crohn's patients stained with either IgG control, anti-PD-L1, or anti-PD-L2. We observed that the

IgG control had 2.23% non-specific binding to DC cells, whereas the anti-PD-L1 antibody stained 28.6% of DC cells as PD-L1<sup>+</sup>. Likewise, in the second experiment, the IgG control bound to only 3.22% of CD11c<sup>+</sup> DC, whereas the anti-PD-L2 antibody detected 62.7% of DC cells as PD-L2<sup>+</sup>.

[0286] **FIGs. 3A-3B** show scatter plots of the percentage of PD-L1<sup>+</sup> cells among CD11c<sup>+</sup> blood dendritic cells (**FIG. 3A**) and the percentage of PD-L2<sup>+</sup> cells among CD11c<sup>+</sup> blood dendritic cells (**FIG. 3B**) from healthy control donors and CD patients. The horizontal bars on the scatter plots show the mean. **FIGs. 3C-3D** show scatter plots of the amount (GMI) of PD-L1 expression (**FIG. 3C**) and the amount (GMI) of PD-L2 expression on CD11c<sup>+</sup> blood dendritic cells from healthy control donors and Crohn's patients (**FIG. 3D**). The horizontal bars on the scatter plots indicate the mean. A single asterisk "\*" indicates a *P*-value = 0.0292. A double asterisk "\*\*" indicates a *P*-value=0.0032.

[0287] **FIGs. 4A-4B** show representative immunostaining of dendritic cells (DC) cells from the blood of two healthy control donors and three Crohn's Disease patients. DCs from healthy controls show high PD-L1 (green) and PD-L2 (red) staining throughout the cell; rendered in gray scale in the attached figures. In contrast, dendritic cells from Crohn's patients show low PD-L1 expression and high levels of PD-L2 which appear aggregated. In some cells, we observed high staining of aggregated PD-L1.

[0288] The results demonstrate that the PD-L2 protein is more highly expressed in blood dendritic cells from Crohn's patients as compared to healthy control donors (*P*-value=0.0032), yielding a higher statistical difference than PD-L1 (*P*-value = 0.0292). These results suggest that the PD-L2 pathway may play an important role in Crohn's Disease and other autoimmune diseases.

### 6.11.3. Example 2: Inhibiting PD-L2 in PBMCs from Crohn's Disease patients results in a clinically favorable cytokine profile

[0289] This study was conducted to determine the effect of inhibiting PD-L2 protein on the cytokine profile in PBMCs from Crohn's Disease (CD) patients, compared to an IgG control.

#### Study Participants

[0290] Blood samples were obtained from 14 different Crohn's disease patients. Peripheral blood mononuclear cells (PBMC) were isolated using heparinized blood by density centrifugation on Ficoll-Paque (Pharmacia, Freiburg, Germany). Isolated PBMCs from

control and CD patients were added to wells ( $2 \times 10^5$  cells/well) pre-coated with anti-CD3. R10 media, supplemented with penicillin (100 IU/ml), streptomycin (0.1 mg/ml) and L-glutamine (0.29 gm/l). Control IgG or blocking anti-PD-L2 (MIH18) antibodies were added to the culture at 20  $\mu$ g/ml.

### **Treatment**

[0291] Matched PBMCs samples were treated with either IgG control or anti-human PD-L2 antibody clone MIH18 (BioLegend) for 36 hours and then assayed.

### **Cytokine Assay**

[0292] The concentration of TNF- $\alpha$ , IFN- $\gamma$ , and IL-10 were measured using BD™ Cytometric Bead Array (CBA) following manufacturer's instructions.

### **Statistical Analyses**

[0293] Wilcoxon matched-pairs signed rank test was conducted using GraphPad Prism (GraphPad Software).

### **Results/Conclusion**

[0294] The mean concentrations of TNF- $\alpha$  and IFN- $\gamma$  from the matched samples are shown in **FIGs. 5A-5B**, respectively. **FIG. 5C** shows the mean IL-10:TNF- $\alpha$  ratio. These results demonstrate that inhibiting PD-L2 results in a clinically favorable cytokine profile in PMBCs from CD patients, by decreasing the levels of pro-inflammatory cytokines TNF- $\alpha$  and IFN- $\gamma$ , and increasing the levels of inhibitory cytokine IL-10.

#### **6.11.4. Example 3: Stimulating or Blocking the GAL9/PD-L2 pathway modulates TNF- $\alpha$ secretion in mouse CD4<sup>+</sup> T cells**

[0295] Previously, we showed that GAL9 can bind soluble PD-L2, and that some of the immunological effects of PD-L2 are mediated through binding of multimeric PD-L2 to GAL9, rather than through PD-1/PD-L1 (WO 2016/008005, which is incorporated herein by reference in its entirety). The current study was conducted to determine if stimulating or blocking the GAL9/PD-L2 pathway can modulate the TNF- $\alpha$  secretion in mouse CD4<sup>+</sup> T cells.

## Animals

[0296] C57BL6/J mice were used for the study. All animals used in the study were housed and cared for in accordance with the National Health Medical Research Council (NHMRC) Guidelines for Animal Use.

## sPD-L2

[0297] Soluble mouse PD-L2 (sPD-L2) with a human IgG1 Fc was custom produced by Genart (Germany).

## Antibodies

[0298] For treatment, inhibitory anti-mouse GAL9 antibody clone 108A2 (BioLegend® San Diego, CA) or rat IgG2a control antibody was used. The anti-mouse GAL9 clone (108A2) binds the linker peptide of murine Galectin-9 (Oomizu, S. et al., PLoS One 7(11):e48574 (2012); Doi: 10.1371/journal.pone.0048574, which is herein incorporated by reference). Anti-CD3 (clone 145.2C11) (Aviva Systems Biology Corp. San Diego, CA) was used for stimulation.

## Cell Separation and Stimulation of CD4<sup>+</sup> T cells

[0299] A suspension of mouse spleen cells was made from five mice. CD4<sup>+</sup> T-cells were isolated using Miltenyi Biotec Inc.(Auburn, CA) kit for untouched CD4<sup>+</sup> T cells. Mouse CD4<sup>+</sup> T cells were stimulated with anti-CD3 clone 145.2C11 (Aviva Systems Biology Corp. San Diego, CA) at 5 µg/ml. Next, the stimulated CD4<sup>+</sup> T cells were treated either with IgG control or sPD-L2 at 20 µg/ml, or with sPD-L2 and anti-GAL9 mAb clone 108A2, both at 20 µg/ml, and then cultured for 36 hours.

## Cytokine Assays

[0300] After 36 hrs of treatment, the concentration of TNF-α was measured using BD™ Cytometric Bead Array following manufacturer's instructions.

## Statistical Analyses

[0301] Non-parametric Mann-Whitney *U* test was conducted using GraphPad Prism (GraphPad Software).

## Results/Conclusion

[0302] **FIG. 6** shows bar graphs of the concentration levels of TNF-α for each treatment group. Treatment of activated CD4<sup>+</sup> T cells with sPD-L2 alone resulted in significantly

increased TNF- $\alpha$  secretion by CD4<sup>+</sup> T cells, as compared to IgG control, \*  $p$ -value <0.0001. Addition of inhibitory anti-mouse GAL9 antibody (108A2) significantly decreased TNF- $\alpha$  secretion from activated CD4<sup>+</sup> T cells, both as compared to activated CD4<sup>+</sup> T cells treated with 108A2, and as compared to IgG control, \*  $p$ -value <0.0001.

[0303] sPD-L2, which binds GAL9 on T cells, induces TNF- $\alpha$  secretion, while inhibiting GAL9 blocks sPD-L2-mediated TNF- $\alpha$  secretion in CD4<sup>+</sup> T cells. These results demonstrate that the GAL9/PD-L2 pathway modulates TNF- $\alpha$  levels in stimulated CD4<sup>+</sup> T cells.

#### **6.11.5. Example 4: Inhibitory anti-mouse GAL9 (108A2) antibodies works independently from PD-1/PD-L1 in CD4<sup>+</sup> T cells from malaria-infected mice, while activating anti-GAL9 antibodies do not**

[0304] This study was conducted to investigate the dependence of inhibitory and activating GAL9 antibodies on the PD-1/PD-L1 pathway.

[0305] Mouse models of malaria-infected mice can be used to study immune mechanisms and susceptibility to drugs. Wykes, MN et al. *Eur J Immunol.* (2009) 39:2004–7, which is incorporated herein by reference in its entirety. Further, it has been shown that *Plasmodium* parasites that cause malaria can exploit the PD-1 pathway to ‘deactivate’ T cell functions. A definitive role for PD-1 in malarial pathogenesis was demonstrated when PD-1-deficient mice were shown to rapidly and completely clear *P. chabaudi* infections. As such, malarial infection models can be used to understand the relative contribution of PD-1 and its ligands, PD-L1 and PD-L2, in immunity.

#### **Antibodies**

[0306] The inhibitory anti-mouse GAL9 antibody (108A2) and the activating anti-mouse GAL9 antibody (RG9.1) (Cat. No. BE0218, InVivoMab Antibodies) were used for this study.

#### **Malaria-infected mouse model**

[0307] Cohorts of C57BL/6 mice were infected with non-lethal malaria (*P. yoelii* 17XNL). After intravenous injection the of 10<sup>5</sup> *P. yoelii* infected red cells, the mice were incubated for 7 days to allow infection to take place.

#### **CD4<sup>+</sup> T Cell isolation and Treatment**

[0308] CD4<sup>+</sup> T cells were isolated from malaria-infected mice using Miltenyi Biotec untouched CD4<sup>+</sup> T cell isolation kits. Next, the isolated T cells were cultured and treated

overnight with either control IgG antibody, inhibitory anti-mouse GAL9 antibody (108A2), or the activating anti-mouse GAL9 antibody (RG9.1).

### **Immunostaining and Microscopy**

[0309] After treatment, the cells were stained with DAPI (to detect DNA), and anti-OX40 (CD134), anti-PD-1, and anti-PD-L1 (BioXCell, Lebanon, NH) antibodies labelled using Lightning-Link Rapid DyLight 647, 594 or 488 kits. Immunostaining was observed by confocal imaging.

### **Results/Conclusion**

[0310] **FIG. 7** shows representative confocal images of CD4<sup>+</sup> T cells treated with either IgG control, inhibitory anti-mouse GAL9 antibody (108A2), or the activating anti-mouse GAL9 antibody (RG9.1). The red staining shows the PD-1 receptor, the green staining shows the PD-L1 ligand, the yellow staining shows the OX40 receptor, and the blue staining shows DNA (DAPI), rendered in gray scale in the attached figures.

[0311] We observed that treatment with the activating anti-mouse GAL9 (RG9.1) antibody reduces the expression of PD-1 receptor (low levels of staining) and the PD-L1 ligand (very reduced levels of staining). In contrast, we observed that treatment with inhibitory anti-GAL9 (108A2) had no effect on the expression PD-1 receptor (staining levels similar to IgG control levels) or the PD-L1 ligand (staining levels similar to IgG control levels). In addition, we observed that treatment with inhibitory anti-GAL9 (108A2) resulted in decreased expression of OX40. These results suggest that inhibiting GAL9 antibodies work independently from PD-1/PD-L1 pathway in CD4<sup>+</sup> T cells.

#### **6.11.6. Example 5: Treatment with Inhibitory anti-mouse GAL9 (108A2) decreases PD-L2-mediated survival of CD4<sup>+</sup> and CD8<sup>+</sup> T cells from malaria-infected mice**

[0312] This study was conducted to determine the effect of an inhibitory anti-mouse GAL9 (108A2) antibody on PD-L2-mediated survival of CD4<sup>+</sup> and CD8<sup>+</sup> T cells from malaria-infected mice.

[0313] PD-L2 has been shown to mediate the survival of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in malaria-infected mice, by increasing the numbers of parasite-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells to protect the mice from the lethal malaria infection. *See Karunarathne et al. Immunity* (2016). Aug 16;45(2):333-45), which is incorporated herein by reference in its entirety.

### Malaria-infected mouse model

[0314] Cohorts of five C57BL/6 mice were infected with non-lethal malaria (*P. yoelii* 17XNL). After intravenous injection of  $10^5$  *P. yoelii* infected red cells, the mice were incubated for 7 days to allow infection to take place. All animals used in the study were housed and cared for in accordance with the National Health Medical Research Council (NHMRC) Guidelines for Animal Use.

### sPD-L2

[0315] As a positive control, CD4<sup>+</sup> and CD8<sup>+</sup> T cells were treated with soluble PD-L2 “sPD-L2” custom produced by Genart (Germany).

### Cell isolation, Treatment, and Viability Assay

[0316] CD4<sup>+</sup> and CD8<sup>+</sup> T cells were isolated from infected mice by FACS using Miltenyi Biotec Inc. (Auburn, CA) kits for untouched CD4<sup>+</sup> and CD8<sup>+</sup> T cells and then cultured for 36 hours at 37 °C. Next, CD4<sup>+</sup> and CD8<sup>+</sup> T cells were treated with either 20 mg/ml of sPD-L2 or 20 mg/ml anti-mouse GAL9 (108A2). After treatment, cells were assayed for viability using a viability dye and flow cytometry.

### Results/Conclusion

[0317] The results for the viability assays for CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cell are shown in **FIG. 8A** and **FIG. 8B**, respectively. Treatment with sPD-L2 increased PD-L2-mediated survival in CD4<sup>+</sup> and CD8<sup>+</sup> T cells. In contrast, treatment with sPD-L2 and anti-GAL9 (108A2) decreased PD-L2-mediated survival in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. These results suggest that PD-L2 works with GAL9 to mediate survival of CD4<sup>+</sup> and CD8<sup>+</sup> T cells.

#### 6.11.7. Example 6: Blocking the GAL9/PD-L2 pathway decreases proinflammatory cytokines in activated CD4<sup>+</sup> T cells from malaria-infected mice

[0318] This study was conducted to determine if blocking the GAL9/PD-L2 pathway by either a blocking anti-PD-L2 antibody or an inhibitory anti-mouse GAL9 (108A2) antibody can decrease secretion of proinflammatory cytokines in activated CD4<sup>+</sup> T cells from malaria-infected mice.

### **Malaria-infected mouse model**

[0319] Cohorts of five C57BL/6 mice were infected with malaria strain *P. yoelii* 17XNL and incubated for 7 days, to allow infection to take place. All animals used in the study were housed and cared for in accordance with the NHMRC Guidelines for Animal Use.

### **Antibodies**

[0320] The blocking anti-mouse PD-L2 mAb clone TY25 (BioXCell, Lebanon, NH) or the inhibitory anti-mouse GAL9 clone 108A2 (BioLegend® San Diego, CA) were used.

### **Cell isolation and Co-culture stimulation**

[0321] CD4<sup>+</sup> T cells and DC cells were isolated from malaria-infected mice by using Miltenyi Biotec kits (Auburn, CA) for CD4<sup>+</sup> T cell isolation and CD11c<sup>+</sup> beads for DC isolation. Next, approximately  $1 \times 10^6$  T cells were cultured with  $2 \times 10^5$  DCs in at least triplicate wells and then cultured with either 20 ug/ml of anti-PD-L2 mAb or 20 ug/ml of anti-Gal9 mAb for 36 hours.

### **Cytokine Assays**

[0322] After treatment, the concentration of INF- $\gamma$  or TNF- $\alpha$  was measured using BD™ Cytometric Bead Array (CBA) following manufacturer's instructions.

### **Statistical Analyses**

[0323] Unpaired t-test with *Welch's* correction was conducted using GraphPad Prism (GraphPad Software).

### **Results/Conclusion**

[0324] **FIG. 9A** shows bar graphs of the IFN- $\gamma$  concentration detected for each treatment group. Treatment with either anti-PD-L2 or anti-GAL9 (108A2) resulted in a significant reduction in IFN- $\gamma$  levels compared to an untreated co-culture control.

[0325] **FIG. 9B** shows bar graphs of the TNF- $\alpha$  concentration detected for each treatment group. Treatment with either anti-PD-L2 or inhibitory anti-mouse GAL9 antibody (108A2) resulted in a significant reduction of TNF- $\alpha$  levels compared to an untreated co-culture control. The asterisk "\*" indicates a statistical significance of  $p$ -value  $<0.05$  compared to control. Notably, treatment with anti-PD-L2 and anti-GAL9 (108A2) reduced the IFN- $\gamma$  and TNF- $\alpha$  to roughly the same concentration level.

### 6.11.8. Example 7: Human GAL9 (anti-human GAL9) Binding Arm Discovery Campaign

**[0326]** A chemically synthetic Fab phage library with diversity introduced into the Fab CDRs was screened against GAL9 antigens using a monoclonal phage ELISA format as described above. Phage clones expressing Fabs that recognized GAL9 were sequenced.

**[0327]** The campaign initially identified 52 GAL9 binding candidates (antigen binding site clones). Functional assays conducted after the variable regions of these clones had been reformatted into a bivalent monospecific human IgG1 format identified 30 antibodies having immune inhibiting properties.

**[0328]** **Table 3** lists the VH CDR1/2/3 sequences from the 30 inhibiting ABS clones, showing only the residues of the CDRs that had been varied in constructing the library.

**Table 4** lists the VL CDR1/2/3 sequences from the identified ABS clones; the light chain CDR1 and CDR2 sequences are invariant, and only the residues of CDR3 that were varied in constructing the library are shown.

Table 3 Candidate anti-human GAL9 VH Antigen Binding Sites						
ABS clone	CDR1 (variant residues)	SEQ ID #	CDR2 (variant residues)	SEQ ID #	CDR3 (variant residues)	SEQ ID #
P9-01	SSYW	7	WIDPDYGTTS	59	AGISYVF	111
P9-02A	SSYW	8	WIDPDYGTTS	60	AQYVPGL	112
P9-03	SGYY	10	VISPYSGYTS	62	ATYMVPYGF	114
P9-06	AYYG	13	YIYPHGYITD	65	DSGVPYYWAVL	117
P9-07	SSYY	14	YISPYGGDTS	66	DSYMSYIDGF	118
P9-11	SSYY	18	YISPSGGYTY	70	GAVLYSSAM	122
P9-12	SSYW	19	SIASYFGQTY	71	GFGYAAM	123
P9-14	GSYY	20	DIYPYFSSTY	72	GSHFGF	124
P9-23	SQYY	28	TIYPRGGYTF	80	KSYWGM	132
P9-24	SSYF	29	SIYPTSHSTS	81	LGYPGVM	133
P9-25	SSYY	30	SIYPYGSYTY	82	LGYSSTM	134
P9-26	SSYY	31	WIESSSHTD	83	LPYKYYYYLGVF	135
P9-29	SSYA	34	YIAPGGSYTY	86	LSYPGVM	138

<b>Table 3</b> <b>Candidate anti-human GAL9 VH Antigen Binding Sites</b>						
<b>ABS clone</b>	<b>CDR1 (variant residues)</b>	<b>SEQ ID #</b>	<b>CDR2 (variant residues)</b>	<b>SEQ ID #</b>	<b>CDR3 (variant residues)</b>	<b>SEQ ID #</b>
P9-30	STYT	35	WIYPKGGSTD	87	PSGYGF	139
P9-34	STYF	38	YIYPQGGYTY	90	QSYPGVF	142
P9-37	WKYG	40	YIYPAGGITS	92	SDYYSGMGM	144
P9-38	SSYW	41	WIDPDYGTTS	93	SETGAAM	145
P9-40	RWYY	43	TIYPDWDYTT	95	SPVTGPYGF	147
P9-41	RYYW	44	AIYPSSDSTY	96	SSPYPYGQGVF	148
P9-42	SSYY	45	AIYSAWGTTY	97	SYGYVFGYYSGM	149
P9-43	HSYW	46	RIDSSKFGTY	98	SYIDYPVSPAVF	150
P9-44	SYYW	47	AISPSGSYTS	99	SYRFRTPYTVM	151
P9-45	FSYV	48	AIYPYSGYTT	100	TKYDYHVF	152
P9-46	SRYY	49	FISSDSGYTQ	101	TMSYSAL	153
P9-50	SSYV	51	LIYSSGGYTQ	103	VGTTYPSRYLEAL	155
P9-51	SSYY	52	GIYPEGSYTY	104	VGYPGVM	156
P9-52	STYL	53	AITPYSGYTS	105	VGYPMVM	157
P9-53	SRYQ	54	YIASASGTTS	106	VPYVAM	158
P9-56	SSYY	56	YIDSSGKYTD	108	YAYPGVM	160
P9-57	SSYY	57	TIYPSGGYTY	109	YSYPGVL	161

<b>Table 4</b> <b>Candidate anti-human GAL9 VL Antigen Binding Sites</b>						
<b>ABS clone</b>	<b>CDR1 (invariant)</b>	<b>SEQ ID #</b>	<b>CDR2 (invariant)</b>	<b>SEQ ID #</b>	<b>CDR3 (variant residues)</b>	<b>SEQ ID #</b>
P9-01	RASQSVSSA	163	SASSLYS	215	QVSDLL	267
P9-02A	RASQSVSSA	164	SASSLYS	216	SYPTLG	268
P9-03	RASQSVSSA	166	SASSLYS	218	GGSFY	270
P9-06	RASQSVSSA	169	SASSLYS	221	HFSSPG	273
P9-07	RASQSVSSA	170	SASSLYS	222	WTSTLW	274

<b>Table 4</b> <b>Candidate anti-human GAL9 VL Antigen Binding Sites</b>						
<b>ABS clone</b>	<b>CDR1 (invariant)</b>	<b>SEQ ID #</b>	<b>CDR2 (invariant)</b>	<b>SEQ ID #</b>	<b>CDR3 (variant residues)</b>	<b>SEQ ID #</b>
P9-11	RASQSVSSA	174	SASSLYS	226	YYPSPS	278
P9-12	RASQSVSSA	175	SASSLYS	227	EYGRPY	279
P9-14	RASQSVSSA	176	SASSLYS	228	HASGPL	280
P9-23	RASQSVSSA	184	SASSLYS	236	WSVYLE	288
P9-24	RASQSVSSA	185	SASSLYS	237	VDSRLA	289
P9-25	RASQSVSSA	186	SASSLYS	238	WAPDLT	290
P9-26	RASQSVSSA	187	SASSLYS	239	YSSSLY	291
P9-29	RASQSVSSA	190	SASSLYS	242	GYSSLL	294
P9-30	RASQSVSSA	191	SASSLYS	243	YLSSPY	295
P9-34	RASQSVSSA	194	SASSLYS	246	WTIALT	298
P9-37	RASQSVSSA	196	SASSLYS	248	YYPSPS	300
P9-38	RASQSVSSA	197	SASSLYS	249	GSYFLQ	301
P9-40	RASQSVSSA	199	SASSLYS	251	PTYSLW	303
P9-41	RASQSVSSA	200	SASSLYS	252	WYSSLW	304
P9-42	RASQSVSSA	201	SASSLYS	253	WSSDLV	305
P9-43	RASQSVSSA	202	SASSLYS	254	VYFSPY	306
P9-44	RASQSVSSA	203	SASSLYS	255	GIDSPE	307
P9-45	RASQSVSSA	204	SASSLYS	256	GWDSLW	308
P9-46	RASQSVSSA	205	SASSLYS	257	YWWSPE	309
P9-50	RASQSVSSA	207	SASSLYS	259	FGSSLP	311
P9-51	RASQSVSSA	208	SASSLYS	260	WGSSLA	312
P9-52	RASQSVSSA	209	SASSLYS	261	LDYSLA	313
P9-53	RASQSVSSA	210	SASSLYS	262	GYPHPG	314
P9-56	RASQSVSSA	212	SASSLYS	264	YDYSLW	316
P9-57	RASQSVSSA	213	SASSLYS	265	SSSFLW	317

[0329] **Table 5** presents the full CDR sequences for the human candidate inhibiting anti-GAL9 antibodies according to multiple art-accepted definitions.

Table 5  
CDR definitions

Region	Definition	Sequence	Residues	Length	SEQ ID NO:
P9-01					
CDR-H1	Chothia	GFTFSSY---	26 - 32	7	318
	AbM	GFTFSSYWIH	26 - 35	10	319
	Kabat	-----SYWIH	31 - 35	5	320
	Contact	-----SSYWIH	30 - 35	6	321
	IMGT	GFTFSSYW--	26 - 33	8	322
CDR-H2	Chothia	-----DPDYGTT-----	52 - 57	6	323
	AbM	----WIDPDYGTT-----	50 - 59	10	324
	Kabat	----WIDPDYGTTSYADSVKGG	50 - 66	17	325
	Contact	WVAVWIDPDYGTT-----	47 - 59	13	326
	IMGT	-----IDPDYGTT-----	51 - 58	8	327
CDR-H3	Chothia	--AGISYVFDY	99 - 107	9	328
	AbM	--AGISYVFDY	99 - 107	9	329
	Kabat	--AGISYVFDY	99 - 107	9	330
	Contact	ARAGISYVFD-	97 - 106	10	331
	IMGT	ARAGISYVFDY	97 - 107	11	332
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	333
	AbM	RASQSVSSAVA--	24 - 34	11	334
	Kabat	RASQSVSSAVA--	24 - 34	11	335
	Contact	-----SSAVAWY	30 - 36	7	336

	IMGT	---QVSSA----	27 - 32	6	337
CDR-I2	Chothia	----SASSLYS	50 - 56	7	338
	AbM	----SASSLYS	50 - 56	7	339
	Kabat	----SASSLYS	50 - 56	7	340
	Contact	LLIYSASSLY-	46 - 55	10	341
	IMGT	----SA-----	50 - 51	2	342
CDR-I3	Chothia	QQQVSDLLT	89 - 97	9	343
	AbM	QQQVSDLLT	89 - 97	9	344
	Kabat	QQQVSDLLT	89 - 97	9	345
	Contact	QQQVSDLL-	89 - 96	8	346
	IMGT	QQQVSDLLT	89 - 97	9	347
<b>P9-02A</b>					
CDR-H1	Chothia	GTFSSY---	26 - 32	7	348
	AbM	GTFSSYWIH	26 - 35	10	349
	Kabat	-----SYWIH	31 - 35	5	350
	Contact	----SSYWIH	30 - 35	6	351
	IMGT	GTFSSYW--	26 - 33	8	352
CDR-H2	Chothia	-----DPDYG	52 - 57	6	353
	AbM	---WIDPDYG	50 - 59	10	354
	Kabat	---WIDPDYG	50 - 66	17	355
	Contact	WVAWIDPDYG	47 - 59	13	356
	IMGT	-----IDPDYG	51 - 58	8	357
CDR-H3	Chothia	--AQYVPGLDY	99 - 107	9	358
	AbM	--AQYVPGLDY	99 - 107	9	359
	Kabat	--AQYVPGLDY	99 - 107	9	360
	Contact	AAQYVPGLD-	97 - 106	10	361
	IMGT	AAQYVPGLDY	97 - 107	11	362

CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	363
	AbM	RASQSVSSAVA--	24 - 34	11	364
	Kabat	RASQSVSSAVA--	24 - 34	11	365
	Contact	-----SSAVAWY	30 - 36	7	366
	IMGT	---QSVSSA----	27 - 32	6	367
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	368
	AbM	-----SASSLYS	50 - 56	7	369
	Kabat	-----SASSLYS	50 - 56	7	370
	Contact	LLIYSASSLY-	46 - 55	10	371
	IMGT	-----SA-----	50 - 51	2	372
CDR-L3	Chothia	QQSYPTLGT	89 - 97	9	373
	AbM	QQSYPTLGT	89 - 97	9	374
	Kabat	QQSYPTLGT	89 - 97	9	375
	Contact	QQSYPTLG-	89 - 96	8	376
	IMGT	QQSYPTLGT	89 - 97	9	377
<b>P9-03</b>					
CDR-H1	Chothia	GFTFSGY---	26 - 32	7	378
	AbM	GFTFSGYYIH	26 - 35	10	379
	Kabat	-----GYIYH	31 - 35	5	380
	Contact	-----SGYIYH	30 - 35	6	381
	IMGT	GFTFSGY--	26 - 33	8	382
CDR-H2	Chothia	-----SPYSGY-----	52 - 57	6	383
	AbM	---VISPYSGYTS-----	50 - 59	10	384
	Kabat	---VISPYSGYTSVADSVKG	50 - 66	17	385
	Contact	WVAVISPYSGYTS-----	47 - 59	13	386
	IMGT	-----ISPYSGYT-----	51 - 58	8	387
CDR-H3	Chothia	--ATYMPYGFYD	99 - 109	11	388

	AbM	--ATYMPYGFYD	99 - 109	11	389
	Kabat	--ATYMPYGFYD	99 - 109	11	390
	Contact	ARATYMPYGFYD-	97 - 108	12	391
	IMGT	ARATYMPYGFYD	97 - 109	13	392
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	393
	AbM	RASQSVSSAVA--	24 - 34	11	394
	Kabat	RASQSVSSAVA--	24 - 34	11	395
	Contact	-----SSAVAWY	30 - 36	7	396
	IMGT	---QSVSSA----	27 - 32	6	397
CDR-L2	Chothia	----SASSLYS	50 - 56	7	398
	AbM	----SASSLYS	50 - 56	7	399
	Kabat	----SASSLYS	50 - 56	7	400
	Contact	LLIYSASSLY-	46 - 55	10	401
	IMGT	----SA-----	50 - 51	2	402
CDR-L3	Chothia	QGGSFPLYT	89 - 97	9	403
	AbM	QGGSFPLYT	89 - 97	9	404
	Kabat	QGGSFPLYT	89 - 97	9	405
	Contact	QGGSFPLY-	89 - 96	8	406
	IMGT	QGGSFPLYT	89 - 97	9	407
<b>P9-06</b>					
CDR-H1	Chothia	GTFAYY---	26 - 32	7	408
	AbM	GTFAYYGIH	26 - 35	10	409
	Kabat	-----YGIH	31 - 35	5	410
	Contact	----AYGIH	30 - 35	6	411
	IMGT	GTFAYYG--	26 - 33	8	412
CDR-H2	Chothia	-----YPHGYI-----	52 - 57	6	413
	AbM	----YIYPHYITD-----	50 - 59	10	414

	Kabat	---YIYPHGVIITDYADSVKGG	50 - 66	17	415
	Contact	WVAIYIPHGVIITD-----	47 - 59	13	416
	IMGT	-----IYPHGVIIT-----	51 - 58	8	417
CDR-H3	Chothia	--DSGVPYYWAVLDY	99 - 111	13	418
	AbM	--DSGVPYYWAVLDY	99 - 111	13	419
	Kabat	--DSGVPYYWAVLDY	99 - 111	13	420
	Contact	ARDSGVPYYWAVLD-	97 - 110	14	421
	IMGT	ARDSGVPYYWAVLDY	97 - 111	15	422
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	423
	AbM	RASQSVSSAVA--	24 - 34	11	424
	Kabat	RASQSVSSAVA--	24 - 34	11	425
	Contact	-----SSAVAWY	30 - 36	7	426
	IMGT	----QSVSSA----	27 - 32	6	427
CDR-L2	Chothia	----SASSLYS	50 - 56	7	428
	AbM	----SASSLYS	50 - 56	7	429
	Kabat	----SASSLYS	50 - 56	7	430
	Contact	LLIYSASSLY-	46 - 55	10	431
	IMGT	----SA-----	50 - 51	2	432
CDR-L3	Chothia	QQHFSSPGT	89 - 97	9	433
	AbM	QQHFSSPGT	89 - 97	9	434
	Kabat	QQHFSSPGT	89 - 97	9	435
	Contact	QQHFSSPG-	89 - 96	8	436
	IMGT	QQHFSSPGT	89 - 97	9	437
P9-07					
CDR-H1	Chothia	GFTFSS---	26 - 32	7	438
	AbM	GFTFSSYYIH	26 - 35	10	439
	Kabat	-----SYLIH	31 - 35	5	440

	Contact	-----SSYIH	30 - 35	6	441
	IMGT	GFTFSYY--	26 - 33	8	442
CDR-H2	Chothia	-----SPYGGD-----	52 - 57	6	443
	AbM	----YISPYGGDT-----	50 - 59	10	444
	Kabat	----YISPYGGDTSYADSVKQ	50 - 66	17	445
	Contact	WVAYISPYGGDT-----	47 - 59	13	446
	IMGT	-----ISPYGGDT-----	51 - 58	8	447
CDR-H3	Chothia	--DSYMSYIDGFDY	99 - 110	12	448
	AbM	--DSYMSYIDGFDY	99 - 110	12	449
	Kabat	--DSYMSYIDGFDY	99 - 110	12	450
	Contact	ARDSYMSYIDGFD-	97 - 109	13	451
	IMGT	ARDSYMSYIDGFDY	97 - 110	14	452
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	453
	AbM	RASQSVSSAVA--	24 - 34	11	454
	Kabat	RASQSVSSAVA--	24 - 34	11	455
	Contact	-----SSAVAWY	30 - 36	7	456
	IMGT	---QSVSSA----	27 - 32	6	457
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	458
	AbM	-----SASSLYS	50 - 56	7	459
	Kabat	-----SASSLYS	50 - 56	7	460
	Contact	LLIYSASSLY-	46 - 55	10	461
	IMGT	-----SA-----	50 - 51	2	462
CDR-L3	Chothia	QQWTSTLWT	89 - 97	9	463
	AbM	QQWTSTLWT	89 - 97	9	464
	Kabat	QQWTSTLWT	89 - 97	9	465
	Contact	QQWTSTLW-	89 - 96	8	466
	IMGT	QQWTSTLWT	89 - 97	9	467

P9-11						
CDR-H1	Chothia	GFTFSS---	26 - 32	7	468	
	AbM	GFTFSSYIH	26 - 35	10	469	
	Kabat	-----SYIH	31 - 35	5	470	
	Contact	-----SSYIH	30 - 35	6	471	
	IMGT	GFTFSSY--	26 - 33	8	472	
CDR-H2	Chothia	-----SPSGG-----	52 - 57	6	473	
	AbM	----YISPSGGTY-----	50 - 59	10	474	
	Kabat	----YISPSGGTYADSVKG	50 - 66	17	475	
	Contact	WVAVISPSGGTY-----	47 - 59	13	476	
	IMGT	-----ISPSGGT-----	51 - 58	8	477	
CDR-H3	Chothia	--GAVLYSSAMDY	99 - 109	11	478	
	AbM	--GAVLYSSAMDY	99 - 109	11	479	
	Kabat	--GAVLYSSAMDY	99 - 109	11	480	
	Contact	ARGAVLYSSAMD-	97 - 108	12	481	
	IMGT	ARGAVLYSSAMDY	97 - 109	13	482	
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	483	
	AbM	RASQSVSSAVA--	24 - 34	11	484	
	Kabat	RASQSVSSAVA--	24 - 34	11	485	
	Contact	-----SSAVAWY	30 - 36	7	486	
	IMGT	---QSVSSA----	27 - 32	6	487	
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	488	
	AbM	-----SASSLYS	50 - 56	7	489	
	Kabat	-----SASSLYS	50 - 56	7	490	
	Contact	LLIYSASSLY-	46 - 55	10	491	
	IMGT	-----SA-----	50 - 51	2	492	
CDR-L3	Chothia	QYYYPSPST	89 - 97	9	493	

	AbM	QQYYPSPST	89 - 97	9	494
	Kabat	QQYYPSPST	89 - 97	9	495
	Contact	QQYYPSPS-	89 - 96	8	496
	IMGT	QQYYPSPST	89 - 97	9	497
<b>P9-12</b>					
CDR-H1	Chothia	GTFSSY---	26 - 32	7	498
	AbM	GTFSSYWIH	26 - 35	10	499
	Kabat	-----SYWIH	31 - 35	5	500
	Contact	-----SSYWIH	30 - 35	6	501
	IMGT	GTFSSYW--	26 - 33	8	502
CDR-H2	Chothia	-----ASYFGQ-----	52 - 57	6	503
	AbM	---SIASYFGQTY-----	50 - 59	10	504
	Kabat	---SIASYFGQTYADSVKG	50 - 66	17	505
	Contact	WVASIASYFGQTY-----	47 - 59	13	506
	IMGT	-----IASYFGQT-----	51 - 58	8	507
CDR-H3	Chothia	--GFGYAAMDY	99 - 107	9	508
	AbM	--GFGYAAMDY	99 - 107	9	509
	Kabat	--GFGYAAMDY	99 - 107	9	510
	Contact	ARGFGYAAMD-	97 - 106	10	511
	IMGT	ARGFGYAAMDY	97 - 107	11	512
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	513
	AbM	RASQSVSSAVA--	24 - 34	11	514
	Kabat	RASQSVSSAVA--	24 - 34	11	515
	Contact	-----SSAVAWY	30 - 36	7	516
	IMGT	---QSVSSA----	27 - 32	6	517
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	518

	AbM	-----SASSLYS	50 - 56	7	519
	Kabat	-----SASSLYS	50 - 56	7	520
	Contact	LLIYSASSLY-	46 - 55	10	521
	IMG1	-----SA-----	50 - 51	2	522
CDR-L3	Chothia	QQEYGRPYT	89 - 97	9	523
	AbM	QQEYGRPYT	89 - 97	9	524
	Kabat	QQEYGRPYT	89 - 97	9	525
	Contact	QQEYGRPY-	89 - 96	8	526
	IMG1	QQEYGRPYT	89 - 97	9	527
P9-14					
CDR-H1	Chothia	GFTFGSY---	26 - 32	7	528
	AbM	GFTFGSYIH	26 - 35	10	529
	Kabat	-----SYI IH	31 - 35	5	530
	Contact	-----GSYI IH	30 - 35	6	531
	IMG1	GFTFGSY--	26 - 33	8	532
CDR-H2	Chothia	-----YPYFSS-----	52 - 57	6	533
	AbM	----DIYPFSSTY-----	50 - 59	10	534
	Kabat	---DIYPFSSTYADSVKG	50 - 66	17	535
	Contact	WVADIYPFSSTY-----	47 - 59	13	536
	IMG1	-----IYPFSS-----	51 - 58	8	537
CDR-H3	Chothia	--GSHFGFDY	99 - 106	8	538
	AbM	--GSHFGFDY	99 - 106	8	539
	Kabat	--GSHFGFDY	99 - 106	8	540

	Contact	ARGSHFGFD-	97 - 105	9	541
	IMGT	ARGSHFGFDY	97 - 106	10	542
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	543
	AbM	RASQSVSSAVA--	24 - 34	11	544
	Kabat	RASQSVSSAVA--	24 - 34	11	545
	Contact	-----SSAVAWY	30 - 36	7	546
	IMGT	---QSVSSA----	27 - 32	6	547
CDR-L2	Chothia	----SASSLYS	50 - 56	7	548
	AbM	----SASSLYS	50 - 56	7	549
	Kabat	----SASSLYS	50 - 56	7	550
	Contact	LLIYSASSLY-	46 - 55	10	551
	IMGT	----SA-----	50 - 51	2	552
CDR-L3	Chothia	QQHASGPLT	89 - 97	9	553
	AbM	QQHASGPLT	89 - 97	9	554
	Kabat	QQHASGPLT	89 - 97	9	555
	Contact	QQHASGPL-	89 - 96	8	556
	IMGT	QQHASGPLT	89 - 97	9	557
P9-23					
CDR-H1	Chothia	GFTFSQY----	26 - 32	7	558
	AbM	GFTFSQYIYH	26 - 35	10	559
	Kabat	-----QYYIH	31 - 35	5	560
	Contact	-----SQYIH	30 - 35	6	561
	IMGT	GFTFSQY--	26 - 33	8	562
CDR-H2	Chothia	-----YPRGGY-----	52 - 57	6	563
	AbM	----TIYPRGGYTF-----	50 - 59	10	564
	Kabat	----TIYPRGGYTFYADSVKGV	50 - 66	17	565
	Contact	WVATIYPRGGYTF-----	47 - 59	13	566

	IMG	-----IYPRGGYT-----	51 - 58	8	567
CDR-H3	Chothia	--KSYWGMDY	99 - 106	8	568
	AbM	--KSYWGMDY	99 - 106	8	569
	Kabat	--KSYWGMDY	99 - 106	8	570
	Contact	ARKSYWGMD-	97 - 105	9	571
	IMG	ARKSYWGMDY	97 - 106	10	572
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	573
	AbM	RASQSVSSAVA--	24 - 34	11	574
	Kabat	RASQSVSSAVA--	24 - 34	11	575
	Contact	-----SSAVAWY	30 - 36	7	576
	IMG	----QSVSSA----	27 - 32	6	577
CDR-L2	Chothia	----SASSLYS	50 - 56	7	578
	AbM	----SASSLYS	50 - 56	7	579
	Kabat	----SASSLYS	50 - 56	7	580
	Contact	LLIYSASSLY-	46 - 55	10	581
	IMG	----SA-----	50 - 51	2	582
CDR-L3	Chothia	QQWSVYLET	89 - 97	9	583
	AbM	QQWSVYLET	89 - 97	9	584
	Kabat	QQWSVYLET	89 - 97	9	585
	Contact	QQWSVYLE-	89 - 96	8	586
	IMG	QQWSVYLET	89 - 97	9	587
P9-24					
CDR-H1	Chothia	GFTFSS---	26 - 32	7	588
	AbM	GFTFSSYFIH	26 - 35	10	589
	Kabat	-----SYFIH	31 - 35	5	590
	Contact	-----SSYFIH	30 - 35	6	591

	IMG	GFTFSSYF--	26 - 33	8	592
CDR-H2	Chothia	-----YPTSHS-----	52 - 57	6	593
	AbM	----SIYPTSHST-----	50 - 59	10	594
	Kabat	----SIYPTSHSTSYADSVK	50 - 66	17	595
	Contact	WVASIYPTSHST-----	47 - 59	13	596
	IMG	-----IYPTSHST-----	51 - 58	8	597
CDR-H3	Chothia	--LGYPGVMDY	99 - 107	9	598
	AbM	--LGYPGVMDY	99 - 107	9	599
	Kabat	--LGYPGVMDY	99 - 107	9	600
	Contact	ARLGYPGVMD-	97 - 106	10	601
	IMG	ARLGYPGVMDY	97 - 107	11	602
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	603
	AbM	RASQSVSSAVA--	24 - 34	11	604
	Kabat	RASQSVSSAVA--	24 - 34	11	605
	Contact	-----SSAVAWY	30 - 36	7	606
	IMG	---QSVSSA----	27 - 32	6	607
CDR-L2	Chothia	----SASSLYS	50 - 56	7	608
	AbM	----SASSLYS	50 - 56	7	609
	Kabat	----SASSLYS	50 - 56	7	610
	Contact	LLIYSASSLY-	46 - 55	10	611
	IMG	-----SA-----	50 - 51	2	612
CDR-L3	Chothia	QQVDSRLAT	89 - 97	9	613
	AbM	QQVDSRLAT	89 - 97	9	614
	Kabat	QQVDSRLAT	89 - 97	9	615
	Contact	QQVDSRLA-	89 - 96	8	616
	IMG	QQVDSRLAT	89 - 97	9	617

CDR-H1	Chothia	GFTFSSY----	26 - 32	7	618
	AbM	GFTFSSYYIH	26 - 35	10	619
	Kabat	-----SYIH	31 - 35	5	620
	Contact	-----SSYYIH	30 - 35	6	621
	IMGT	GFTFSSYY--	26 - 33	8	622
CDR-H2	Chothia	-----YPYGSY-----	52 - 57	6	623
	AbM	----SIYPYGSYTY-----	50 - 59	10	624
	Kabat	----SIYPYGSYTYADSVKVG	50 - 66	17	625
	Contact	WVASIYPYGSYTY-----	47 - 59	13	626
	IMGT	----IYPYGSYTY-----	51 - 58	8	627
CDR-H3	Chothia	--LGYSSGMDY	99 - 107	9	628
	AbM	--LGYSSGMDY	99 - 107	9	629
	Kabat	--LGYSSGMDY	99 - 107	9	630
	Contact	ARLYSSGMD-	97 - 106	10	631
	IMGT	ARLYSSGMDY	97 - 107	11	632
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	633
	AbM	RASQSVSSAVA--	24 - 34	11	634
	Kabat	RASQSVSSAVA--	24 - 34	11	635
	Contact	-----SSAVAWY	30 - 36	7	636
	IMGT	----QSVSSA----	27 - 32	6	637
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	638
	AbM	-----SASSLYS	50 - 56	7	639
	Kabat	----SASSLYS	50 - 56	7	640
	Contact	LLIYSASSLY-	46 - 55	10	641
	IMGT	-----SA-----	50 - 51	2	642
CDR-L3	Chothia	QQWAPDLTT	89 - 97	9	643
	AbM	QQWAPDLTT	89 - 97	9	644
	Kabat	QQWAPDLTT	89 - 97	9	645
	Contact	QQWAPDLT-	89 - 96	8	646

	IMGT	QQWAPDLTT	89 - 97	9	647
<b>P9-26</b>					
CDR-H1	Chothia	GFTFSSY---	26 - 32	7	648
	AbM	GFTFSSYIH	26 - 35	10	649
	Kabat	-----SYIH	31 - 35	5	650
	Contact	-----SSYIH	30 - 35	6	651
	IMGT	GFTFSSY--	26 - 33	8	652
CDR-H2	Chothia	-----ESSSH	52 - 57	6	653
	AbM	---WIESSHTD-----	50 - 59	10	654
	Kabat	---WIESSSHTDYADSVKG	50 - 66	17	655
	Contact	WVWIESSSHTD-----	47 - 59	13	656
	IMGT	----IESSSHT-----	51 - 58	8	657
CDR-H3	Chothia	--LPKYYYLGVFDY	99 - 111	13	658
	AbM	--LPKYYYLGVFDY	99 - 111	13	659
	Kabat	--LPKYYYLGVFDY	99 - 111	13	660
	Contact	ARLPKYYYLGVFD-	97 - 110	14	661
	IMGT	ARLPKYYYLGVFDY	97 - 111	15	662
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	663
	AbM	RASQSVSSAVA--	24 - 34	11	664
	Kabat	RASQSVSSAVA--	24 - 34	11	665
	Contact	-----SSAVAWY	30 - 36	7	666
	IMGT	----QSVSSA----	27 - 32	6	667
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	668
	AbM	-----SASSLYS	50 - 56	7	669
	Kabat	-----SASSLYS	50 - 56	7	670
	Contact	LLIYSASSLY-	46 - 55	10	671
	IMGT	-----SA-----	50 - 51	2	672

CDR-L3	Chothia	QQYSSSLYT	89 - 97	9	673
	AbM	QQYSSSLYT	89 - 97	9	674
	Kabat	QQYSSSLYT	89 - 97	9	675
	Contact	QQYSSSLY-	89 - 96	8	676
	IMGT	QQYSSSLYT	89 - 97	9	677
<b>P9-29</b>					
CDR-H1	Chothia	GFTFSSY---	26 - 32	7	678
	AbM	GFTFSSYAIH	26 - 35	10	679
	Kabat	-----SYAIH	31 - 35	5	680
	Contact	-----SSYAIH	30 - 35	6	681
	IMGT	GFTFSSYA--	26 - 33	8	682
CDR-H2	Chothia	-----APGGSY-----	52 - 57	6	683
	AbM	----YIAPGGSYTY-----	50 - 59	10	684
	Kabat	----YIAPGGSYTYVADSVKG	50 - 66	17	685
	Contact	WVAYIAPGGSYTY-----	47 - 59	13	686
	IMGT	-----IAPGGSYT-----	51 - 58	8	687
CDR-H3	Chothia	--LSYFGVMDY	99 - 107	9	688
	AbM	--LSYFGVMDY	99 - 107	9	689
	Kabat	--LSYFGVMDY	99 - 107	9	690
	Contact	ARLSYFGVMD-	97 - 106	10	691
	IMGT	ARLSYFGVMDY	97 - 107	11	692
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	693
	AbM	RASQSVSSAVA--	24 - 34	11	694
	Kabat	RASQSVSSAVA--	24 - 34	11	695
	Contact	-----SSAVAWY	30 - 36	7	696
	IMGT	----QSVSSA----	27 - 32	6	697
CDR-L2	Chothia	----SASSLYS	50 - 56	7	698

	AbM	-----SASSLYS	50 - 56	7	699
	Kabat	-----SASSLYS	50 - 56	7	700
	Contact	LLIYSASSLY-	46 - 55	10	701
	IMG1	-----SA-----	50 - 51	2	702
CDR-I3	Chothia	QQGYSSLLT	89 - 97	9	703
	AbM	QQGYSSLLT	89 - 97	9	704
	Kabat	QQGYSSLLT	89 - 97	9	705
	Contact	QQGYSSLL-	89 - 96	8	706
	IMG1	QQGYSSLLT	89 - 97	9	707
<b>P9-30</b>					
CDR-H1	Chothia	GFTFSY---	26 - 32	7	708
	AbM	GFTFSYTIH	26 - 35	10	709
	Kabat	-----TYTIH	31 - 35	5	710
	Contact	-----STYTIH	30 - 35	6	711
	IMG1	GFTFSYTI--	26 - 33	8	712
CDR-H2	Chothia	-----YPKGGS-----	52 - 57	6	713
	AbM	----WIYPKGGSTD-----	50 - 59	10	714
	Kabat	---WIYPKGGSTDYADSVKG	50 - 66	17	715
	Contact	WVAWIYPKGGSTD-----	47 - 59	13	716
	IMG1	-----IYPKGGST-----	51 - 58	8	717
CDR-H3	Chothia	--PSGYGFDY	99 - 106	8	718
	AbM	--PSGYGFDY	99 - 106	8	719
	Kabat	--PSGYGFDY	99 - 106	8	720
	Contact	ARPSGYGFD-	97 - 105	9	721
	IMG1	ARPSGYGFDY	97 - 106	10	722
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	723
	AbM	RASQSVSSAVA--	24 - 34	11	724

	Kabat	RASQSVSSAVA--	24 - 34	11	725
	Contact	-----SSAVAWY	30 - 36	7	726
	IMGT	---QSVSSA----	27 - 32	6	727
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	728
	AbM	-----SASSLYS	50 - 56	7	729
	Kabat	-----SASSLYS	50 - 56	7	730
	Contact	LLIYSASSLY-	46 - 55	10	731
	IMGT	-----SA-----	50 - 51	2	732
CDR-L3	Chothia	QQYLSSPYT	89 - 97	9	733
	AbM	QQYLSSPYT	89 - 97	9	734
	Kabat	QQYLSSPYT	89 - 97	9	735
	Contact	QQYLSSPY-	89 - 96	8	736
	IMGT	QQYLSSPYT	89 - 97	9	737
<b>P9-34</b>					
CDR-H1	Chothia	GFTFSTY----	26 - 32	7	738
	AbM	GFTFSTYFIH	26 - 35	10	739
	Kabat	-----TYFIH	31 - 35	5	740
	Contact	-----STYFIH	30 - 35	6	741
	IMGT	GFTFSTYF--	26 - 33	8	742
CDR-H2	Chothia	-----YPQGGY-----	52 - 57	6	743
	AbM	---YIYPQGGTY-----	50 - 59	10	744
	Kabat	---YIYPQGGTYADSVKVG	50 - 66	17	745
	Contact	WVAIYPQGGTY-----	47 - 59	13	746
	IMGT	-----IYPQGGYT-----	51 - 58	8	747
CDR-H3	Chothia	--QSYPGVFDY	99 - 107	9	748
	AbM	--QSYPGVFDY	99 - 107	9	749
	Kabat	--QSYPGVFDY	99 - 107	9	750

	Contact	ARQSYPGVFD-	97 - 106	10	751
	IMGT	ARQSYPGVFDY	97 - 107	11	752
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	753
	AbM	RASQSVSSAVA--	24 - 34	11	754
	Kabat	RASQSVSSAVA--	24 - 34	11	755
	Contact	-----SSAVAWY	30 - 36	7	756
	IMGT	---QSVSSA----	27 - 32	6	757
CDR-L2	Chothia	----SASSLYS	50 - 56	7	758
	AbM	----SASSLYS	50 - 56	7	759
	Kabat	----SASSLYS	50 - 56	7	760
	Contact	LLIYSASSLY-	46 - 55	10	761
	IMGT	----SA-----	50 - 51	2	762
CDR-L3	Chothia	QQTIALTT	89 - 97	9	763
	AbM	QQTIALTT	89 - 97	9	764
	Kabat	QQTIALTT	89 - 97	9	765
	Contact	QQTIALTT-	89 - 96	8	766
	IMGT	QQTIALTT	89 - 97	9	767
P9-37					
CDR-H1	Chothia	GFTFSSY----	26 - 32	7	768
	AbM	GFTFSSYWIH	26 - 35	10	769
	Kabat	-----SYWIH	31 - 35	5	770
	Contact	-----SSYWIH	30 - 35	6	771
	IMGT	GFTFSSYW--	26 - 33	8	772
CDR-H2	Chothia	-----DPDYG	52 - 57	6	773
	AbM	---WIDPDYGTS-----	50 - 59	10	774
	Kabat	---WIDPDYGTSYADSVKG	50 - 66	17	775
	Contact	WVAWIDPDYGTS-----	47 - 59	13	776

	IMG	-----IDPDYGT-----	51 - 58	8	777
CDR-H3	Chothia	--SETGAAMDY	99 - 107	9	778
	AbM	--SETGAAMDY	99 - 107	9	779
	Kabat	--SETGAAMDY	99 - 107	9	780
	Contact	ARSETGAAMD-	97 - 106	10	781
	IMG	ARSETGAAMDY	97 - 107	11	782
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	783
	AbM	RASQSVSSAVA--	24 - 34	11	784
	Kabat	RASQSVSSAVA--	24 - 34	11	785
	Contact	-----SSAVAWY	30 - 36	7	786
	IMG	---QSVSSA----	27 - 32	6	787
CDR-L2	Chothia	----SASSLYS	50 - 56	7	788
	AbM	----SASSLYS	50 - 56	7	789
	Kabat	----SASSLYS	50 - 56	7	790
	Contact	LLIYSASSLY-	46 - 55	10	791
	IMG	----SA-----	50 - 51	2	792
CDR-L3	Chothia	QQGSYFLQT	89 - 97	9	793
	AbM	QQGSYFLQT	89 - 97	9	794
	Kabat	QQGSYFLQT	89 - 97	9	795
	Contact	QQGSYFLQ-	89 - 96	8	796
	IMG	QQGSYFLQT	89 - 97	9	797
<b>P9-40</b>					
CDR-H1	Chothia	GTFRWY---	26 - 32	7	798
	AbM	GTFRWYIYH	26 - 35	10	799
	Kabat	-----WYIYH	31 - 35	5	800
	Contact	----RWYIYH	30 - 35	6	801
	IMG	GTFRWYIYH	26 - 33	8	802

CDR-H2	Chothia	-----YPDWDY-----	52 - 57	6	803
	AbM	---TIYPDWDYTT-----	50 - 59	10	804
	Kabat	---TIYPDWDYTYADSVKG	50 - 66	17	805
	Contact	WVATIYPDWDYTT-----	47 - 59	13	806
	IMGT	-----IYPDWDYTT-----	51 - 58	8	807
CDR-H3	Chothia	--SPVTGPGYGFY	99 - 109	11	808
	AbM	--SPVTGPGYGFY	99 - 109	11	809
	Kabat	--SPVTGPGYGFY	99 - 109	11	810
	Contact	ARSPVTGPGYGFY-	97 - 108	12	811
	IMGT	ARSPVTGPGYGFY	97 - 109	13	812
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	813
	AbM	RASQSVSSAVA--	24 - 34	11	814
	Kabat	RASQSVSSAVA--	24 - 34	11	815
	Contact	-----SSAVAWY	30 - 36	7	816
	IMGT	---QSVSSA----	27 - 32	6	817
CDR-L2	Chothia	----SASSLYS	50 - 56	7	818
	AbM	----SASSLYS	50 - 56	7	819
	Kabat	----SASSLYS	50 - 56	7	820
	Contact	LLIYSASSLY-	46 - 55	10	821
	IMGT	-----SA-----	50 - 51	2	822
CDR-L3	Chothia	QQPTYSLWT	89 - 97	9	823
	AbM	QQPTYSLWT	89 - 97	9	824
	Kabat	QQPTYSLWT	89 - 97	9	825
	Contact	QQPTYSLW-	89 - 96	8	826
	IMGT	QQPTYSLWT	89 - 97	9	827
<b>P9-41</b>					
CDR-H1	Chothia	GFTRYI----	26 - 32	7	828

	AbM	GFTFRYYWIH	26 - 35	10	829
	Kabat	-----YYWIH	31 - 35	5	830
	Contact	-----RYWIH	30 - 35	6	831
	IMGT	GFTFRYYW--	26 - 33	8	832
CDR-H2	Chothia	-----YPSSDS-----	52 - 57	6	833
	AbM	---A IYSSDSTV-----	50 - 59	10	834
	Kabat	---A IYSSDSTVYADSVKG	50 - 66	17	835
	Contact	WVAA IYSSDSTV-----	47 - 59	13	836
	IMGT	-----IYSSDST-----	51 - 58	8	837
CDR-H3	Chothia	--SSPYPGQGVFDY	99 - 111	13	838
	AbM	--SSPYPGQGVFDY	99 - 111	13	839
	Kabat	--SSPYPGQGVFDY	99 - 111	13	840
	Contact	ARSSPYPGQGVFD-	97 - 110	14	841
	IMGT	ARSSPYPGQGVFDY	97 - 111	15	842
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	843
	AbM	RASQSVSSAVA--	24 - 34	11	844
	Kabat	RASQSVSSAVA--	24 - 34	11	845
	Contact	-----SSAVAWY	30 - 36	7	846
	IMGT	---QSVSSA-----	27 - 32	6	847
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	848
	AbM	-----SASSLYS	50 - 56	7	849
	Kabat	-----SASSLYS	50 - 56	7	850
	Contact	LLIYSASSLY-	46 - 55	10	851
	IMGT	-----SA-----	50 - 51	2	852
CDR-L3	Chothia	QQWYSSLWT	89 - 97	9	853
	AbM	QQWYSSLWT	89 - 97	9	854
	Kabat	QQWYSSLWT	89 - 97	9	855
	Contact	QQWYSSLW-	89 - 96	8	856
	IMGT	QQWYSSLWT	89 - 97	9	857

## P9-42

CDR-H1	Chothia	GFTFFSSY---	26 - 32	7	858
	AbM	GFTFFSSYYIH	26 - 35	10	859
	Kabat	-----SYVIH	31 - 35	5	860
	Contact	-----SSYVIH	30 - 35	6	861
	IMGT	GFTFFSSYY--	26 - 33	8	862
CDR-H2	Chothia	-----YSAWGT-----	52 - 57	6	863
	AbM	---AAYSAWGTTY-----	50 - 59	10	864
	Kabat	---AAYSAWGTTYADSVKG	50 - 66	17	865
	Contact	WVAAAYSAWGTTY-----	47 - 59	13	866
	IMGT	-----IYSAWGTT-----	51 - 58	8	867
CDR-H3	Chothia	--SYGVVFGYVSGMDY	99 - 112	14	868
	AbM	--SYGVVFGYVSGMDY	99 - 112	14	869
	Kabat	--SYGVVFGYVSGMDY	99 - 112	14	870
	Contact	ARSYGVVFGYVSGMD-	97 - 111	15	871
	IMGT	ARSYGVVFGYVSGMDY	97 - 112	16	872
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	873
	AbM	RASQSVSSAVA--	24 - 34	11	874
	Kabat	RASQSVSSAVA--	24 - 34	11	875
	Contact	-----SSAVAWY	30 - 36	7	876
	IMGT	---QSVSSA----	27 - 32	6	877
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	878
	AbM	-----SASSLYS	50 - 56	7	879
	Kabat	-----SASSLYS	50 - 56	7	880
	Contact	LLIYSASSLY-	46 - 55	10	881
	IMGT	-----SA-----	50 - 51	2	882
CDR-L3	Chothia	QQWSSDLVT	89 - 97	9	883

	AbM	QQWSSDLVT	89 - 97		9	884
	Kabat	QQWSSDLVT	89 - 97		9	885
	Contact	QQWSSDLV-	89 - 96		8	886
	IMGT	QQWSSDLVT	89 - 97		9	887
<b>P9-43</b>						
CDR-H1	Chothia	GTFHSHY---	26 - 32		7	888
	AbM	GTFHSHYIH	26 - 35		10	889
	Kabat	-----SYWIH	31 - 35		5	890
	Contact	----HSYWIH	30 - 35		6	891
	IMGT	GTFHSHYW--	26 - 33		8	892
CDR-H2	Chothia	-----DSSKFG-----	52 - 57		6	893
	AbM	---RIDSSKFGTY-----	50 - 59		10	894
	Kabat	---RIDSSKFGTYADSVKG	50 - 66		17	895
	Contact	WVARIDSSKFGTY-----	47 - 59		13	896
	IMGT	-----IDSSKFGT-----	51 - 58		8	897
CDR-H3	Chothia	--SYIDYVPVSPAVFDY	99 - 112		14	898
	AbM	--SYIDYVPVSPAVFDY	99 - 112		14	899
	Kabat	--SYIDYVPVSPAVFDY	99 - 112		14	900
	Contact	ARSYIDYVPVSPAVFD-	97 - 111		15	901
	IMGT	ARSYIDYVPVSPAVFDY	97 - 112		16	902
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34		11	903
	AbM	RASQSVSSAVA--	24 - 34		11	904
	Kabat	RASQSVSSAVA--	24 - 34		11	905
	Contact	-----SSAVAWY	30 - 36		7	906
	IMGT	---QSVSSA----	27 - 32		6	907
CDR-L2	Chothia	-----SASSLYS	50 - 56		7	908
	AbM	-----SASSLYS	50 - 56		7	909

	Kabat	-----SASSLYS	50 - 56	7	910
	Contact	LLIYSASSLY-	46 - 55	10	911
	IMGT	-----SA-----	50 - 51	2	912
CDR-L3	Chothia	QQVYFSPYT	89 - 97	9	913
	AbM	QQVYFSPYT	89 - 97	9	914
	Kabat	QQVYFSPYT	89 - 97	9	915
	Contact	QQVYFSPY-	89 - 96	8	916
	IMGT	QQVYFSPYT	89 - 97	9	917
<b>P9-44</b>					
CDR-H1	Chothia	GFTFSY----	26 - 32	7	918
	AbM	GFTFSYWIH	26 - 35	10	919
	Kabat	-----YYWIH	31 - 35	5	920
	Contact	-----SYWIH	30 - 35	6	921
	IMGT	GFTFSY--	26 - 33	8	922
CDR-H2	Chothia	-----SPSGY-----	52 - 57	6	923
	AbM	---AISPSGSYTS-----	50 - 59	10	924
	Kabat	---AISPSGSYTSYADSVKG	50 - 66	17	925
	Contact	WVAAISPSGSYTS-----	47 - 59	13	926
	IMGT	-----ISPSGSYT-----	51 - 58	8	927
CDR-H3	Chothia	--SYRFRTPYTMVDY	99 - 112	14	928
	AbM	--SYRFRTPYTMVDY	99 - 112	14	929
	Kabat	--SYRFRTPYTMVDY	99 - 112	14	930
	Contact	ARSYRFRTPYTMVD-	97 - 111	15	931
	IMGT	ARSYRFRTPYTMVDY	97 - 112	16	932
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	933
	AbM	RASQSVSSAVA--	24 - 34	11	934
	Kabat	RASQSVSSAVA--	24 - 34	11	935

	Contact	-----SSAVAWY	30 - 36	7	936
	IMGT	---QSVSSA----	27 - 32	6	937
CDR-L2	Chothia	----SASSLYS	50 - 56	7	938
	AbM	----SASSLYS	50 - 56	7	939
	Kabat	----SASSLYS	50 - 56	7	940
	Contact	LLIYSASSLY-	46 - 55	10	941
	IMGT	----SA-----	50 - 51	2	942
CDR-L3	Chothia	QQGIDSPET	89 - 97	9	943
	AbM	QQGIDSPET	89 - 97	9	944
	Kabat	QQGIDSPET	89 - 97	9	945
	Contact	QQGIDSPET	89 - 96	8	946
	IMGT	QQGIDSPET	89 - 97	9	947
P9-45					
CDR-H1	Chothia	GFTFFSY---	26 - 32	7	948
	AbM	GFTFFSYVIH	26 - 35	10	949
	Kabat	-----SYVIH	31 - 35	5	950
	Contact	----FSYVIH	30 - 35	6	951
	IMGT	GFTFFSYV--	26 - 33	8	952
CDR-H2	Chothia	-----YPYSGY-----	52 - 57	6	953
	AbM	---AIPYSGYTT-----	50 - 59	10	954
	Kabat	---AIPYSGYTYADSVKG	50 - 66	17	955
	Contact	WVAAIYPYSGYTT-----	47 - 59	13	956
	IMGT	-----IYPYSGY-----	51 - 58	8	957
CDR-H3	Chothia	--TKYYDYHVFDY	99 - 109	11	958
	AbM	--TKYYDYHVFDY	99 - 109	11	959
	Kabat	--TKYYDYHVFDY	99 - 109	11	960
	Contact	ARTKYYDYHVFD-	97 - 108	12	961

	IMGT	ARTKYDYHVFYD	97 - 109	13	962
CDR-I1	Chothia	RASQSVSSAVA--	24 - 34	11	963
	AbM	RASQSVSSAVA--	24 - 34	11	964
	Kabat	RASQSVSSAVA--	24 - 34	11	965
	Contact	-----SSAVAWY	30 - 36	7	966
	IMGT	---QSVSSA----	27 - 32	6	967
CDR-I2	Chothia	----SASSLYS	50 - 56	7	968
	AbM	----SASSLYS	50 - 56	7	969
	Kabat	----SASSLYS	50 - 56	7	970
	Contact	LLIYSASSLY-	46 - 55	10	971
	IMGT	----SA-----	50 - 51	2	972
CDR-I3	Chothia	QQGWDSLVT	89 - 97	9	973
	AbM	QQGWDSLVT	89 - 97	9	974
	Kabat	QQGWDSLVT	89 - 97	9	975
	Contact	QQGWDSLVT-	89 - 96	8	976
	IMGT	QQGWDSLVT	89 - 97	9	977
P9-46					
CDR-H1	Chothia	GFTFSRY---	26 - 32	7	978
	AbM	GFTFSRYIH	26 - 35	10	979
	Kabat	-----RYIH	31 - 35	5	980
	Contact	----SRXYIH	30 - 35	6	981
	IMGT	GFTFSRY---	26 - 33	8	982
CDR-H2	Chothia	-----SSDSGY-----	52 - 57	6	983
	AbM	----FISSDSGYTQ-----	50 - 59	10	984
	Kabat	----FISSDSGYTQVADSVKG	50 - 66	17	985
	Contact	WVAFISSDSGYTQ-----	47 - 59	13	986

	IMG	-----ISSDSGYT-----	51 - 58	8	987
CDR-H3	Chothia	--TMSYSALDY	99 - 107	9	988
	AbM	--TMSYSALDY	99 - 107	9	989
	Kabat	--TMSYSALDY	99 - 107	9	990
	Contact	ARTMSYSALD-	97 - 106	10	991
	IMG	ARTMSYSALDY	97 - 107	11	992
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	993
	AbM	RASQSVSSAVA--	24 - 34	11	994
	Kabat	RASQSVSSAVA--	24 - 34	11	995
	Contact	-----SSAVAWY	30 - 36	7	996
	IMG	---QSVSSA----	27 - 32	6	997
CDR-L2	Chothia	----SASSLYS	50 - 56	7	998
	AbM	----SASSLYS	50 - 56	7	999
	Kabat	----SASSLYS	50 - 56	7	1000
	Contact	LLIYSASSLY-	46 - 55	10	1001
	IMG	----SA-----	50 - 51	2	1002
CDR-L3	Chothia	QYWWSPET	89 - 97	9	1003
	AbM	QYWWSPET	89 - 97	9	1004
	Kabat	QYWWSPET	89 - 97	9	1005
	Contact	QYWWSPE-	89 - 96	8	1006
	IMG	QYWWSPET	89 - 97	9	1007
P9-50					
CDR-H1	Chothia	GTFSSY---	26 - 32	7	1008
	AbM	GTFSSVVIH	26 - 35	10	1009
	Kabat	-----SYVIH	31 - 35	5	1010
	Contact	-----SSVVIH	30 - 35	6	1011
	IMG	GTFSSVVIH	26 - 33	8	1012

CDR-H2	Chothia	-----YSSGGY-----	52 - 57	6	1013
	AbM	---LIYSSGGYTQ-----	50 - 59	10	1014
	Kabat	---LIYSSGGYTQYADSVKG	50 - 66	17	1015
	Contact	WVALIYSSGGYTQ-----	47 - 59	13	1016
	IMG1	-----IYSSGGYT-----	51 - 58	8	1017
CDR-H3	Chothia	--VGTTPSPRYLEALDY	99 - 113	15	1018
	AbM	--VGTTPSPRYLEALDY	99 - 113	15	1019
	Kabat	--VGTTPSPRYLEALDY	99 - 113	15	1020
	Contact	ARVGTTPSPRYLEALD-	97 - 112	16	1021
	IMG1	ARVGTTPSPRYLEALDY	97 - 113	17	1022
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	1023
	AbM	RASQSVSSAVA--	24 - 34	11	1024
	Kabat	RASQSVSSAVA--	24 - 34	11	1025
	Contact	-----SSAVAWY	30 - 36	7	1026
	IMG1	---QSVSSA----	27 - 32	6	1027
CDR-L2	Chothia	----SASSLYS	50 - 56	7	1028
	AbM	----SASSLYS	50 - 56	7	1029
	Kabat	----SASSLYS	50 - 56	7	1030
	Contact	LLIYSASSLY-	46 - 55	10	1031
	IMG1	-----SA-----	50 - 51	2	1032
CDR-L3	Chothia	QQFGSSLPT	89 - 97	9	1033
	AbM	QQFGSSLPT	89 - 97	9	1034
	Kabat	QQFGSSLPT	89 - 97	9	1035
	Contact	QQFGSSLP-	89 - 96	8	1036
	IMG1	QQFGSSLPT	89 - 97	9	1037

CDR-H1	Chothia	GFTFSSY----	26 - 32	7	1038
	AbM	GFTFSSYYIH	26 - 35	10	1039
	Kabat	-----SYIH	31 - 35	5	1040
	Contact	-----SSYYIH	30 - 35	6	1041
	IMGT	GFTFSSYY--	26 - 33	8	1042
CDR-H2	Chothia	-----YPEGSY-----	52 - 57	6	1043
	AbM	----GIYPEGSYTY-----	50 - 59	10	1044
	Kabat	----GIYPEGSYTYADSVKVG	50 - 66	17	1045
	Contact	WVAGIYPEGSYTY-----	47 - 59	13	1046
	IMGT	----IYPEGSYT-----	51 - 58	8	1047
CDR-H3	Chothia	--VGYPGVMDY	99 - 107	9	1048
	AbM	--VGYPGVMDY	99 - 107	9	1049
	Kabat	--VGYPGVMDY	99 - 107	9	1050
	Contact	ARVGYPGVMD-	97 - 106	10	1051
	IMGT	ARVGYPGVMDY	97 - 107	11	1052
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	1053
	AbM	RASQSVSSAVA--	24 - 34	11	1054
	Kabat	RASQSVSSAVA--	24 - 34	11	1055
	Contact	-----SSAVAWY	30 - 36	7	1056
	IMGT	----QSVSSA----	27 - 32	6	1057
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	1058
	AbM	-----SASSLYS	50 - 56	7	1059
	Kabat	----SASSLYS	50 - 56	7	1060
	Contact	LLIYSASSLY-	46 - 55	10	1061
	IMGT	-----SA-----	50 - 51	2	1062
CDR-L3	Chothia	QQWGSSLAT	89 - 97	9	1063
	AbM	QQWGSSLAT	89 - 97	9	1064
	Kabat	QQWGSSLAT	89 - 97	9	1065
	Contact	QQWGSSLA-	89 - 96	8	1066

	IMG	QWGSLAT	89 - 97	9	1067
<b>P9-52</b>					
CDR-H1	Chothia	GFFFSYTV----	26 - 32	7	1068
	AbM	GFFFSYLLIH	26 - 35	10	1069
	Kabat	-----TYLIH	31 - 35	5	1070
	Contact	-----STLIH	30 - 35	6	1071
	IMG	GFFFSYTL--	26 - 33	8	1072
CDR-H2	Chothia	-----TPYSGY-----	52 - 57	6	1073
	AbM	---AIPYSGYTS-----	50 - 59	10	1074
	Kabat	---AIPYSGYTSYADSVK	50 - 66	17	1075
	Contact	WVAALTPYSGYTS-----	47 - 59	13	1076
	IMG	-----ITPYSGYT-----	51 - 58	8	1077
CDR-H3	Chothia	--VGYPMVMDY	99 - 107	9	1078
	AbM	--VGYPMVMDY	99 - 107	9	1079
	Kabat	--VGYPMVMDY	99 - 107	9	1080
	Contact	ARVGYPMVMD-	97 - 106	10	1081
	IMG	ARVGYPMVMDY	97 - 107	11	1082
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	1083
	AbM	RASQSVSSAVA--	24 - 34	11	1084
	Kabat	RASQSVSSAVA--	24 - 34	11	1085
	Contact	-----SSAVAWY	30 - 36	7	1086
	IMG	----QSVSSA----	27 - 32	6	1087
CDR-L2	Chothia	-----SASSLYS	50 - 56	7	1088
	AbM	-----SASSLYS	50 - 56	7	1089
	Kabat	-----SASSLYS	50 - 56	7	1090
	Contact	LIIYSASSLY-	46 - 55	10	1091
	IMG	-----SA-----	50 - 51	2	1092

CDR-L3	Chothia	QQLDYSLAT	89 - 97	9	1093
	AbM	QQLDYSLAT	89 - 97	9	1094
	Kabat	QQLDYSLAT	89 - 97	9	1095
	Contact	QQLDYSLA-	89 - 96	8	1096
	IMGT	QQLDYSLAT	89 - 97	9	1097
<b>P9-53</b>					
CDR-H1	Chothia	GFTFSRY---	26 - 32	7	1098
	AbM	GFTFSRYQIH	26 - 35	10	1099
	Kabat	-----RYQIH	31 - 35	5	1100
	Contact	-----SRYQIH	30 - 35	6	1101
	IMGT	GFTFSRYQ--	26 - 33	8	1102
CDR-H2	Chothia	-----ASASGT-----	52 - 57	6	1103
	AbM	----YIASASGTS-----	50 - 59	10	1104
	Kabat	----YIASASGTTSYADSVKG	50 - 66	17	1105
	Contact	WVAYIASASGTT-----	47 - 59	13	1106
	IMGT	-----IASASGTT-----	51 - 58	8	1107
CDR-H3	Chothia	---VPYVAMDY	99 - 106	8	1108
	AbM	--VPYVAMDY	99 - 106	8	1109
	Kabat	---VPYVAMDY	99 - 106	8	1110
	Contact	ARVPYVAMD-	97 - 105	9	1111
	IMGT	ARVPYVAMDY	97 - 106	10	1112
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	1113
	AbM	RASQSVSSAVA--	24 - 34	11	1114
	Kabat	RASQSVSSAVA--	24 - 34	11	1115
	Contact	-----SSAVAWY	30 - 36	7	1116

	IMGT	---QSVSSA----	27 - 32	6	1117
CDR-I2	Chothia	----SASSLYS	50 - 56	7	1118
	AbM	----SASSLYS	50 - 56	7	1119
	Kabat	----SASSLYS	50 - 56	7	1120
	Contact	LLIYSASSLY-	46 - 55	10	1121
	IMGT	----SA-----	50 - 51	2	1122
CDR-I3	Chothia	QQGYPHPGT	89 - 97	9	1123
	AbM	QQGYPHPGT	89 - 97	9	1124
	Kabat	QQGYPHPGT	89 - 97	9	1125
	Contact	QQGYPHPG-	89 - 96	8	1126
	IMGT	QQGYPHPGT	89 - 97	9	1127
<b>P9-56</b>					
CDR-H1	Chothia	GFTFSSY---	26 - 32	7	1128
	AbM	GFTFSSYIH	26 - 35	10	1129
	Kabat	-----SYIH	31 - 35	5	1130
	Contact	----SSYIH	30 - 35	6	1131
	IMGT	GFTFSSY--	26 - 33	8	1132
CDR-H2	Chothia	-----DSSGKY-----	52 - 57	6	1133
	AbM	---YIDSSGKYTD-----	50 - 59	10	1134
	Kabat	---YIDSSGKYTDYADSVKG	50 - 66	17	1135
	Contact	WVAXIDSSGKYTD-----	47 - 59	13	1136
	IMGT	-----IDSSGKYT-----	51 - 58	8	1137
CDR-H3	Chothia	--YAYPGVMDY	99 - 107	9	1138
	AbM	--YAYPGVMDY	99 - 107	9	1139
	Kabat	--YAYPGVMDY	99 - 107	9	1140
	Contact	ARYAYPGVMD-	97 - 106	10	1141

	IMG	ARYAYPGVMDY	97 - 107	11	1142
CDR-I1	Chothia	RASQSVSSAVA--	24 - 34	11	1143
	AbM	RASQSVSSAVA--	24 - 34	11	1144
	Kabat	RASQSVSSAVA--	24 - 34	11	1145
	Contact	-----SSAVAWY	30 - 36	7	1146
	IMG	---QSVSSA----	27 - 32	6	1147
CDR-I2	Chothia	----SASSLYS	50 - 56	7	1148
	AbM	----SASSLYS	50 - 56	7	1149
	Kabat	----SASSLYS	50 - 56	7	1150
	Contact	LIYSASSLY-	46 - 55	10	1151
	IMG	----SA-----	50 - 51	2	1152
CDR-I3	Chothia	QQYDYSLWT	89 - 97	9	1153
	AbM	QQYDYSLWT	89 - 97	9	1154
	Kabat	QQYDYSLWT	89 - 97	9	1155
	Contact	QQYDYSLW-	89 - 96	8	1156
	IMG	QQYDYSLWT	89 - 97	9	1157
P9-57					
CDR-H1	Chothia	GFTFSSY---	26 - 32	7	1158
	AbM	GFTFSSYYIH	26 - 35	10	1159
	Kabat	-----SYIYH	31 - 35	5	1160
	Contact	----SSYYIH	30 - 35	6	1161
	IMG	GFTFSSYY--	26 - 33	8	1162
CDR-H2	Chothia	-----YPSGGY-----	52 - 57	6	1163
	AbM	----TIYPSGGYTY-----	50 - 59	10	1164
	Kabat	---TIYPSGGTYVADSVKVG	50 - 66	17	1165
	Contact	WVATIYPSGGYTY-----	47 - 59	13	1166

	IMG	-----IYPSGGYT-----	51 - 58	8	1167
CDR-H3	Chothia	--YSYPGVLDY	99 - 107	9	1168
	AbM	--YSYPGVLDY	99 - 107	9	1169
	Kabat	--YSYPGVLDY	99 - 107	9	1170
	Contact	ARYSYPGVLD-	97 - 106	10	1171
	IMG	ARYSYPGVLDY	97 - 107	11	1172
CDR-L1	Chothia	RASQSVSSAVA--	24 - 34	11	1173
	AbM	RASQSVSSAVA--	24 - 34	11	1174
	Kabat	RASQSVSSAVA--	24 - 34	11	1175
	Contact	-----SSAVAWY	30 - 36	7	1176
	IMG	---QSVSSA----	27 - 32	6	1177
CDR-L2	Chothia	----SASSLYS	50 - 56	7	1178
	AbM	----SASSLYS	50 - 56	7	1179
	Kabat	----SASSLYS	50 - 56	7	1180
	Contact	LLIYSASSLY-	46 - 55	10	1181
	IMG	----SA-----	50 - 51	2	1182
CDR-L3	Chothia	QQSSSFLWT	89 - 97	9	1183
	AbM	QQSSSFLWT	89 - 97	9	1184
	Kabat	QQSSSFLWT	89 - 97	9	1185
	Contact	QQSSSFLW-	89 - 96	8	1186
	IMG	QQSSSFLWT	89 - 97	9	1187

**[0330]** **Table 6** presents full immunoglobulin heavy and full immunoglobulin light chain sequences, and the VH and VL sequences, of various ABS candidates formatted into a bivalent monospecific human full-length IgG1 architecture.

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-01	EVQLVESGGGLVQPGGS LRLSCAASGFTFSSYWIH WVRQAPGKGLEWVAWI DPDYGTTSYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARAGIS YVFDYWGQGTLVTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTP EVTCTVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL KNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFCSSV MHEALHNHYTQKSLSLS PGK	DIQMTQSPSSLSASVGDRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQQVSDL LTFGQGTKVEIKRTVAAPS VFIFPPSDSQLKSGTASVVC LLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFSSYWI HWVRQAPGKGG LEWVAWIDPD YGTTSYADSVK GRFTISADTSKN TAYLQMNSLRA EDTAVYYCAR AGISYVFDYWG QGTLTVTVSS	DIQMTQSPSS LSASVGDRV TITCRASQSV SSAVAWYQQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFLTISSLQ PEDFATYYC QQQVSDLLT FGQGTKVEIK RTV

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-02A	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYWIHWVRQAPGK GLEWVAVI DPDYGTTSYADSVKGRF TISADTSKNTAYLQMNSLRAEDTAVYYC ARAQYVPGLDYWGQGT LTVTS SASTKGPSVFLAPSSKS TSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTP EVTCTVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFCSSV MHEALHNHYTQKSLSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSA VAWYQQKPGKAPKLLI YSASSLYSGVPSRFSG SRSGTDFTLTISSLQ PEDFATYYCQGSYPTL GTFGQGTKVEIKRTVA AAPSVFIFPPSDSQLK SGTASVVCLENNFY PREAKVQWKVDNALQ SGNSQESVTEQDSKDS TYSLSSTLTLSKADY EKHKVYACEVTHQGL SSPVTKSFNRGEC	EVQLVESGGGLVQP GGSLRLSCAASGFTF SSYWIHWVRQAPGK GLEWVAVI DPDYGT TSYADSVKGRFTIS ADTSKNTAYLQMNS LRAEDTAVYYCARA QYVPGLDYWGQGT LTVTS GRFTISADTS KNTAYLQMNSLRA EDTAVYYCARAQY VPGLDYWGQGT LTVTS	DIQMTQSPSSLSA SVGDRVLSASV GDRVTITCRASQSV SSAVAWYQQSSA VAWYQQKPGKAPK LLIYSASSLYSGV YSSASSLYSGVPS RFSGSRSGTDFTL TISSLPEDFATYYC QGSYPTLGTGQGT KVEIKR TV
P9-03	EVQLVESGGGLVQPGGSLRLS CAASGFTFSGYYIHWVRQAPGK GLEWVAVI SPYSGYTSYADSVKGRF TISADTSKNTAYLQMNSLRAEDTAVYYC ARATY MVPYGF DYWGQGT LTVTS VSSASTKGPSV FLAPSSKSTSGGTAALGCLVKDY FPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSS VTVPSSSLGTQTYICNVNHKPSNTK VDKKVEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTP EVTCTVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWES NGQPENNYKTTPPVLDSDGSFFLYSK LTVDKSRWQQGNVFCSSVMHEALHN HYTQKSLSLSPGK	DIQMTQSPSSLSA SVGDRV TITCRASQSVSSA VAWYQQKPGKAPKLLI YSASSLYSGVPSRFSG SRSGTDFTLTISSLQ PEDFATYYCQGGG SFPYTFGQGTKVEIKRTVA AAPSVFIFPPSDSQLK SGTASVVCLENNFY PREAKVQWKVDNALQ SGNSQESVTEQDSKDS TYSLSSTLTLSKADY EKHKVYACEVTHQGL SSPVTKSFNRGEC	EVQLVESGGGLVQP GGSLRLSCAASGFTF SGYYIHWVRQAPGK GLEWVAVI SPYSGY TSYADSVKGRFTIS ADTSKNTAYLQMNS LRAEDTAVYYCARA TYMVPYGFYWGQGT LTVTS RFTISADTSK NTAYLQMNSLRAE DTAVYYCARATY MVPYGFYWGQGT LTVTS	DIQMTQSPSSLSA SVGDRVLSASV GDRVTITCRASQSV SSAVAWYQQSSA VAWYQQKPGKAPK LLIYSASSLYSGV YSSASSLYSGVPS RFSGSRSGTDFTL TISSLPEDFATYYC QGGGSPYTFGQGT KVEIKR TV

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-06	EVQLVESGGGLVQPGGS LRLSCAASGFTFAYYGIH WVRQAPGKGLEWVAYI YPHGYITDYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARDG VPYYWAVLDYWGQGT LTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKVV EPKSCDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHY TQKLSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSAV AWYQQ KPGKAPKLLIYSAS SLYSG VPSRFSGSRSGTDF TLTISS LQPEDFATYYCQQH FSSPG TFGQGTKVEIKRTV AAPS V FIFPPSDSQLKSGT ASV VCL LNNFY FPREAKVQWKVDN ALQSGNSQESVTEQ DSKDS TYSLSSTLTLKADY EKHK VYACEVTHQGLSSP VTKSF NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFAYYG IHWVRQAPGKG LEWVAYIYPHG YITDYADSVK GRFTISADTSKNT AYLQMNSLRAE DTAVYYCARDG S GVPYYWAVLD YWGQGT LTV SS	DIQMTQSPSS LSASV GDRV TITCRASQSV SSAVAWYQQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFTLTISS LQ PEDFATYYC QQHFSSPGTF GQGTKVEIKR TV
P9-07	EVQLVESGGGLVQPGGS LRLSCAASGFTFSSYYIH WVRQAPGKGLEWVAYI SPYGGDTSYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARDG MSYIDGFDYWGQGT LTVSSASTKGPSVFPLAP SSKSTSGGTTALGCLVKD YFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKVV EPKSCDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHY TQKLSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSAV AWYQQ KPGKAPKLLIYSAS SLYSG VPSRFSGSRSGTDF TLTISS LQPEDFATYYCQQW TSTL WTFGQGTKVEIKRTV AAPS V V FIFPPSDSQLKSGT ASV VC LNNFY FPREAKVQWKVDN ALQSGNSQESVTEQ DSKDS TYSLSSTLTLKADY EKHK VYACEVTHQGLSSP VTKSF NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFSSYYI HWVRQAPGKG LEWVAYISPYG GDSYADSVK GRFTISADTSKNT AYLQMNSLRAE DTAVYYCARDG YMSYIDGFDY WGQGT LTVSS	DIQMTQSPSS LSASV GDRV TITCRASQSV SSAVAWYQQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFTLTISS LQ PEDFATYYC QQWTSTLWT FGQGTKVEIK RTV

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-11	EVQLVESGGGLVQPGGS LRLSCAASGFTFSSYYIH WVRQAPGKGLEWVAYI SPSGGYTTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARGAV LYSSAMDYWGQGLTVT VSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDY FPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVS VLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGF YPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFL YSKLTVDKSRWQQGNV FSCSV MHEALHNHYTQ KSLSLSPGK	DIQMTQSPSSLSASVGD TITCRASQSVSSAVAWY KPGKAPKLLIYSASSLY VPSRFSGSRSGTDFTLT LQPEDFATYYCQYYPS TFGQGTKVEIKRTVAAP FIFPPSDSQLKSGTASV LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK TYSLSSTLTLSKADYEH VYACEVTHQGLSSPVTK NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFSSYYI HWVRQAPGKKG LEWVAYISPSG GYTTYADSVK GRFTISADTSKN TAYLQMNSLRA EDTAVYYCAR GAVLYSSAMD YWGQGLTVTV SS	DIQMTQSPSS LSASVGD TITCRASQSV SSAVAWYQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFTLTISS LQ PEDFATYYC QYYPSPSTF GQGTKVEIKR TV
P9-12	EVQLVESGGGLVQPGGS LRLSCAASGFTFSSYWIH WVRQAPGKGLEWVASI ASYFGQTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARGFG YAAMDYWGQGLTVTVS SASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSV VTPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTP EVTVCVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL KNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNV FSCSV MHEALHNHYTQKSLSL PGK	DIQMTQSPSSLSASVGD TITCRASQSVSSAVAWY KPGKAPKLLIYSASSLY VPSRFSGSRSGTDFTLT LQPEDFATYYCQYEGRP YTFGQGTKVEIKRTVAAP VFIFPPSDSQLKSGTASV LLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK TYSLSSTLTLSKADYEH VYACEVTHQGLSSPVTK NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFSSYWI HWVRQAPGKKG LEWVASIASYF GQTYADSVK GRFTISADTSKN TAYLQMNSLRA EDTAVYYCAR GFGYAAMDYW GQGLTVTVSS	DIQMTQSPSS LSASVGD TITCRASQSV SSAVAWYQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFTLTISS LQ PEDFATYYC QYEGRPY FGQGTKVEIK RTV

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-14	EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYIH WVRQAPGKGLEWVADI YPYFSSYYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARGSHF GFDYWGQGTLLTVSSAS TKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFP AVLQSSGLYSLSSVTV PSSSLGTQTYICNVNHP SNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEV TCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQP REPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDI AVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSL	DIQMTQSPSSLSASVGD RV TITCRASQSVSSAVAWY QQ KPGKAPKLLIYSASSLY SG VPSRFGSRSRGTDFTL TISS LQPEDFATYYCQQHASG PL TFGQGTKVEIKRTVAAP SV FIFPPSDSQLKSGTASV VCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK DS TYSLSSTLTLSKADYEK HKH VYACEVTHQGLSSPVTK SF NRGEC	EVQLVESGGGLVQPGGSLRLSCAASGFTFGSYIH WVRQAPGKGLEWVADI YPYFSSYYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARGSHF GFDYWGQGTLLTVSSAS TKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPV TVSWNSGALTSGVHTFP AVLQSSGLYSLSSVTV PSSSLGTQTYICNVNHP SNTKVDKKVEPKSCDKT HTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEV TCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQP REPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDI AVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSL	DIQMTQSPSSLSASVGD RV TITCRASQSVSSAVAWY QQ KPGKAPKLLIYSASSLY SG VPSRFGSRSRGTDFTL TISS LQPEDFATYYCQQHASG PL TFGQGTKVEIKRTVAAP SV FIFPPSDSQLKSGTASV VCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK DS TYSLSSTLTLSKADYEK HKH VYACEVTHQGLSSPVTK SF NRGEC
P9-23	EVQLVESGGGLVQPGGSLRLSCAASGFTFSQYYIH WVRQAPGKGLEWVATI YPRGGYTFYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARKSY WGMDYWGQGTLLTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVTV VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTP EVTCTVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSL PGK	DIQMTQSPSSLSASVGD RV TITCRASQSVSSAVAWY QQ KPGKAPKLLIYSASSLY SG VPSRFGSRSRGTDFTL TISS LQPEDFATYYCQQWSV YL ETFGQGTKVEIKRTVAAP S VFIFPPSDSQLKSGTASV VC LLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK DS TYSLSSTLTLSKADYEK HKH VYACEVTHQGLSSPVTK SF NRGEC	EVQLVESGGGLVQPGGSLRLSCAASGFTFSQYYIH WVRQAPGKGLEWVATI YPRGGYTFYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARKSY WGMDYWGQGTLLTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVTV VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTP EVTCTVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSL PGK	DIQMTQSPSSLSASVGD RV TITCRASQSVSSAVAWY QQ KPGKAPKLLIYSASSLY SG VPSRFGSRSRGTDFTL TISS LQPEDFATYYCQQWSV YL ETFGQGTKVEIKRTVAAP S VFIFPPSDSQLKSGTASV VC LLNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK DS TYSLSSTLTLSKADYEK HKH VYACEVTHQGLSSPVTK SF NRGEC

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-24	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYFIHWVRQAPGKGLEWVASIYPTSHSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARLGYPGVMDYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQVDSRLATFGQGTKVEIKRTVAAPSVFIFPPSDSQLKSGTASVVCLLNRFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSLSSLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYFIHWVRQAPGKGLEWVASIYPTSHSTSYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARLGYPGVMDYWGQGTLLVTVSS	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQVDSRLATFGQGTKVEIKRTV
P9-25	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYIHWVRQAPGKGLEWVASIYPYGSYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARLGYSGMDYWGQGTLLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQWAPDLATFGQGTKVEIKRTVAAPSVFIFPPSDSQLKSGTASVVCLLNRFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSLSSLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYIHWVRQAPGKGLEWVASIYPYGSYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARLGYSSGMDYWGQGTLLVTVSS	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQWAPDLATFGQGTKVEIKRTV

<b>Table 6</b>					
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>					
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>	
P9-26	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVAVI ESSSHTDYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARLPYK YYLGVFDYWGQGLV TVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSL SSVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVE PKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTL MISRTPEVTCVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHY TQKLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQYSSSLY TFGQGTKVEIKRTVAAPSV FIFPPSDSQLKSGTASVCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVAVI ESSSHTDYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARLPYK YYLGVFDYWGQGLV TVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSL SSVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVE PKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTL MISRTPEVTCVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHY TQKLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQYSSSLY TFGQGTKVEIKRTVAAPSV FIFPPSDSQLKSGTASVCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVAVI ESSSHTDYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARLPYK YYLGVFDYWGQGLV TVSSASTKGPSVFPLAPS SKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSL SSVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVE PKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTL MISRTPEVTCVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHY TQKLSLSPGK
NEG. CON					
P9-29	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYAIH WVRQAPGKGLEWVAI APGGSYTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARLSYP GVMDYWGQGLVTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELGGPS VFLFPPKPKDTLMISRT PEVTCVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFCSSV MHEALHNHYTQKLSLS PGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQGYSSLL TFGQGTKVEIKRTVAAPSV FIFPPSDSQLKSGTASVCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYAIH WVRQAPGKGLEWVAI APGGSYTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARLSYP GVMDYWGQGLVTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELGGPS VFLFPPKPKDTLMISRT PEVTCVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFCSSV MHEALHNHYTQKLSLS PGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQGYSSLL TFGQGTKVEIKRTVAAPSV FIFPPSDSQLKSGTASVCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYAIH WVRQAPGKGLEWVAI APGGSYTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARLSYP GVMDYWGQGLVTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELGGPS VFLFPPKPKDTLMISRT PEVTCVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFCSSV MHEALHNHYTQKLSLS PGK

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-30	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYTIHWVRQAPGKGLEWVAVIYPKGGSTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARPSGYGFDYWGQGLVTVSSASTKGPSVFPLAPSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQYLSSPYTFGQGTKVEIKRTVAAPSVFIFPPSDSQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYTIHWVRQAPGKGLEWVAVIYPKGGSTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARPSGYGFDYWGQGLVTVSS	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQYLSSPYTFGQGTKVEIKRTV
P9-34	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYFIHWVRQAPGKGLEWVAIYPQGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARQSYPGVFDYWGQGLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQWTIALTFGQGTKVEIKRTVAAPSVFIFPPSDSQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYFIHWVRQAPGKGLEWVAIYPQGGYTYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARQSYPGVFDYWGQGLVTVSS	DIQMTQSPSSLSASVGRVTITCRASQSVSSAVAWYQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFLTISLQPEDFATYYCQQWTIALTFGQGTKVEIKRTV

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-37	EVQLVESGGGLVQPGGS LRLSCAASGFTFWKYGI HWVRQAPGKGLEWVA YIYPAGGITSYADSVKG RFTISADTSKNTAYLQM NSLRAEDTAVYYCARSD YYSGMGMDYWGQGT LTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTL MISRTPEVTCVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMEALHNHY TQKSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSAVAWY QQ KPGKAPKLLIYSASSLYS G VPSRFSGSRSGTDFLT TISS LQPEDFATYYCQYYPS PS TFGQGTKVEIKRTVAAP SV FIFPPSDSQLKSGTASV VCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK DS TYSLSSTLTLKADYEK HK VYACEVTHQGLSSPVTK SF NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFWKYG IHWVRQAPGKG LEWVAIYPAG GITSYADSVKG RFTISADTSKNT AYLQMNSLRAE DTAVYYCARSD YYSGMGMDY WGQGT LTVSS	DIQMTQSPSS LSASV GDRV TITCRASQSV SSAVAWYQQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFLT TISSLQ PEDFATYYC QYYPS PSTF GQGTKVEIKR TV
P9-38	EVQLVESGGGLVQPGGS LRLSCAASGFTFSSYWI HWVRQAPGKGLEWVAWI DPDYGTTSYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARSETG AAMDYWGQGT LTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTS GVHT FPAVLQSSGLYS LSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRT PEVTCVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKL TVDKSRWQQGNV FSCSV MetHEALHNHYTQKSL SPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSAVAWY QQ KPGKAPKLLIYSASSLYS G VPSRFSGSRSGTDFLT TISS LQPEDFATYYCQQGSY FLQ TFGQGTKVEIKRTVAAP SV FIFPPSDSQLKSGTASV VCL LNNFYPREAKVQWKVDN ALQSGNSQESVTEQDSK DS TYSLSSTLTLKADYEK HK VYACEVTHQGLSSPVTK SF NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFSSYWI HWVRQAPGKG LEWVAWIDPD YGTTSYADSVK GRFTISADTSKN TAYLQMNSLRA EDTAVYYCARS ETGAAMDYWG QGT LTVSS	DIQMTQSPSS LSASV GDRV TITCRASQSV SSAVAWYQQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFLT TISSLQ PEDFATYYC QQGSYFLQTF GQGTKVEIKR TV

<b>Table 6</b>					
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>					
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>	
P9-40	EVQLVESGGGLVQPGGSLRLS CAASGFTFRWYYIHWVRQAPGK GLEWVAT IYPDWDYTTYADSVKGR FTISADTSKNTAYLQMN SLRAEDTAVYYCARSPV TGPYGFQDYWGQGLVT VSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDY FPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSS VVTVPSSSLGTQTYICNV NHKPSNTKVDKKEPKS CDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNA KTKPREEQYNSTYRVVS VLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGF YPSDIAVEWESNGQPEN NYKTTTPPVLDSDGSFFL YSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQ KSLSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSA VAWYQQ KPGKAPKLLI YSASSLYSG VPSRFSGS RSRGTDFLTISS LQPE DFATYYCQQPTYSL WTFGQGTKVEIKRTVA AAPS VFIFPPSDSQLK SGTASVVC LLNMFYP BREAKVQWKVDN ALQ SGNSQESVTEQDSKDS TYSLSSTLTLSKADY EKHK VYACEVTHQGL SSPVTKSF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFR WYYIHWVRQAPGK GLEWVAT IYPDWDY TTYADSVKGR FTIS ADTSKNTAYLQMN SLRAEDTAVYYCAR SPV TGPYGFQDYW GQGLVT VSSASTK GPSVFPLAPSS KSTSGGTAALGCL VKDY FPEPVTVSW NSGALTSG VHTFPA VLQSSGLYSLSS VVTVPSSSLGTQTY ICNV NHKPSNTK VDKKEPKS CDKTH TCPPCPAPELLG GPSVFLFPPKPKD TLMIS RTPEVTCV VVDVSHEDP EVK FNWYVDGVEVHNA KTKPREEQYNSTY RVVS VLTVLHQD WLNGKEYK CKVSN KALPAPIEKTISK AKGQPREPQVYTL PPSR DELTKNQV SLTCLVKGF YPS DIAVEWESNGQ PEN NYKTTTPPV LDSDGSFFL YSK LTVDKSRWQQGN V FSCSVMHEAL HNHYTQ KSLSL SPGK	DIQMTQSPSSLSAS V GDRV TITCRASQSV SSA VAWYQQ KPGKAPK LLI YSASSLYSG VPSR FSGS RSRGTDFLTISS L QPE DFATYYCQQPTYSL WTF GQGTKVEIKRTVA AAPS VFIFPPSDSQLKSG TAS VVC LLNMFYPRE AKV QWKVDN ALQSGNS QES VTEQDSKDS TYS LSST LTLSKADY EKHK VYAC EVTHQGLSSPVTK SF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFR WYYIHWVRQAPGK GLEWVAT IYPDWDY TTYADSVKGR FTIS ADTSKNTAYLQMN SLRAEDTAVYYCAR SPV TGPYGFQDYW GQGLVT VSSASTK GPSVFPLAPSS KSTSGGTAALGCL VKDY FPEPVTVSW NSGALTSG VHTFPA VLQSSGLYSLSS VVTVPSSSLGTQTY ICNV NHKPSNTK VDKKEPKS CDKTH TCPPCPAPELLG GPSVFLFPPKPKD TLMIS RTPEVTCV VVDVSHEDP EVK FNWYVDGVEVHNA KTKPREEQYNSTY RVVS VLTVLHQD WLNGKEYK CKVSN KALPAPIEKTISK AKGQPREPQVYTL PPSR DELTKNQV SLTCLVKGF YPS DIAVEWESNGQ PEN NYKTTTPPV LDSDGSFFL YSK LTVDKSRWQQGN V FSCSVMHEAL HNHYTQ KSLSL SPGK
P9-41	EVQLVESGGGLVQPGGSLRLS CAASGFTFRYYWIHWVRQAPGK GLEWVA AIYPSDSTYYADSVK GRFTISADTSKNTAYLQM NSLRAEDTAVYYCARSS PYPYGGQGVFDYWGQGT LVTVSSASTKGPSVFPLA PSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTL MISRTPPEVTCVVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL P PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTTTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHY TQKSLSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSA VAWYQQ KPGKAPKLLI YSASSLYSG VPSRFSGS RSRGTDFLTISS LQPE DFATYYCQQWYSSL WTFGQGTKVEIKRTVA AAPS VFIFPPSDSQLK SGTASVVC LLNMFYP BREAKVQWKVDN ALQ SGNSQESVTEQDSKDS TYSLSSTLTLSKADY EKHK VYACEVTHQGL SSPVTKSF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFR YYWIHWVRQAPGK GLEWVA AIYPSDST YYADSVKGR FTIS ADTSKNTAYLQM NSLRAEDTAVYYC ARSS PYPYGGQGV FDYWGQGT LVTV SSASTKGPSVFPL APSSKSTSGGTA ALGCLV KDYFPE PVTVSWNSGAL TSGVHTFPAVLQ SSGLY SLSSVVT VPSSSLGTQTY ICNVNHKPSNTK VDKKV EPKSCDK THTCPPCPAPE LLGGPSVFLFPP KPKDTLMISRTP PEVTCVVVDVSH EDPEVKFNWYV DGVEV HNAKTK PREEQYNSTYR VVSVLTVLHQD WLNGKEYK EYK CKVSNKALPAPI EK TISKAKGQPR EPQVYTL PPSR DELTKNQVSLT CLVKGFYPSDIA VEWESNGQ PEN NYKTTTPPVLD SDGSFFLYSKLT VDKSRWQQGN VFSCSVMHEAL HNHYTQ KSLSL SPGK	DIQMTQSPSSLSAS V GDRV TITCRASQSV SSA VAWYQQ KPGKAPK LLI YSASSLYSG VPSR FSGS RSRGTDFLTISS L QPE DFATYYCQQWYSSL WTF GQGTKVEIKRTVA AAPS VFIFPPSDSQLKSG TAS VVC LLNMFYPRE AKV QWKVDN ALQSGNS QES VTEQDSKDS TYS LSST LTLSKADY EKHK VYAC EVTHQGLSSPVTK SF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFR YYWIHWVRQAPGK GLEWVA AIYPSDST YYADSVKGR FTIS ADTSKNTAYLQM NSLRAEDTAVYYC ARSS PYPYGGQGV FDYWGQGT LVTV SSASTKGPSVFPL APSSKSTSGGTA ALGCLV KDYFPE PVTVSWNSGAL TSGVHTFPAVLQ SSGLY SLSSVVT VPSSSLGTQTY ICNVNHKPSNTK VDKKV EPKSCDK THTCPPCPAPE LLGGPSVFLFPP KPKDTLMISRTP PEVTCVVVDVSH EDPEVKFNWYV DGVEV HNAKTK PREEQYNSTYR VVSVLTVLHQD WLNGKEYK EYK CKVSNKALPAPI EK TISKAKGQPR EPQVYTL PPSR DELTKNQVSLT CLVKGFYPSDIA VEWESNGQ PEN NYKTTTPPVLD SDGSFFLYSKLT VDKSRWQQGN VFSCSVMHEAL HNHYTQ KSLSL SPGK

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-42	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVA AIYSAWGTTYADSVKGR FTISADTSKNTAYLQMN SLRAEDTAVYYCARSYG YVFGYYSGMDYWGQGT LVTVSSASTKGPSVFPLA PSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLY SLSSVTVPSSSLGTQTY ICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL P PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMEALHNHY TQKLSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSAV AWYQQ KPGKAPKLLIYSAS SLYSG VPSRFGSRSRGTDF TLTISS LQPEDFATYYCQQW SSDL VTFGQGTKVEIKRT VAAPS VFIFPPSDSQLKSG TASVVC LLNMFYPREAKVQW KVDN ALQSGNSQESVTEQ DSKDS TYSLSSTLTLKADY EKHK VYACEVTHQGLSSP VTKSF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFSSYYIH WVRQAPGKGLEW VA AIYSAWGTTYADSV KGR FTISADTSKNTAY LQMN SLRAEDTAVYYCA RSYGYVFGYYSA GMDYWGQGT LVTVSS	DIQMTQSPSSLSAS V GDRV TITCRASQSVSSAV AWYQQ KPGKAPKLLIYSAS SLYSG VPSRFGSRSRGTDF TLTISS LQPEDFATYYCQQW SSDL VTFGQGTKVEIKRT VAAPS VFIFPPSDSQLKSG TASVVC LLNMFYPREAKVQW KVDN ALQSGNSQESVTEQ DSKDS TYSLSSTLTLKADY EKHK VYACEVTHQGLSSP VTKSF NRGEC
P9-43	EVQLVESGGGLVQPGGSLRLS CAASGFTFHSYWI HWVRQAPGKGLEWVAR IDSSKFGTYADSVKGR FTISADTSKNTAYLQMN SLRAEDTAVYYCARSYI DYVPSPAVFDYWGQGT LVTVSSASTKGPSVFPLA PSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLY SLSSVTVPSSSLGTQTY ICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL P PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSVMEALHNHY TQKLSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSAV AWYQQ KPGKAPKLLIYSAS SLYSG VPSRFGSRSRGTDF TLTISS LQPEDFATYYCQQV YFSPY TFGQGTKVEIKRT VAAPSV FIFPPSDSQLKSG TASVVC LLNMFYPREAKVQW KVDN ALQSGNSQESVTEQ DSKDS TYSLSSTLTLKADY EKHK VYACEVTHQGLSSP VTKSF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFHSYWI HWVRQAPGKGLEW VAR IDSSKFGTYADSV KGR FTISADTSKNTAY LQMN SLRAEDTAVYYCA RSYGYVFGYYSA GMDYWGQGT LVTVSS	DIQMTQSPSSLSAS V GDRV TITCRASQSVSSAV AWYQQ KPGKAPKLLIYSAS SLYSG VPSRFGSRSRGTDF TLTISS LQPEDFATYYCQQV YFSPY TFGQGTKVEIKRT VAAPSV FIFPPSDSQLKSG TASVVC LLNMFYPREAKVQW KVDN ALQSGNSQESVTEQ DSKDS TYSLSSTLTLKADY EKHK VYACEVTHQGLSSP VTKSF NRGEC

<b>Table 6</b>					
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>					
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>	
P9-44	EVQLVESGGGLVQPGGSLRLS CAASGFTFSYYWIHWVRQAPGK GLEWVA AISPSGSYTSYADSVKGR FTISADTSKNTAYLQMN SLRAEDTAVYYCARSYY RFRTPYTVMDYWGQGT LVTVSSASTKGPSVFPLA PSSKSTSGGTAALGCLV KDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLY SLSSVTVPSSSLGTQTY ICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTL MISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFSCSV MHEALHNHY TQKSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSA VAWYQQ KPGKAPKLLI YSASSLYSG VPSRFSGS RSRGTDFLTISS LQPE DFATYYCQQGIDSPE TFGQGTKVEIKRTVA AAPSV FIFPPSDSQLK SGTASV VCL LNNFYP PREAKVQWKVDN ALQ SGNSQESVTEQDSKDS TYSLSSTLTL SKADY EKHK VYACEVTHQGL SSPVTKSF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFS YYWIHWVRQAPGK GLEWVA AISPSGSY TSYADSVKGR FTIS ADTSKNTAYLQMN SLRAEDTAVYYC ARSYYRFRTPYTV MDYWGQGT LVTV SSASTKGPSVFPLA PSSKSTSGGTAAL GCLVKDYFPEPVT VSWNSGALTSGV HTFPAVLQSSGLY SLSSVTVPSSSLG TQTYICNVNHKPS NTKVDKKV EPKSC DKTHTCPPCPAPE LLGGPSVFLFPPK PKDTLMISRTPEV TCVVVDVSHEDP EVKFNWYVDGVEV HNAKTKPREEQYN STYRVVSVLTVLH QDWLNGKEYKCKV SNKALPAPIEKTI SKAKGQPREPQVY TLPPSRDELTKNQ VSLTCLVKGFYPS DIAVEWESNGQPEN NYKTPPVLDSDGS FFLYSKLTVDKSR WQQGNV FSCSV M HEALHNHYTQKSL SPGK	EVQLVESGGGLVQP GGSLRLSC AASGFTFS YYWIHWVRQAPGK GLEWVA AISPSGSY TSYADSVKGR FTIS ADTSKNTAYLQMN SLRAEDTAVYYC ARSYYRFRTPYTV MDYWGQGT LVTV SSASTKGPSVFPLA PSSKSTSGGTAAL GCLVKDYFPEPVT VSWNSGALTSGV HTFPAVLQSSGLY SLSSVTVPSSSLG TQTYICNVNHKPS NTKVDKKV EPKSC DKTHTCPPCPAPE LLGGPSVFLFPPK PKDTLMISRTPEV TCVVVDVSHEDP EVKFNWYVDGVEV HNAKTKPREEQYN STYRVVSVLTVLH QDWLNGKEYKCKV SNKALPAPIEKTI SKAKGQPREPQVY TLPPSRDELTKNQ VSLTCLVKGFYPS DIAVEWESNGQPEN NYKTPPVLDSDGS FFLYSKLTVDKSR WQQGNV FSCSV M HEALHNHYTQKSL SPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSA VAWYQQ KPGKAPKLLI YSASSLYSG VPSRFSGS RSRGTDFLTISS LQPE DFATYYCQQGIDSPE TFGQGTKVEIKRTVA AAPSV FIFPPSDSQLK SGTASV VCL LNNFYP PREAKVQWKVDN ALQ SGNSQESVTEQDSKDS TYSLSSTLTL SKADY EKHK VYACEVTHQGL SSPVTKSF NRGEC
P9-45	EVQLVESGGGLVQPGGSLRLS CAASGFTFFSYVIHWVRQAPGK GLEWVA AIYPYSGYTTYADSVKGRF TISADTSKNTAYLQMN LRAEDTAVYYCARTKY YDYHVFYWGQGT LVT VSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDY FPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSS VTVPSSSLGTQTYICNV NHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDP EVKFNWYVDGVEVHNA KTKPREEQYNSTYRVV VSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTI SKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGF YPSDIAVEWESNGQPEN NYKTPPVLDSDGSFFL YSKLTVDKSRWQQGNV FSCSV MHEALHNHYTQ KSLSPGK	DIQMTQSPSSLSASV GDRV TITCRASQSVSSA VAWYQQ KPGKAPKLLI YSASSLYSG VPSRFSGS RSRGTDFLTISS LQPE DFATYYCQQGWDSL VTFGQGTKVEIKRTVA AAPS VFIFPPSDSQLK SGTASV VC LNNFYP PREAKVQWKVDN ALQ SGNSQESVTEQDSKDS TYSLSSTLTL SKADY EKHK VYACEVTHQGL SSPVTKSF NRGEC	EVQLVESGGGLVQP GGSLRLSC AASGFTFF SYVIHWVRQAPGK GLEWVA AIYPYSGY TTYADSVKGR FTIS ADTSKNTAYLQMN LRAEDTAVYYC ARTKY YDYHVFYWG QGT LVT VSSASTK GPSVFPLAPSS KST SGGTAALGCLVKDY FPEPVTVSWNSG ALTSGVHTFPAVLQ SSGLYSLSSVTVP SSSLGTQTYICNV NHKPSNTKVDKK VEPKS CDKTHTCPP CPAPELLG GPSVFL FPPKPKDTLMIS RTPEVTCVVVDV SHEDPEVKFNWYV DGVEVHNA KTKPR EEQYNSTYRVVSV LTVLHQDWLNGK EYKCKVSNKALP APIEKTI SKAKGQ PREPQVYTLPPSR DELTKNQVSLTCL VKGFYPSDIAVEW ESNGQPEN NYKTP PPVLDSDGSFFL YSKLTVDKSRWQQ GNV FSCSV MHEA LHNHYTQKSLSPG K	EVQLVESGGGLVQP GGSLRLSC AASGFTFF SYVIHWVRQAPGK GLEWVA AIYPYSGY TTYADSVKGR FTIS ADTSKNTAYLQMN LRAEDTAVYYC ARTKY YDYHVFYWG QGT LVT VSSASTK GPSVFPLAPSS KST SGGTAALGCLVKDY FPEPVTVSWNSG ALTSGVHTFPAVLQ SSGLYSLSSVTVP SSSLGTQTYICNV NHKPSNTKVDKK VEPKS CDKTHTCPP CPAPELLG GPSVFL FPPKPKDTLMIS RTPEVTCVVVDV SHEDPEVKFNWYV DGVEVHNA KTKPR EEQYNSTYRVVSV LTVLHQDWLNGK EYKCKVSNKALP APIEKTI SKAKGQ PREPQVYTLPPSR DELTKNQVSLTCL VKGFYPSDIAVEW ESNGQPEN NYKTP PPVLDSDGSFFL YSKLTVDKSRWQQ GNV FGGQGTKVEIK RTV	

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-46	EVQLVESGGGLVQPGGSLRLS CAASGFTFSRYIHWVRQAPGK GLEWVAFISSDSGYTQYADSVKGRF TISADTSKNTAYLQMNSLRAEDTAVYYCARTMS YSALDYWGQGLVTVSASTKGPSVFLAPSSKS TSGGTAALGCLVKDYFPEPVT VSWNSGALTSVHTEFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHPKSN TKVDKKEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTIKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFC SVMHEALHNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQKPGKAPKLLI YSASSLYSGVPSRFSGSRSGTDFLTISS LQPEDFATYYCQQYWWSPEFEGQGT KVEIKRTVAAPSFIFPPS DQLKSGTASVVCVLLNNFY FPREAKVQWVKVDNALQSGNSQESVTEQD SKDSTYLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSRYIHWVRQAPGK GLEWVAFISSDSGYTQYADSVKGRF TISADTSKNTAYLQMNSLRAEDTAVYYCARTMS YSALDYWGQGLVTVSASTKGPSVFLAPSSKS TSGGTAALGCLVKDYFPEPVT VSWNSGALTSVHTEFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHPKSN TKVDKKEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTIKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFC SVMHEALHNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQKPGKAPKLLI YSASSLYSGVPSRFSGSRSGTDFLTISS LQPEDFATYYCQQYWWSPEFEGQGT KVEIKRTVAAPSFIFPPS DQLKSGTASVVCVLLNNFY FPREAKVQWVKVDNALQSGNSQESVTEQD SKDSTYLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC
P9-50	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYVIHWVRQAPGK GLEWVALIYSSGGYTQYADSVKGRF TISADTSKNTAYLQMNSLRAEDTAVYYCARVGT TYPSTRYLEALDYWGQGLTVTVSSASTKGPSVFL APSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSVHTEFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHPKSN TKVDKKEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTIKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFC SVMHEALHNHYTQKSLSLSPG	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQKPGKAPKLLI YSASSLYSGVPSRFSGSRSGTDFLTISS LQPEDFATYYCQYFGSSLPTEFGQGT KVEIKRTVAAPSFIFPPS DQLKSGTASVVCVLLNNFY FPREAKVQWVKVDNALQSGNSQESVTEQD SKDSTYLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYVIHWVRQAPGK GLEWVALIYSSGGYTQYADSVKGRF TISADTSKNTAYLQMNSLRAEDTAVYYCARVGT TYPSTRYLEALDYWGQGLTVTVSSASTKGPSVFL APSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSVHTEFPAVLQSSGLYSLSSV VTVPSSSLGTQTYICNVNHPKSN TKVDKKEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTIKAKGQPREP QVYTLPPSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPPVLDSDG SFFLYSKLTVDKSRWQQGNVFC SVMHEALHNHYTQKSLSLSPG	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQKPGKAPKLLI YSASSLYSGVPSRFSGSRSGTDFLTISS LQPEDFATYYCQYFGSSLPTEFGQGT KVEIKRTVAAPSFIFPPS DQLKSGTASVVCVLLNNFY FPREAKVQWVKVDNALQSGNSQESVTEQD SKDSTYLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-51	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYIH WVRQAPGKGLEWVAGI YPEGSYTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARVGY PGVMDYWGQGLTVTVS SASTKGPSVFLAPSSKS TSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTP EVTCTVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL KNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSL PGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQWGSSL ATFGQGTKVEIKRTVAAPS VFIFPPSDSQLKSGTASVVC LLNFPYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLSC AASGFTFSSYYIH HWVRQAPGKGL LEWVAGIYPEG SYTYADSVKGRF RFTISADTSKNT AYLQMNSLRAE DTAVYYCARV GYPGVMYDYG QGLTVTVSS	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQWGSSL ATFGQGTKVEIKRTVAAPS VFIFPPSDSQLKSGTASVVC LLNFPYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC
P9-52	EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYLIH WVRQAPGKGLEWVAI TPYSGYTSYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARVGY PMVMDYWGQGLTVTVS SASTKGPSVFLAPSSKS TSGGTAALGCLVKDYFP EPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTP EVTCTVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL KNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSL PGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQLDYSL ATFGQGTKVEIKRTVAAPS VFIFPPSDSQLKSGTASVVC LLNFPYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLSC AASGFTFSTYLI HWVRQAPGKGL LEWVAAITPYS GYTSYADSVKGRF RFTISADTSKNT AYLQMNSLRAE DTAVYYCARV GYPMVMDYW GQGLTVTVSS	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQLDYSL ATFGQGTKVEIKRTVAAPS VFIFPPSDSQLKSGTASVVC LLNFPYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-53	EVQLVESGGGLVQPGGS LRLSCAASGFTFSRYQIH WVRQAPGKGLEWVAYI ASASGTTSYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARVPY VAMDYWGQGTTLTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKEPKSCD KTHTCPPELLEGGPS VFLFPPKPKDTLMISRT EVTCTVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDEL KNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLT VDKSRWQQGNVFCSSV MHEALHNHYTQKSLSL PG	DIQMTQSPSSLSASVGDRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLT LTISS LQPEDFATYYCQ QGYPHP GTFGQGTKVEIK RTVAAPS VFIFPPSDSQLK SGTASVVC LLNFPYPREAK VQWKVDN ALQSGNSQESVTE QDSKDS TYSLSSTLTLSKAD YEKHK VYACEVTHQGLSSP VTKSF NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFSRYQI HWVRQAPGK LEWVAYIASAS GTTSYADSVK RFTISADTSKNT AYLQMNSLRAE DTAVYYCARVP YVAMDYWGQ GTLTVSS	DIQMTQSPSS LSASVGDRV TITCRASQSV SSAVAWYQQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFLT TISSLQ PEDFATYYC QQGYPHPGT FGQGTKVEIK RTV
P9-55  NEG. CON.	EVQLVESGGGLVQPGGS LRLSCAASGFTFATYYIH WVRQAPGKGLEWVAYI DSESGYTTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARVSR GSSGTHVMDYWGQGT LTVSSASTKGPSVFPLAP SSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYI CNVNHKPSNTKVDKKE PKSCDKTHTCPPELLE GGPSVFLFPPKPKDTL MISRTPEVTCTVVDVSH EDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYR VSVLTVLHQDWLNGK EYKCKVSNKALPAPIEK TISKAKGQPREPQVYTL P PSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQG NVFCSVMHEALHNHY TQKSLSLSPGK	DIQMTQSPSSLSASVGDRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLT LTISS LQPEDFATYYCQ QRYSSLL TFGQGTKVEIK RTVAAPSV FIFPPSDSQLK SGTASVVC LLNFPYPREAK VQWKVDN ALQSGNSQESVTE QDSKDS TYSLSSTLTLSKAD YEKHK VYACEVTHQGLSSP VTKSF NRGEC	EVQLVESGGGL VQPGGSLRLSC AASGFTFATYYI HWVRQAPGK LEWVAYIDSES GYTTYADSVK GRFTISADTSKN TAYLQMNSLRA EDTAVYYCAR VSRGSSGTHVM DYWGQGTTLV VSS	DIQMTQSPSS LSASVGDRV TITCRASQSV SSAVAWYQQ KPGKAPKLLI YSASSLYSGV PSRFSGSRSG TDFLT TISSLQ PEDFATYYC QCRYSSLLTF GQGTKVEIK TV

<b>Table 6</b>				
<b>Full chain sequences and VH/VL sequences of candidate GAL9 ABS clones and IgG formatted antibodies comprising GAL9 ABSs</b>				
<b>ABS clone</b>	<b>Full IgG Heavy Chain</b>	<b>Full IgG Light Chain</b>	<b>VH sequence</b>	<b>VL sequence</b>
P9-56	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVAYI DSSGKYTDYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARYAY PGVMDYWGQGLTVTVS SASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPE PVTVSWNSGALTSQVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPP VLDRDGSFFLYSKLTVDK SRWQQGNVFCFSVMEAL HNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQYDYS LWTFGQGTKVEIKRTVA AAPS VFIFPPSDSQLKSG TASVVC LLNFPYPREAKV QWKVDN ALQSGNSQESVTE QDSKDS TYSLSSTLTLSK ADYEKHK VYACEVTHQGL SSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVAYI DSSGKYTDYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARYAY PGVMDYWGQGLTVTVS SASTKGPSVFPLAPSSKS TSGGTAALGCLVKDYFPE PVTVSWNSGALTSQVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPP VLDRDGSFFLYSKLTVDK SRWQQGNVFCFSVMEAL HNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQYDYS LWTFGQGTKVEIKRTVA AAPS VFIFPPSDSQLKSG TASVVC LLNFPYPREAKV QWKVDN ALQSGNSQESVTE QDSKDS TYSLSSTLTLSK ADYEKHK VYACEVTHQGL SSPVTKSF NRGEC
P9-57	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVATI YPSGGYTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARYSYP GVLVDYWGQGLTVTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSQVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPP VLDSGDSFFLYSKLTVDK SRWQQGNVFCFSVMEAL HNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQSSSFLW TFGQGTKVEIKRTVAAPSV FIFPPSDSQLKSGTASVVC LLNFPYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC	EVQLVESGGGLVQPGGSLRLS CAASGFTFSSYYIH WVRQAPGKGLEWVATI YPSGGYTYADSVKGRF TISADTSKNTAYLQMNS LRAEDTAVYYCARYSYP GVLVDYWGQGLTVTVSS ASTKGPSVFPLAPSSKST SGGTAALGCLVKDYFPE PVTVSWNSGALTSQVHT FPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNH KPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPE VTCVVVDVSHEDPEVK FNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLT VLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPP VLDSGDSFFLYSKLTVDK SRWQQGNVFCFSVMEAL HNHYTQKSLSLSPGK	DIQMTQSPSSLSASVGRV TITCRASQSVSSAVAWYQQ KPGKAPKLLIYSASSLYSG VPSRFSGSRSGTDFLTISS LQPEDFATYYCQQSSSFLW TFGQGTKVEIKRTVAAPSV FIFPPSDSQLKSGTASVVC LLNFPYPREAKVQWKVDN ALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHK VYACEVTHQGLSSPVTKSF NRGEC

**[0331]** Select GAL9 binding candidates were analyzed for binding properties: cross-reactive binding with murine GAL9; qualitative binding; epitope binning (Bin 2 - candidates bin with Commercial antibody Clone ECA8 from LS Bio [LS-C179448]; Bin 3 - candidates Bins with Commercial antibody Clone ECA42 from LS Bio [LS-C179449], which is the “tool antibody” referenced in **FIG. 10**), and monovalent affinity binding. Analysis results are presented in **Table 7**.

<b>Table 7: Candidate anti-human GAL9 Binding Properties</b>				
<b>ABS</b>	<b>Mouse Cross-reactivity</b>	<b>Binding Off-Rate (++ = moderate; +++ = slow)</b>	<b>Bin</b>	<b>Calculated K<sub>D</sub> (M)</b>
P9-01	Y	+++	1	
P9-02A	Y	+++	1	
P9-03		+++	1	
P9-06		++	1	
P9-07	Y	++	3	
P9-11	Y	+++	1	6.554x10 <sup>-9</sup>
P9-12		++	3	
P9-14		+++	2	
P9-24		+++	1	5.409 x 10 <sup>-9</sup>
P9-25		+++	1	3.48 x 10 <sup>-9</sup>
P9-26		Negative Control (NC)		
P9-29		+++	1	
P9-30		+++	1	
P9-34		+++	1	
P9-37	Y	+++	1	4.543 x 10 <sup>-9</sup>
P9-38		++	1	
P9-40	Y	+++	1	
P9-41		++	1	
P9-42	Y	++	1	

Table 7: Candidate anti-human GAL9 Binding Properties				
ABS	Mouse Cross-reactivity	Binding Off-Rate (++ = moderate; +++ = slow)	Bin	Calculated K <sub>D</sub> (M)
P9-43	Y	+++	1	
P9-45		++	3	
P9-46		+++	2	
P9-50	Y	+++	3	1.206 x 10 <sup>-9</sup>
P9-51		+++	1	
P9-52		+++	1	
P9-53		+++	1	
P9-55		Negative Control (NC)		
P9-56	Y	+++	1	
P9-57	Y	+++	1	2.557 x 10 <sup>-9</sup>

**[0332]** Select GAL9 binding candidates were further analyzed for sequence motifs that could adversely affect antibody properties that are relevant to clinical development, such as stability, mutability, and immunogenicity. Computational analysis was performed according to Kumar and Singh (*Developability of biotherapeutics: computational approaches*. Boca Raton: CRC Press, Taylor & Francis Group, 2016). Analysis results are presented in **Table 8**, and demonstrate a limited number of adverse sequence motifs are present in the listed clones, indicating the potential for further clinical development.

**Table 8: Candidate anti-human GAL9 Antibody Properties**

ABS	CDR3 Loop Length	Yield (ug/mL)	Mol Weight (kDa)	Isoelectric Point	Number Deamidation Sites <sup>1</sup>	Number Isomerization Sites <sup>2</sup>	Number Fragmentation Sites <sup>3</sup>	Number N-linked Glycosylation Sites <sup>4</sup>	Cys in CDR	Number Other Sites <sup>5</sup>	Number T-cell Epitopes <sup>6</sup>
P9-07	15	45	1.453x10 <sup>5</sup>	8.08	0	3	1	0	No	0	1
P9-11	14	68.85	1.446x10 <sup>5</sup>	8.42	0	1	1	0	No	0	2
P9-24	12	72.15	1.438x10 <sup>5</sup>	8.43	0	2	2	0	No	0	0
P9-25	12	163.5	1.444x10 <sup>5</sup>	8.32	0	1	1	0	No	0	0
P9-37	14	108.45	1.447x10 <sup>5</sup>	8.42	0	1	2	0	No	0	1
P9-50	18	78.6	1.453x10 <sup>5</sup>	8.22	0	1	1	0	No	0	0
P9-55	-	-	1.452x10 <sup>5</sup>	8.42	0	2	1	0	No	0	0
P9-57	12	30	1.442x10 <sup>5</sup>	8.42	0	1	1	0	No	0	0

<sup>1</sup> (NG, NS, NA, NH, ND)

<sup>2</sup> (DG, DP, DS)

<sup>3</sup> (DP, DY, HS, KT, HXS, SXH)

<sup>4</sup> (NXS/T)

<sup>5</sup> (LLQG, HPQ, FHENSP, LPRWG, HHH)

<sup>6</sup> 3% in at least 2 of DRB1\_0101,DRB1\_0301,DRB1\_0401,DRB1\_0701,DRB1\_1101,DRB1\_1301,DRB1\_1501,DRB1\_0801

### 6.11.9. Example 8: Anti-human GAL9 candidates' effect on cytokine production in peripheral blood mononuclear cells (PBMCs)

[0333] Candidate anti-human GAL9 antigen binding sites (ABSs) were formatted into a bivalent monospecific native human full-length IgG1 heavy chain and light chain architecture (SEQ ID NO:5 and SEQ ID NO:3, respectively) and were tested for their effect on cytokine production by human PBMCs following peptide stimulation. PBMCs were stimulated essentially as described in **Section 6.11.1** above. Briefly, PBMCs were harvested from human donors known to be responsive to human CMV virus (HCMV) placed in culture, and stimulated with HCMV PepMix to prime an antigen specific response, and treated with one of: control IgG, a comparator anti-human GAL9 tool activating mAb (clone ECA42, murine IgG2a),  $\alpha$ -PD1 (Nivolumab), or candidate anti-GAL9 antibodies formatted as bivalent monospecific full-length human IgG1 antibodies. Cytokine secretion was measured at 24 and 72 hrs post-treatment by bead cytokine array. Results for INF- $\gamma$  and TNF- $\alpha$  are depicted in **FIGs. 10A** and **10B**. The data shown in **FIG. 10** is described in more detail in **Table 9** and **Table 10** provided below.

		<b>Table 9</b>				
		<b>INF-<math>\gamma</math> 72hr</b>				
		Average/ donor			Average	as %
Donor 19	Donor 25	Donor 27				
IgG	pg/ml	5922	43775	1657		
P9-11	pg/ml	5891	22998	891		
	<b>Fold change</b>	<b>0.99</b>	<b>0.52</b>	<b>0.53</b>	<b>0.68</b>	68.2
P9-24	pg/ml	NT	35748	1258		
	<b>Fold change</b>		<b>0.82</b>	<b>0.78</b>	<b>0.80</b>	87.6
P9-34	pg/ml	NT	44378	1048		
	<b>Fold change</b>		<b>1.01</b>	<b>0.74</b>	<b>0.88</b>	87.6
P9-37	pg/ml	3231	NT	NT		
	<b>Fold change</b>	<b>0.55</b>			<b>0.55</b>	54.56
P9-57	pg/ml	4939	NT	NT		
	<b>Fold change</b>	<b>0.83</b>			<b>0.83</b>	83.4

		<b>Table 10</b>				
		<b>TNF-<math>\alpha</math> 72hr</b>				
		Average/ donor			Average	as %
Donor 19	Donor 25	Donor 27				
IgG	pg/ml	777	1284	929		
P9-11	pg/ml	607	982	374		
	<b>Fold change</b>	<b>0.78</b>	<b>0.76</b>	<b>0.40</b>	<b>0.64</b>	64.7
P9-24	pg/ml	NT	962	299		
	<b>Fold change</b>		<b>0.75</b>	<b>0.32</b>	<b>0.54</b>	53.5
P9-34	pg/ml	NT	874	596		
	<b>Fold change</b>		<b>0.68</b>	<b>0.79</b>	<b>0.74</b>	73.7
P9-37	pg/ml	429	NT	NT		
	<b>Fold change</b>	<b>0.55</b>			<b>0.55</b>	55.2
P9-57	pg/ml	417	NT	NT		
	<b>Fold change</b>	<b>0.54</b>			<b>0.54</b>	53.66

**6.11.10. Example 9: Treating with anti-human GAL9 IgG1 antibodies P9-11, P9-37, or P9-57 decreases production of TNF- $\alpha$  and IFN- $\gamma$  in activated PBMCs**

[0334] Selected inhibitory anti-human GAL9 candidates from Example 7, formatted as bivalent monospecific human IgG1 antibodies, were further tested on PBMCs from three additional human donors for their ability to inhibit cytokine production in PBMCs.

**Stimulation of PBMCs**

[0335] Human primary PBMC were collected from donor 19, donor RCB, and donor RG, which are known to have strong responses to human CMV virus (HCMV). PBMCs were stimulated essentially as described in **Section 6.11.1** above. Briefly, PBMCs were harvested from human donors known to be responsive to human CMV virus (HCMV), placed in culture, stimulated with HCMV PepMix to prime an antigen specific response, and treated with P9-41, P9-42, P9-53, P9-11, P9-37, or P9-57, formatted as bivalent monospecific full length human IgG1 antibodies, or a human IgG control.

### Cytokine Assay

[0336] Secretion of TNF- $\alpha$  and IFN- $\gamma$  was measured at 24 hrs and 72 hrs post-treatment using BD™ Cytometric Bead Array (CBA) following the manufacturer's instructions. Assays were performed in quadruplicate.

### Results/Conclusion

[0337] Representative data from 72 hrs of treatment are shown in **FIGs. 11A-11C**. The average is indicated as a horizontal bar on the scatter plots. Error bars show standard deviation.

[0338] **FIGs. 11A-11B** show scatter plots of TNF- $\alpha$  levels after with treatment with human IgG control (hIgG) and inhibitory anti-human GAL9 candidates. Treatment with P9-11, P9-37, or P9-57 formatted as human IgG1 antibodies, decreased TNF- $\alpha$  levels in PBMCs from all three human donors compared to IgG control. **FIG. 11C** show scatter plots of IFN- $\gamma$  levels after treatment with a human control IgG (hIgG) or the anti-human GAL9 candidates. Treatment with either P9-11, P9-37, or P9-57 decreased IFN- $\gamma$  levels in PBMCs as compared to control.

[0339] Treatment with either P9-41, P9-42, or P9-53 gave neutral or weak TNF- $\alpha$  and IFN- $\gamma$  secretion (data not shown).

#### **6.11.11. Example 10: Treating with anti-human GAL9 P9-11, P9-24, or P9-34 decreases TNF- $\alpha$ and INF- $\gamma$ production and increases IL-10 production in activated PBMCs**

[0340] This study was conducted to determine the effect of select inhibitory anti-human GAL9 candidates from Example 7 on secretion of TNF- $\alpha$ , INF- $\gamma$ , and IL-10 in activated human PBMCs.

### Stimulation of PBMCs

[0341] PBMCs were stimulated essentially as described in **Section 6.11.1** above. Briefly, PBMCs were harvested from human donors known to be highly responsive to human CMV virus (HCMV), placed in culture, stimulated with HCMV PepMix to prime an antigen specific response, and treated with one of P9-11, P9-24, and P9-34, formatted as a bivalent, monospecific, human IgG1 antibody, or a human IgG control.

## Cytokine Assay

[0342] Cytokine secretion of TNF- $\alpha$ , INF- $\gamma$ , and IL-10 was measured 72 hrs post-treatment using BD™ Cytometric Bead Array (CBA) following manufacturer's instructions.

### Results/Conclusion

[0343] **FIG. 12A** shows bar graphs of TNF- $\alpha$  levels after treatment with control IgG (hIgG) or inhibitory anti-human GAL9 candidates. Treatment with anti-human IgG1 P9-11, P9-24, or P9-34 resulted in a decrease of TNF- $\alpha$  secretion from PBMCs compared to IgG control.

**FIG. 12 B** shows bar graphs of INF- $\gamma$  levels after with treatment with control IgG (hIgG) or inhibitory anti-GAL9 candidates. Treatment with anti-human GAL9 antibodies P9-11, P9-24, or P9-34 resulted in a decrease of INF- $\gamma$  secretion from PBMCs compared to IgG control.

**FIG. 12C** shows bar graphs of IL-10 levels after with treatment inhibitory anti-human GAL9 candidates or IgG control. Treatment with P9-11, P9-24, or P9-34 antibodies increased IL-10 secretion in PBMCs as compared to control.

### **6.11.12. Example 11: Treating activated CD3<sup>+</sup> T-cells with anti-human GAL9 antibodies P9-11, P9-24, or P9-34 improves the cytokine profile, while anti-mouse GAL9 (108A2) results in a complete block of cytokine secretion**

[0344] We measured INF- $\gamma$ , TNF- $\alpha$ , or IL-10 cytokine secretion to determine the effect of anti-mouse GAL9 (clone 108A2) and anti-human GAL9 antibodies P9-11, P9-24, or P9-34, formatted as human IgG1 antibodies, on the cytokine profile in activated CD3<sup>+</sup> T-cells from mice.

### **Animals and Isolation of CD3<sup>+</sup> T-cells**

[0345] Five mice were used for each treatment group. All animals used in the study were housed and cared for in accordance with the NHMRC Guidelines for Animal Use.

### **Antibodies**

[0346] Antibodies P9-11, P9-24, and P9-34, formatted as bivalent monospecific human IgG1 antibodies, and a human IgG control were used. In addition, the inhibitory anti-mouse GAL9 clone 108A2 "mGAL9" (BioLegend® San Diego, CA) was used.

### **Simulation of CD3<sup>+</sup> T-cells**

[0347] CD3<sup>+</sup> T-cells (CD90.2<sup>+</sup> CD3<sup>+</sup>) were isolated from the spleens of naïve mice. Mouse CD3<sup>+</sup> T cells were stimulated with anti-CD3 clone 145.2C11 (Aviva Systems Biology Corp.

San Diego, CA) at 5  $\mu\text{g/ml}$ . Next, the stimulated  $\text{CD3}^+$  T cells were treated either with IgG control or one of the inhibitory antibodies at 20  $\mu\text{g/ml}$  and cultured for 72 hours.

### Cytokine Assays

[0348] After 72 hrs of treatment, the concentration of  $\text{INF-}\gamma$ ,  $\text{TNF-}\alpha$ , or IL-10 was measured using BD™ Cytometric Bead Array (CBA) following the manufacturer's instructions.

### Statistical Analyses

[0349] Non-parametric unpaired t-test was conducted using GraphPad Prism (GraphPad Software).

### Results/Conclusion

[0350] The results are shown in **FIGs. 13A** and **13B**. A reduced ratio of  $\text{TNF-}\alpha$ :IL-10 or  $\text{INF-}\gamma$ :IL-10 indicates a reduction in pro-inflammatory cytokines with an increase in the inhibitory cytokine, IL-10. Treatment with the anti-mouse GAL9 (108A2) antibody significantly reduced secretion of  $\text{TNF-}\alpha$ ,  $\text{INF-}\gamma$ , and IL-10. See **FIG. 13A**. In contrast, treatment with either anti-human GAL9 antibody P9-11, P9-24, or P9-34 (human IgG1 Fc) did not reduce  $\text{TNF-}\alpha$  or  $\text{INF-}\gamma$  secretion, and IL-10 secretion was significantly increased. See **FIG. 13B**. The asterisk “\*” indicates a statistical significance of  $p$ -value  $<0.05$  compared to control.

[0351] Treatment with anti-human P9-11 and P9-24 antibodies, formatted as human IgG1 antibodies, resulted in an improved inflammatory environment, decreasing secretion of  $\text{TNF-}\alpha$ ,  $\text{INF-}\gamma$ , and increasing IL-10 secretion. Notably, treatment with anti-mouse GAL9 (108A2) resulted in a complete block of cytokine response, including IL-10 secretion. The differences in the cytokine profiles generated by anti-human GAL9 and anti-murine GAL9 (108A2) suggest that anti-human GAL9 and anti-mouse GAL9 (108A2) antibodies have a different mechanism of action.

#### **6.11.13. Example 12: Treating with anti-human GAL9 does not substantially change the expression of Immune Checkpoint Molecules in stimulated $\text{CD4}^+$ and $\text{CD8}^+$ T cells, and decreases 4-1BB, CD40L, and OX40 costimulatory molecules in $\text{CD8}^+$ T cells**

[0352] This study was conducted to determine the effect of anti-human GAL9 candidates P9-11, P9-24, and P9-34 on the expression of select checkpoint molecules in stimulated  $\text{CD8}^+$

and CD4<sup>+</sup> T cells and the effect of anti-human GAL9 P9-11 on select costimulatory molecules in stimulated CD8<sup>+</sup> T cells.

### Stimulation & Treatment

[0353] PBMCs, which include the population of CD8<sup>+</sup> or CD4<sup>+</sup> T-cells, were stimulated as described above and treated with anti-human GAL9 P9-11, P9-24, P9-34, formatted as bivalent monospecific human IgG1 antibodies, or a human IgG control.

### Immunolabelling

[0354] PMBCs were resuspended at  $5 \times 10^6$  cells/mL in 10% FBS in RPMI. 200  $\mu$ L of resuspended cells were aliquoted to 96 well plates, then stained with Fixable Viability Dye eFluor® 780 for 30 minutes at 2-8°C to irreversibly label dead cells. Cells were then washed and incubated with human Fc Block solution (Cat. No. 14-9161-73, eBiosciences) for 10 minutes at room temperature. The surface expression of PD-L1, PD-1, CTLA-4, TIM3, LAG3, 4-1BB, CD27, CD40L, ICOS, or OX40 was assessed by flow cytometry.

### Flow Cytometry

[0355] Flow cytometry analysis was performed using a BD LSR Fortessa flow cytometer and BD FACSDiva software (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). For each sample, at least  $5 \times 10^5$  events were collected.

[0356] Representative data for the percentage of CD4<sup>+</sup> or CD8<sup>+</sup> T-cells that stained positive for immune checkpoint molecules are presented in **Table 11** and **Table 12** below. Data for the percentage of CD8<sup>+</sup> T-cells that stained positive for costimulatory molecules are presented in **Table 13** below.

[0357] The “% value” represents the % of cells with detectable levels of the indicated marker. “(x)” indicates the fold change after treatment with the selected  $\alpha$ -GAL9 antibody candidates as compared to a human IgG control.

Marker	PD-L1	PD-1	GAL9	CTLA-4	TIM3	LAG3
<b>hIgG</b>	43.6%	14.2%	3.02%	0.67 %	0.99 %	1.00 %
<b>Control</b>						
<b>P9-11</b>	37.3% <b>(0.9x)</b>	14.2% <b>(1.0x)</b>	2.21% <b>(0.7x)</b>	0.71% <b>(1.0x)</b>	1.14 % <b>(1.1x)</b>	0.93 % <b>(0.9x)</b>

<b>Table 11: Percent CD4<sup>+</sup> cells positive for selected immune checkpoint molecules</b>						
<b>Marker</b>	<b>PD-L1</b>	<b>PD-1</b>	<b>GAL9</b>	<b>CTLA-4</b>	<b>TIM3</b>	<b>LAG3</b>
<b>P9-24</b>	40.2% <b>(0.9x)</b>	15.0 % <b>(1.0x)</b>	2.05% <b>(0.6x)</b>	0.67% <b>(1.0x)</b>	0.93 % <b>(0.9x)</b>	1.03 % <b>(1.0x)</b>
<b>P9-34</b>	42.3% <b>(0.9x)</b>	16.0 % <b>(1.1x)</b>	2.63% <b>(0.8x)</b>	0.71% <b>(1.0x)</b>	1.03 % <b>(1.0x)</b>	1.12 % <b>(1.1x)</b>

<b>Table 12: Percent CD8<sup>+</sup> cells positive for selected immune checkpoint molecules</b>						
<b>Marker</b>	<b>PD-L1</b>	<b>PD-1</b>	<b>GAL9</b>	<b>CTLA-4</b>	<b>TIM3</b>	<b>LAG3</b>
<b>hIgG</b>	29.1 %	16.1 %	4.35 %	18.7 %	0.81 %	2.25 %
<b>Control</b>						
<b>P9-11</b>	26.7% <b>(0.9x)</b>	16.5% <b>(1.0x)</b>	1.63% <b>(0.3x)</b>	15.2% <b>(0.8x)</b>	0.95 % <b>(1.1x)</b>	2.00 % <b>(0.9x)</b>
<b>P9-24</b>	24.5% <b>(0.8x)</b>	16.7% <b>(1.0x)</b>	1.82% <b>(0.4x)</b>	15.1% <b>(0.8x)</b>	0.88 % <b>(1.0x)</b>	1.88 % <b>(0.8x)</b>
<b>P9-34</b>	26.3% <b>(0.9x)</b>	17.0% <b>(1.0x)</b>	2.79% <b>(0.6x)</b>	15.0% <b>(0.8x)</b>	0.82 % <b>(1.0x)</b>	2.40 % <b>(1.0x)</b>

<b>Table 13: Percent CD8<sup>+</sup> cells positive for selected costimulatory molecules</b>					
<b>Marker</b>	<b>4-1BB</b>	<b>CD27</b>	<b>CD40L</b>	<b>ICOS</b>	<b>OX40</b>
<b>hIgG control</b>	5.64%	53.5%	2.57%	6.39%	9.95%
<b>P9-11</b>	3.03% <b>(0.53x)</b>	52.6% <b>(0.98x)</b>	1.85% <b>(0.72x)</b>	5.56% <b>(0.87x)</b>	5.2% <b>(0.5x)</b>

### **Results/Conclusion**

**[0358]** There was no substantial change in the expression of any of the immune checkpoint molecules in stimulated CD8<sup>+</sup> or CD4<sup>+</sup> T-cells. However, we observed a decrease in the

costimulatory molecules 4-1BB, CD40L, and OX40 in stimulated CD8<sup>+</sup> T-cells. These results suggest that the effects of the anti-human GAL9 candidates on cytokine response is driven by the inhibition of GAL9, and not through PD-1/PD-L1 immune checkpoint pathway or other checkpoint molecules such as CTLA-4, TIM3, or LAG3.

## 7. EQUIVALENTS

**[0359]** While various specific embodiments have been illustrated and described, the above specification is not restrictive. It will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s). Many variations will become apparent to those skilled in the art upon review of this specification.

## CLAIMS

What is claimed is:

- 1.** A Galectin-9 (GAL9) antigen binding molecule, comprising: a first antigen binding site (ABS) specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 2.** A Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site (ABS) specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VL CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 3.** A Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site (ABS) specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 4.** A Galectin-9 (GAL9) antigen binding molecule, comprising a first antigen binding site (ABS) specific for a first epitope of a first GAL9 antigen, comprising the VL sequence and the VH sequence from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 5.** The GAL9 antigen binding molecule of claim 4, wherein the first antigen binding site (ABS) further comprises a first IgG heavy chain polypeptide and a first light chain polypeptide.
- 6.** The GAL9 antigen binding molecule of any one of claims 1-5, wherein the GAL9 antigen is a human GAL9 antigen.

7. The GAL9 antigen binding molecule of any of claims 1-6, wherein the GAL9 antigen binding molecule further comprises a second antigen binding site (ABS).
8. The GAL9 antigen binding molecule of claim 7, wherein the second ABS is specific for a GAL9 antigen.
9. The GAL9 antigen binding molecule of claim 7, wherein the second ABS is specific for a second epitope of the first GAL9 antigen.
10. The GAL9 antigen binding molecule of claim 7, wherein the second ABS is specific for the first epitope of the first GAL9 antigen and is identical to the first ABS.
11. The GAL9 antigen binding molecule of any one of claims 7-10, wherein the second ABS comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from another ABS clone selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
12. The GAL9 antigen binding molecule of claim 11, wherein the second antigen binding site comprises the VL sequence and the VH sequence from the other ABS clone.
13. The GAL9 antigen binding molecule of claim 12, wherein the second antigen binding site comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence from the other ABS clone.
14. The GAL9 antigen binding molecule of claim 7, wherein the second antigen binding site is specific for an antigen other than the first GAL9 antigen.
15. The GAL9 antigen binding molecule of any one of the preceding claims, wherein the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-11, P9-24, P9-34, and P9-37.
16. The GAL9 antigen binding molecule of any of claims 1-14, wherein the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from P9-11, P9-24, and P9-34.

17. The GAL9 antigen binding molecule of any of claims 1-14, wherein the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-11.
18. The GAL9 antigen binding molecule of any of claims 1-14, wherein the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-24.
19. The GAL9 antigen binding molecule of any of claims 1-14, wherein the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-34.
20. The GAL9 antigen binding molecule of any of claims 1-14, wherein the first antigen binding site comprises all three VH CDRs, all three VL CDRs, or all three VH CDRs and all three VL CDRs from ABS clone P9-37.
21. The GAL9 antigen binding molecule of any of claims 1-20, wherein the GAL9 antigen binding molecule comprises an antibody format selected from the group consisting of: full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, and B-bodies.
22. The GAL9 antigen binding molecule of any of claims 1-21, wherein the GAL9 antigen binding molecule decreases TNF- $\alpha$  secretion by activated immune cells upon contact, wherein the decrease is about at least a 30%, 35%, 40%, 45%, 50%, 55%, or 60% decrease, relative to activated immune cells treated with a control agent.
23. The GAL9 antigen binding molecule of any of claims 1-22, wherein the GAL9 antigen binding molecule decreases IFN- $\gamma$  secretion by activated immune cells upon contact, wherein the decrease is about at least a 20%, 25%, 30%, 35%, 40%, 45%, or 50% decrease relative to activated immune cells treated with a control agent.
24. The GAL9 antigen binding molecule of any of claims 1-23, wherein the GAL9 antigen binding molecule increases IL-10 secretion by activated immune cells upon contact, wherein the increase is about at least a 5%, 10%, 15%, 20%, 25%, 30%, 35% or 40% increase relative to activated immune cells treated with a control agent.
25. The GAL9 antigen binding molecule of any of claims 1-24, wherein the GAL9 antigen binding molecule does not modulate PD-1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

26. The GAL9 antigen binding molecule of any of claims 1-25, wherein the GAL9 antigen binding molecule does not modulate PD-L1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
27. The GAL9 antigen binding molecule of any of claims 1-26, wherein the GAL9 antigen binding molecule does not modulate CTLA-4 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
28. The GAL9 antigen binding molecule of any of claims 1-27, wherein the GAL9 antigen binding molecule does not modulate TIM3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
29. The GAL9 antigen binding molecule of any of claims 1-28, wherein the GAL9 antigen binding molecule does not modulate LAG3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
30. The GAL9 antigen binding molecule of any of claims 1-29, wherein the GAL9 antigen binding molecule decreases 4-1BB surface expression on CD8<sup>+</sup> T-cells, relative to CD8<sup>+</sup> T-cells treated with a control agent.
31. The GAL9 antigen binding molecule of any of claims 1- 30, wherein the GAL9 antigen binding molecule decreases CD40L surface expression on CD8<sup>+</sup> T-cells, relative to CD8<sup>+</sup> T-cells treated with a control agent.
32. The GAL9 antigen binding molecule of any of claims 1- 31, wherein the GAL9 antigen binding molecule decreases OX40 surface expression on CD8<sup>+</sup> T-cells, relative to CD8<sup>+</sup> T-cells treated with a control agent.
33. The GAL9 antigen binding molecule of any of claims 22-32, wherein the control agent is a negative control agent or positive control agent.
34. The GAL9 antigen binding molecule of claim 33, wherein the control agent is a control antibody.
35. The GAL9 antigen binding molecule of claim 34, wherein the control antibody is selected from the group consisting of: an ECA42 clone anti-GAL9 antibody, an RG9.1 clone anti-GAL9 antibody, an RG9.35 clone anti-GAL9 antibody, an anti-PD1 antibody, a 108A2 clone anti-GAL9 antibody, and a non-GAL9 binding isotype control antibody.

36. The GAL9 antigen binding molecule of any one of claims 22-35, wherein the activated immune cells were activated by peptide stimulation, anti-CD3, or dendritic cells.
37. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule decreases TNF- $\alpha$  secretion by activated immune cells upon contact, wherein the decrease is about at least a 30%, 35%, 40%, 45%, 50%, 55%, or 60% decrease relative to activated immune cells treated with a control agent.
38. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule decreases IFN- $\gamma$  secretion by activated immune cells upon contact, wherein the decrease is about at least a 20%, 25%, 30%, 35%, 40%, 45%, or 50% decrease relative to activated immune cells treated with a control agent.
39. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule increases IL-10 secretion by activated immune cells upon contact, wherein the increase is about at least a 5%, 10%, 15%, 20%, 25%, 30%, 35% or 40% increase relative to activated immune cells treated with a control agent
40. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule does not modulate PD-1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
41. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule does not modulate PD-L1 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
42. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule does not modulate CTLA-4 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
43. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule does not modulate TIM3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.
44. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule does not modulate LAG-3 surface expression on activated immune cells relative to activated immune cells treated with a control agent.

45. A GAL9 antigen binding molecule decreases 4-1BB surface expression on activated CD8<sup>+</sup> T-cells relative to activated CD8<sup>+</sup> T-cells treated with a control agent.
46. A GAL9 antigen binding molecule decreases CD40L surface expression on activated CD8<sup>+</sup> T-cells relative to activated CD8<sup>+</sup> T-cells treated with a control agent.
47. A GAL9 antigen binding molecule decreases OX40 surface expression on activated CD8<sup>+</sup> T-cells relative to activated CD8<sup>+</sup> T-cells treated with a control agent.
48. A GAL9 antigen binding molecule, wherein the GAL9 antigen binding molecule demonstrates one or more of the following properties:
- A) decreases TNF- $\alpha$  secretion by activated immune cells, wherein the decrease is about at least a 30%, 35%, 40%, 45%, 50%, 55%, or 60% decrease relative to activated immune cells treated with a control agent;
- B) decreases IFN- $\gamma$  secretion by activated immune cells, wherein the decrease is about at least a 20%, 25%, 30%, 35%, 40%, 45%, or 50% decrease relative to activated immune cells treated with a control agent;
- C) increases IL-10 secretion by activated immune cells, wherein the increase is about at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% increase relative to activated immune cells treated with a control agent;
- D) does not modulate PD-1 surface expression on activated immune cells relative to activated immune cells treated with a control agent;
- E) does not modulate PD-L1 surface expression on activated immune cells relative to activated immune cells treated with a control agent;
- F) does not modulate CTLA-4 surface expression on activated immune cells relative to activated immune cells treated with a control agent;
- G) does not modulate TIM3 surface expression on activated immune cells relative to activated immune cells treated with a control agent;
- H) does not modulate LAG3 surface expression on activated immune cells relative to activated immune cells treated with a control agent;
- I) decreases 4-1BB surface expression on activated CD8<sup>+</sup> T-cells relative to activated CD8<sup>+</sup> T-cells treated with a control agent;

- J) decreases CD40L surface expression on activated CD8<sup>+</sup> T-cells relative to activated CD8<sup>+</sup> T-cells treated with a control agent; or
- K) decreases OX40 surface expression on activated CD8<sup>+</sup> T-cells relative to activated CD8<sup>+</sup> T-cells treated with a control agent.
- 49.** The GAL9 antigen binding molecule of any one of claims 37-48, wherein the control agent is a negative control agent or positive control agent.
- 50.** The GAL9 antigen binding molecule of claim 49, wherein the control agent is a control antibody.
- 51.** The GAL9 antigen binding molecule of claim 50, wherein the control antibody is selected from the group consisting of: an ECA42 clone anti-GAL9 antibody, an RG9.1 clone anti-GAL9 antibody, an RG9.35 clone anti-GAL9 antibody, an anti-PD1 antibody, an 108A2 clone anti-GAL9 antibody, and an non-GAL9 binding isotype control antibody.
- 52.** The GAL9 antigen binding molecule of any one of claims 37-51, wherein the activated immune cells, were activated by were activated by peptide stimulation, anti-CD3 or dendritic cells.
- 53.** The GAL9 antigen binding molecule of any of claims 37-49, comprising a first antigen binding site specific for a first epitope of a first GAL9 antigen, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 54.** The GAL9 antigen binding molecule of claim 53, comprising the VL sequence and the VH sequence from any one of the ABS clones selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 55.** The GAL9 antigen binding molecule of claim 54, comprising a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence, wherein the VH sequence and the VL sequence are from any one of the ABS clones selected from P9-01, P9-02A, P9-03,

- P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 56.** The GAL9 antigen binding molecule of any one of claims 37-55, wherein the GAL9 antigen is a human GAL9 antigen.
- 57.** The GAL9 antigen binding molecule of any of claims 37-56, wherein the GAL9 antigen binding molecule further comprises a second antigen binding site.
- 58.** The GAL9 antigen binding molecule of claim 57, wherein the second antigen binding site is specific for the GAL9 antigen.
- 59.** The GAL9 antigen binding molecule of claim 58, wherein the second antigen binding site is identical to the first antigen binding site.
- 60.** The GAL9 antigen binding molecule of claim 57, wherein the second antigen binding site is specific for a second epitope of the first GAL9 antigen.
- 61.** The GAL9 antigen binding molecule of claim 60, wherein the second antigen binding site comprises all three VH CDRs and all three VL CDRs from another ABS clone selected from P9-01, P9-02A, P9-03, P9-06, P9-07, P9-11, P9-12, P9-14, P9-23, P9-24, P9-25, P9-29, P9-30, P9-34, P9-37, P9-38, P9-40, P9-41, P9-42, P9-43, P9-44, P9-45, P9-46, P9-50, P9-51, P9-52, P9-53, P9-56, and P9-57.
- 62.** The GAL9 antigen binding molecule of claim 61, wherein the second antigen binding site comprises the VL sequence and the VH sequence from the other ABS clone.
- 63.** The GAL9 antigen binding molecule of claim 62, wherein the second antigen binding site comprises a full immunoglobulin heavy chain sequence comprising the VH sequence and a full immunoglobulin light chain sequence comprising the VL sequence from the other ABS clone.
- 64.** The GAL9 antigen binding molecule of claim 57, wherein the second antigen binding site is specific for an antigen other than the first GAL9 antigen.
- 65.** The GAL9 antigen binding molecule of any of claims 53-64, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-11, P9-24, P9-34, and P9-37.

66. The GAL9 antigen binding molecule of any of claims 53-64, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from any one of the ABS clones selected from: P9-11, P9-24, and P9-34 .
67. The GAL9 antigen binding molecule of any of claims 53-64, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-11.
68. The GAL9 antigen binding molecule of any of claims 53-64, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-24.
69. The GAL9 antigen binding molecule of any of claims 53-64, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-34.
70. The GAL9 antigen binding molecule of any of claims 53-64, wherein the first antigen binding site comprises all three VH CDRs and all three VL CDRs from ABS clone P9-37.
71. The GAL9 antigen binding molecule of any of claims 37-70, wherein the GAL9 antigen binding molecule comprises an antibody format selected from the group consisting of: full-length antibodies, Fab fragments, Fvs, scFvs, tandem scFvs, Diabodies, scDiabodies, DARTs, tandAbs, minibodies, and B-bodies.
72. A GAL9 antigen binding molecule which binds to the same epitope as a GAL9 antigen binding molecule of any one of the preceding claims.
73. A GAL9 antigen binding molecule which competes for binding with a GAL9 antigen binding molecule of any one of the preceding claims.
74. The GAL9 antigen binding molecule of any one of the preceding claims, which is purified.
75. A pharmaceutical composition comprising the GAL9 antigen binding molecule of any one of the preceding claims and a pharmaceutically acceptable diluent.
76. A method for treating a subject with an autoimmune disease, comprising:  
administering a therapeutically effective amount of the pharmaceutical composition of claim 75 to the subject.

77. The method of claim 76, wherein the subject with an autoimmune disease has increased PD-L2 expression on dendritic cells relative to dendritic cells from a healthy control.
78. The method of claim 76, wherein the autoimmune disease is selected from the group consisting of: inflammatory bowel disease, Crohn's disease, ulcerative colitis, colitis, celiac disease, rheumatoid arthritis, Behçet's disease, amyloidosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus nephritis, graft-versus-host disease (GvHD), nonalcoholic steatohepatitis (NASH), and ankylosing spondylitis.
79. The method of claim 76, wherein the treatment results in reducing inflammation, reducing an autoimmune response, prolonging remission, inducing remission, re-establishing immune tolerance, improving organ function, reducing progression of a disease, reducing the risk of progression or development of a second disease, or increasing overall survival.

Query protein sequence	E	V	Q	L	V	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L
Chothia numbering	H1	H2	H3	H4	H5	H6	H7	H8	H9	H10	H11	H12	H13	H14	H15	H16	H17	H18	H19	H20
Martin numbering	H1	H2	H3	H4	H5	H6	H7	H8	H9	H10	H11	H12	H13	H14	H15	H16	H17	H18	H19	H20
Kabat numbering	H1	H2	H3	H4	H5	H6	H7	H8	H9	H10	H11	H12	H13	H14	H15	H16	H17	H18	H19	H20
REGIONS: CHOTHIA	HFR1																			
ABM	HFR1																			
KABAT	HFR1																			
CONTACT	HFR1																			



S	C	A	A	S	G	F	T	F	S	T	Y	F	I	H	W	V	R	Q	A	P	G	K
H21	H22	H23	H24	H25	H26	H27	H28	H29	H30	H31	H32	H33	H34	H35	H36	H37	H38	H39	H40	H41	H42	H43
H21	H22	H23	H24	H25	H26	H27	H28	H29	H30	H31	H32	H33	H34	H35	H36	H37	H38	H39	H40	H41	H42	H43
H21	H22	H23	H24	H25	H26	H27	H28	H29	H30	H31	H32	H33	H34	H35	H36	H37	H38	H39	H40	H41	H42	H43
CDR-H1											HFR2											
CDR-H1											HFR2											
CDR-H1											HFR2											
CDR-H1											HFR2											

G	L	E	W	V	A	Y	I	Y	P	Q	G	G	Y	T	Y	A	D	S	V	K	G	
H44	H45	H46	H47	H48	H49	H50	H51	H52	H52A	H53	H54	H55	H56	H57	H58	H59	H60	H61	H62	H63	H64	H65
H44	H45	H46	H47	H48	H49	H50	H51	H52	H52A	H53	H54	H55	H56	H57	H58	H59	H60	H61	H62	H63	H64	H65
H44	H45	H46	H47	H48	H49	H50	H51	H52	H52A	H53	H54	H55	H56	H57	H58	H59	H60	H61	H62	H63	H64	H65
CDR-H2											HFR3											
CDR-H2											HFR3											
CDR-H2											HFR3											
CDR-H2											HFR3											



FIG. 1A

R	F	T	I	S	A	D	T	S	K	N	T	A	Y	L	Q	M	N	S	L	R	A	E
H66	H67	H68	H69	H70	H71	H72	H73	H74	H75	H76	H77	H78	H79	H80	H81	H82	H82A	H82B	H82C	H83	H84	H85
H66	H67	H68	H69	H70	H71	H72	H72A	H72B	H72C	H73	H74	H75	H76	H77	H78	H79	H80	H81	H82	H83	H84	H85
H66	H67	H68	H69	H70	H71	H72	H73	H74	H75	H76	H77	H78	H79	H80	H81	H82	H82A	H82B	H82C	H83	H84	H85
HFR3																						

4																						
D	T	A	V	Y	Y	C	A	R	Q	S	Y	P	G	V	F	D	Y	W	G	Q	G	T
H86	H87	H88	H89	H90	H91	H92	H93	H94	H95	H96	H97	H98	H99	H100	H100A	H101	H102	H103	H104	H105	H106	H107
H86	H87	H88	H89	H90	H91	H92	H93	H94	H95	H96	H97	H98	H99	H100	H100A	H101	H102	H103	H104	H105	H106	H107
H86	H87	H88	H89	H90	H91	H92	H93	H94	H95	H96	H97	H98	H99	H100	H100A	H101	H102	H103	H104	H105	H106	H107
CDR-H3												HFR4										
CDR-H3												HFR4										
CDR-H3												HFR4										
CDR-H3												HFR4										

FIG. 1A (Cont.)

Query protein sequence	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T
Chothia numbering	L1	L2	L3	L4	L5	L6	L7	L8	L9	L10	L11	L12	L13	L14	L15	L16	L17	L18	L19	L20
Martin numbering	L1	L2	L3	L4	L5	L6	L7	L8	L9	L10	L11	L12	L13	L14	L15	L16	L17	L18	L19	L20
Kabat numbering	L1	L2	L3	L4	L5	L6	L7	L8	L9	L10	L11	L12	L13	L14	L15	L16	L17	L18	L19	L20

REGIONS: CHOTHIA	LFR1
ABM	LFR1
KABAT	LFR1
CONTACT	LFR1

	I	T	C	R	A	S	Q	S	V	S	S	A	V	A	W	Y	Q	Q	K	P	G	K	A
L21	L22	L23	L24	L25	L26	L27	L28	L29	L30	L31	L32	L33	L34	L35	L36	L37	L38	L39	L40	L41	L42	L43	L43
L21	L22	L23	L24	L25	L26	L27	L28	L29	L30	L31	L32	L33	L34	L35	L36	L37	L38	L39	L40	L41	L42	L43	L43
L21	L22	L23	L24	L25	L26	L27	L28	L29	L30	L31	L32	L33	L34	L35	L36	L37	L38	L39	L40	L41	L42	L43	L43
	CDR-L1											LFR2											
	CDR-L1											LFR2											
	CDR-L1											LFR2											
	CDR-L1											LFR2											

	P	K	L	L	I	Y	S	A	S	S	L	Y	S	G	V	P	S	R	F	S	G	S	R
L44	L45	L46	L47	L48	L49	L50	L51	L52	L53	L54	L55	L56	L57	L58	L59	L60	L61	L62	L63	L64	L65	L66	L66
L44	L45	L46	L47	L48	L49	L50	L51	L52	L53	L54	L55	L56	L57	L58	L59	L60	L61	L62	L63	L64	L65	L66	L66
L44	L45	L46	L47	L48	L49	L50	L51	L52	L53	L54	L55	L56	L57	L58	L59	L60	L61	L62	L63	L64	L65	L66	L66
	CDR-L2											LFR3											
	CDR-L2											LFR3											
	CDR-L2											LFR3											
	CDR-L2											LFR3											

FIG. 1B

S	G	T	I	A	L	T	F	G	Q	G	T	K	V	E	I	K	R	T	V			
L67	L68	L69	L70	L71	L72	L73	L74	L75	L76	L77	L78	L79	L80	L81	L82	L83	L84	L85	L86	L87	L88	L89
L67	L68	L69	L70	L71	L72	L73	L74	L75	L76	L77	L78	L79	L80	L81	L82	L83	L84	L85	L86	L87	L88	L89
L67	L68	L69	L70	L71	L72	L73	L74	L75	L76	L77	L78	L79	L80	L81	L82	L83	L84	L85	L86	L87	L88	L89
CDR-L3																						
CDR-L3																						
CDR-L3																						
CDR-L3																						

✳

Q	W	T	I	A	L	T	F	G	Q	G	T	K	V	E	I	K	R	T	V		
L90	L91	L92	L93	L94	L95	L96	L97	L98	L99	L100	L101	L102	L103	L104	L105	L106	L107	L108	L109	L110	
L90	L91	L92	L93	L94	L95	L96	L97	L98	L99	L100	L101	L102	L103	L104	L105	L106	L107	L108	L109	L110	
L90	L91	L92	L93	L94	L95	L96	L97	L98	L99	L100	L101	L102	L103	L104	L105	L106	L107	L108	L109	L110	
LFR4																					
LFR4																					
LFR4																					
LFR4																					

FIG. 1B (Cont.)




FIG. 2




FIG. 3B




FIG. 3A




FIG. 3D




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 5C




FIG. 5B




FIG. 5A




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9B




FIG. 9A

14/21




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13B




FIG. 13A